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Continuous glucose monitoring (CGM) devices are becoming ubiquitous in the of care individuals 
with type 1 and type 2 diabetes. However, to a lesser extent, these devices could have further benefit 
in optimising blood glucose (BG) levels and related aspects in individuals without diabetes in 
physiologically stressful situations. This research centres on the metabolic effects of systemic 
inflammation and the use of these emerging glucose sensors to detect metabolic changes for use in 
computer aided monitoring and decision support. Specifically, this work investigates the use of CGM 
sensors in critically ill patients and endurance athletes to improve performance of glycaemic control 
and optimise nutrition delivery. 
 
Critically ill patients often experience high levels of insulin resistance and stress-induced 
hyperglycaemia, which can negatively impact outcomes. Studies have shown glycaemic control (GC) 
can reduce intensive care unit (ICU) patient mortality. However, there is a significant difficulty in 
creating protocols that produce GC without excessive hypoglycaemia. Thus, continuous glucose 
monitors with their 2-5 minute measurement provide the opportunity to better monitor BG levels and 
thus aviod hypoglycaemia. 
 
Recently, a CGM device specifically designed for the ICU became available, The Sentrino (Medtronic, 
MiniMed, Northridge, California). Hence, a large scale study was designed for implementation in 
Christchurch Hospital mixed medical ICU to gather further information about the feasibility of CGM in 
ICU. First, the performance of the Sentrino CGM system in a mixed medical ICU environment was 
analysed. CGM and BG data were gathered from 13 patients recruited to Phase 1 of the trial.  The 
Sentrino device achieved a mean absolute relative difference (MARD) of 14.7%. Overall, the Sentrino 
performance was acceptable, but required calibration measurements every 4 hours on average. 
xi 
 
Hence, questions still remain if this CGM system can reduce the time and workload cost of glycaemic 
control.   
 
Phase IIA was an observational study of the performance and integration of hyper- and hypo- 
glycaemic guardrail alarms with an existing, proven GC protocol. This study analysed sensor glucose 
(SG) and BG data, and alarm data from 8 patients recruited to this phase of the trial. Overall, sensor 
and alarm performance was good, only 32/93 total alarms required calibration due to a significant 
difference between SG and BG. However, there was a high rate of false positive alarms, 27/29 
hypoglycaemic alarms were false positives. 
 
An analysis was undertaken to better understand the impact of sepsis, oedema, and some medications 
on CGM results, as well as to assess the nurse compliance and feedback to gain insight of the clinical 
impact of using CGM to guide GC. This analysis used data from 21 patients in Phase I and Phase IIA. 
Approximately 50% of all enrolled subjects were severely oedematous and/or septic by design. For 
any CGM to be successful in reducing nurse workload and increasing patient safety, the following 
recommendations are made:  
 Avoid severely oedematous patients where fluid is likely to leak from ruptured skin  
 Waterproof CGM sensors  
 Reconsider insertion technique to lessen the risk of capillary damage   
 Wireless transmission between sensor and monitor unit for ease of patient mobility  
 
Before CGM can be used to guide glycaemic control protocols, the impact of suboptimal accuracy 
resulting from CGM error must first be characterised. The impact of CGM sensor error on the 
Stochastic TARgeted (STAR) GC protocol was then investigated using the simple CGM error model 
xii 
 
generated from the Sentrino data. Currently, the sensor technology trialled here is not accurate 
enough and if it was used to guide glycaemic control there would be a large increase in hypoglycaemic 
events with a median time below 4.4 mmol/L of 2.25%. In addition, the STAR protocol achieves very 
good and safe control already. Hence, improving the “safety” of the protocol is difficult with only 
1.35% time below 4.4 mmol/L. Potentially, a less successful glycaemic control protocol would display 
the greater benefit of the Sentrino guardrails and CGM in general.  
 
The glucose metabolism of athletes is not fully defined in current literature and nor are the effects of 
exercise on the overall glucose metabolism of athletes. There are only a few studies that investigate 
how metabolic parameters, such as endogenous glucose production change with exercise, and none 
that attempt to quantify endogenous insulin secretion or sensitivity during exercise.  Additionally, an 
individual’s tolerance of carbohydrate is highly variable and is related to a number of factors including 
age and genetics. CGM devices have the potential to personalise nutrition based on glucose response. 
Such research using continuous glucose monitors has not been undertaken in athletic subjects before.   
 
In a study of 10 sub-elite athletes, it was found hyperglycaemia persists >60 mins post exercise after 
race simulation exercise test. Plasma insulin and insulin secretion both peaked 60 mins post intense 
exercise to median cohort values of 256 pmol/L and 1150 pmol/min, respectively. These median peak 
values of plasma insulin and insulin secretion were approximately 5 and 9 times higher than the 
median fasting levels in this cohort, respectively. In general, this response is greater and more 
prolonged than reported in previous studies.  The most likely reason for this outcome is subjects 
received two glucose boluses, one during and immediately one post exercise, as per recommended 




From the same 10 athletes, a simple 1-dimensional model of endogenous insulin secretion was 
created, with an R2 = 0.53 and a glucose coefficient (a1) of 2559 mU.l/mmol.hr. The proposed model 
of endogenous insulin secretion, based on physiological measurements, provides a simple estimate of 
insulin secretion with comparable physiological parameters to existing literature.  
 
The successful Intensive Control Insulin-Nutrition-Glucose model was adapted to allow insulin 
sensitivity to be identified during and after exercise in a well-trained cohort. The model appeared to 
be best able to identify insulin sensitivity during steady state periods of exercise as insulin sensitivity 
(SI) trends in these periods match known physiology. However, when boluses were delivered non-
physiological jumps in SI occur as the model does not capture the highly patient-specific transient 
effects of glucose boluses, and non-constant rates of endogenous glucose production and/or non-
insulin mediated glucose uptake.  
 
The performance of CGM during exercise was investigated by comparing reference measurements to 
CGM data collected form the 10 subjects during the exercise test. During steady state exercise, all 
sensors performed better than results reported for diabetes cohorts with median MARD of 9.7%, 9.6% 
and 11.1% for each sensor analysed. Sensors agreed very well with each other with zero-lag cross-
correlation coefficients between 0.88 and 0.97 for the different sensor pairings. Overall, these results 
demonstrate the good accuracy and performance of CGM devices in active athletes while exercising, 
confirming the applicability of these monitors for use in this new domain.  
 
When the sensor glucose profiles of 10 athletes over a 6 day monitoring period 4/10 athletes studied 
spent more than 70% of the total monitoring time above 6 mmol/L even with the 2 hour period after 
meals removed. Only one participant spent substantial time below 4 mmol/L and this was largely due 
xiv 
 
to a significantly lower overall calorie intake compared to recommendations. This study provides a 
unique insight in to the day to day glucose levels of athletes that could only be achieved through the 
use of CGM devices highlighting the need for further investigation on the recommend diets of athletes 
to better determine the causes and impact of the hyperglycaemia seen on health and performance.   
 
Overall this research delineates the potential and pitfalls of using CGM to optimise blood glucose levels 
in ICU and athletes. In particular, it highlights areas that need to be improved before they can be relied 
upon to guide GC protocols in ICU. In addition, the ability to examine blood glucose trends over a 
longer period highlighted several aspects of the athlete metabolism that are contradictory to current 
literature. The results presented are promising for these devices in both fields. However, improvement 
in CGM sensor technology and further research is needed before CGM can be used to optimise 





Les dispositifs de monitoring continu de la glycémie (CGM) deviennent omniprésents chez les 
personnes atteintes du diabète de type 1 et de type 2. Cependant, ces dispositifs pourraient être 
avantageusement utiliser pour optimiser les niveaux de glucose dans le sang (BG) chez des individus 
sans diabète et dans des situations physiologiquement stressantes. Cette recherche porte sur les 
effets métaboliques de l'inflammation systémique et l'utilisation de ces capteurs de glucose 
émergents pour détecter les changements métaboliques pour une utilisation dans la surveillance 
assistée par ordinateur et l'aide à la décision. Plus précisément, ce travail étudie l'utilisation des 
capteurs CGM chez les patients critiques et les athlètes afin d'améliorer les performances du contrôle 
glycémique et d'optimiser l'apport nutritionnel. 
 
Les patients critiques présentent souvent des niveaux élevés de résistance à l'insuline et 
d'hyperglycémie induite par le stress, ce qui peut avoir un impact négatif sur les résultats cliniques. 
Des études ont montré que le contrôle glycémique (GC) peut réduire la mortalité des patients des 
soins intensifs (ICU). Cependant, il existe une difficulté importante dans la création de protocoles qui 
produisent un GC sans hypoglycémie excessive. Ainsi, les dispositifs de monitoring continu du glucose 
avec leur mesure toutes les 2-5 minutes offrent la possibilité de mieux surveiller les niveaux de BG et 
donc d'éviter l'hypoglycémie. 
 
Récemment, un dispositif CGM spécialement conçu pour les soins intensifs , le Sentrino (Medtronic, 
MiniMed, Northridge, Californie), est devenu disponible. Une étude à grande échelle a été développée 
à dans une unité médicale mixte de soins intensifs de l'hôpital de Christchurch pour recueillir de plus 
amples informations sur la faisabilité de l’utilisation de CGM aux soins intensifs. Tout d'abord, nous 
avons analysé les performances du système Sentrino CGM aux soins intensifs. Les données de CGM et 
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de BG ont été recueillies auprès de 13 patients recrutés lors de la phase 1 de l'essai. Le dispositif 
Sentrino a obtenu une moyenne absolue des différences relatives (MARD) de 14,7%. Dans l'ensemble, 
la performance du Sentrino était acceptable, mais il exigeait des mesures d'étalonnage toutes les 4 
heures en moyenne. Par conséquent, des questions demeurent pour savoir si ce système CGM peut 
réduire le temps et le coût de la charge de travail du contrôle glycémique. 
 
La phase IIA était une étude observationnelle de la performance et de l'intégration des alarmes hyper-
hypo-glycémiques avec un protocole existant et vérifié de GC. Cette étude a analysé les données des 
capteurs de glucose (SG) et du BG, et les données d'alarme de 8 patients recrutés pour cette cette 
phase de l'essai. Dans l'ensemble, les performances des capteurs et des alarmes étaient bonnes, 
seules 32/93 alarmes ont nécessité un étalonnage en raison d'une différence significative entre SG et 
BG. Cependant, il y avait un taux élevé de faux positifs avec 27/29 alarmes hypoglycémiques qui 
étaient des faux positifs. 
 
Une analyse a été entreprise afin de mieux comprendre l'impact du sepsis, de l'œdème et de certains 
médicaments sur les résultats des CGM, ainsi que pour évaluer la compliance des infirmières pour 
mieux comprendre l'impact clinique de l'utilisation des CGM pour guider le GC. Cette analyse a utilisé 
les données de 21 patients des Phase I et Phase IIA. Environ 50% de tous les sujets étaient sévèrement 
œdémateux et / ou septiques. Pour que les CGM puissent permettre de réduire la charge de travail 
des infirmières et augmenter la sécurité des patients, les recommandations suivantes sont faites: 
 Évitez les patients sévèrement œdémateux où du fluide risque de fuir en cas de rupture de la 
peau 
 Capteurs CGM étanches 
 Reconsidérer la technique d'insertion pour diminuer le risque de dommages capillaires 
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 Transmission sans fil entre capteur et unité de surveillance pour faciliter la mobilité des 
patients 
 
Avant que les CGM puissent être utilisés pour guider les protocoles de contrôle glycémique, l'impact 
de la précision sous-optimale résultant de l'erreur des CGM doit tout d'abord être caractérisé. L'impact 
de l'erreur du capteur CGM sur le protocole de Stochastic TARgeted (STAR) GC a ensuite été étudié en 
utilisant le modèle d'erreur simple généré à partir des données Sentrino. Actuellement, la technologie 
des capteurs testés ici n'est pas suffisamment précise et si elle était utilisée pour guider le contrôle 
glycémique, il y aurait une forte augmentation des hypoglycémies avec un temps médian inférieur à 
4,4 mmol/L de 2,25%. De plus, le protocole STAR permet déjà un contrôle très efficace et sûr. Par 
conséquent, l'amélioration de la «sécurité» du protocole est difficile avec seulement 1,35% de temps 
en dessous de 4,4 mmol/L. Potentiellement, un protocole de contrôle glycémique moins efficace 
afficherait un plus grand bénéfice de l’utilisation du Sentrino et des CGM en général. 
 
Le métabolisme du glucose des athlètes ainsi que les effets de l'exercice sur ce dernier ne sont pas 
parfaitement caractérisés dans la littérature. Il existe seulement quelques études qui étudient 
comment les paramètres métaboliques, tels que la production endogène de glucose changent avec 
l'exercice, et aucune n’essaye de quantifier la sécrétion endogène d’insuline ou la sensibilité à 
l’insuline pendant l'exercice. En outre, la tolérance d'un individu à l'égard des glucides est très variable 
et est liée à un certain nombre de facteurs, tels que l'âge et la génétique. Les dispositifs de CGM offrent 
la possibilité de personnaliser la nutrition en se basant sur la réponse glycémique. Une telle recherche 




Dans une étude sur 10 athlètes, il a été constaté que l'hyperglycémie persiste> 60 minutes après 
l'exercice après le test de simulation de course. L'insuline plasmatique et la sécrétion d'insuline ont 
tous deux atteint un maximum 60 minutes après un exercice intensif, avec des valeurs médianes de 
cohorte de 256 pmol/L et 1150 pmol/min, respectivement. Ces valeurs médianes du pic de l'insuline 
plasmatique et de la sécrétion d'insuline étaient respectivement environ 5 et 9 fois plus élevées que 
les niveaux médians à jeun dans cette cohorte. En général, cette réponse est plus grande et plus 
longue que celle rapportée dans des études antérieures. La raison la plus probable de ce résultat est 
que les sujets ont reçu deux bolus, un pendant et un immédiatement après l'exercice, selon les 
directives nutritionnelles recommandées pour la compétition tandis que dans d'autres études les 
athlètes sont restés à jeun. 
 
A partir de ces mêmes 10 athlètes, nous avons créé un modèle simple unidimensionnel de la sécrétion 
d'insuline endogène, avec un R2 = 0,53 et un coefficient de glucose (a1) de 2559 mU.l/mmol.hr. Le 
modèle proposé de sécrétion d'insuline endogène, basé sur des mesures physiologiques, fournit une 
estimation simple de la sécrétion d'insuline avec des paramètres physiologiques comparables à la 
littérature existante. 
 
Le modèle de contrôle intensif d'insuline-nutrition-glucose a été adapté pour permettre 
l'identification de la sensibilité à l'insuline pendant et après l'effort. Le modèle semblait être le plus 
apte à identifier la sensibilité à l'insuline pendant les périodes d'exercice à l'état d'équilibre, car les 
tendances de la sensibilité à l'insuline (SI) pendant ces périodes correspondent à une physiologie 
connue. Cependant, lorsque des bolus ont été administrés, des sauts de SI non physiologiques 
apparaissent car le modèle ne capture pas les effets transitoires hautement patient-spécifiques des 
bolus de glucose et des taux non constants de production de glucose endogène et/ou d'absorption de 
glucose non insulinodéprimée. 
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La performance des CGM pendant l'exercice a été étudiée en comparant les mesures de référence aux 
données de CGM recueillies sur 10 sujets pendant le test d'exercice. Au cours de l'exercice en régime 
permanent, tous les capteurs ont obtenu de meilleurs résultats que ceux rapportés pour les cohortes 
de diabètes avec une DMAR médiane de 9,7%, 9,6% et 11,1% pour chaque capteur analysé. 
Globalement, ces résultats démontrent la bonne précision et la performance des dispositifs CGM chez 
les athlètes actifs pendant l'exercice, ce qui confirme l'applicabilité de ces moniteurs pour l'utilisation 
dans ce nouveau domaine. 
 
Les profils de glucose des capteurs des 10 athlètes sur une période de surveillance de 6 jours montrent 
que 4/10 athlètes étudiés ont passé plus de 70% du temps de surveillance totale au-dessus de 6 
mmol/L même en enlevant la période de 2 heures après les repas. Un seul participant a passé 
beaucoup de temps en dessous de 4 mmol/L, ce qui s'explique en grande partie par un apport 
calorique global nettement inférieur aux recommandations. Cette étude fournit un aperçu unique sur 
l’évolution quotidienne des niveaux de glucose des athlètes qui ne pouvait être obtenue sans 
l'utilisation de dispositifs CGM. Elle souligne également la nécessité d'une analyse plus approfondie 
des régimes recommandé aux athlètes pour mieux déterminer les causes et l'impact de 
l'hyperglycémie sur leur santé et leur rendement. 
 
En conclusion, cette recherche étudie les avantages et les inconvénients de l'utilisation de CGM pour 
optimiser la glycémie chez les patients critiques et chez les athlètes. En particulier, elle met en 
évidence les domaines qui doivent être améliorés avant que les CGM ne puissent être utilisés pour 
guider les protocoles de GC auxsoins intensifs. De plus, la capacité d'examiner les tendances de la 
glycémie sur une période plus longue met en évidence plusieurs aspects du métabolisme des athlètes 
qui sont en contradiction avec la littérature actuelle. Les résultats présentés dans ce travail sont 
prometteurs  dans ces deux cohortes de patients extrêmes. Toutefois, l'amélioration de la technologie 
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des capteurs CGM et de nouvelles recherches sont nécessaires avant que les CGM ne puissent être 






Chapter 1. Introduction 
Continuous glucose monitoring (CGM) devices are becoming ubiquitous in the care of type 1 and 
type 2 diabetes (T1DM and T2DM) (Breton et al., 2008, Klonoff, 2005a, Klonoff, 2005b). However, to 
a lesser extent, these devices could have further benefit in optimising blood glucose (BG) levels and 
related aspects in individuals without diabetes in physiologically stressful situations. This research 
centres on the metabolic effects of systemic inflammation and the use of these emerging glucose 
sensors to detect these changes for use in computer aided monitoring and decision support. It thus 
seeks to broaden approaches to metabolic care and management through the model-based analysis 
of this metabolic impact. Specifically, this work investigates the use of CGM sensors in critically ill 
patients and endurance athletes to improve performance of glycaemic control and optimise nutrition 
delivery.  
 
Critically ill patients can behave similarly to individuals with diabetes resulting in high blood glucose 
levels, hyperglycaemia, and insulin resistance due the bodies stress response to trauma or illness 
(Capes et al., 2000, Finney et al., 2003, Krinsley, 2003, McCowen et al., 2001, Mizock, 2001, Umpierrez 
et al., 2002, Van den Berghe et al., 2001). This metabolic response can negatively impact outcomes 
and increase the length of patient stay in the intensive care unit (ICU) (Capes et al., 2000, Finney et 
al., 2003, Krinsley, 2003, Bistrian, 2001, Van den Berghe et al., 2001). Studies have shown that 
controlling blood glucose levels to a more normal range can reduce ICU patient mortality (Van den 
Berghe et al., 2001, Van den Berghe et al., 2006, Krinsley, 2004, Chase et al., 2008b). However, there 
is difficulty in creating protocols that produce good control of glucose levels without excessive low 
blood glucose, hypoglycaemia, and a significant increase in nursing workload. Thus, continuous 
glucose monitors with their 2-5 minute measurement provide the opportunity to better monitor BG 
levels so hypoglycaemia can be avoided.  
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Typically in critical care situations, BG is measured 1-4 hourly and more frequently only if the levels 
are hypoglycaemic or nearly so. More frequent measurement is uncommon due to the clinical effort 
required in a very busy clinical environment (Mackenzie et al., 2005, Chase et al., 2008a, Carayon et 
al., 2005). The result can be extremely variable glycaemic control, especially with longer measurement 
intervals (Chase et al., 2011, Lonergan et al., 2006b). Thus, CGM may allow BG levels to be managed 
more successfully, while minimizing glycaemic variability and reducing nurse work load (Krinsley, 
2008, Egi et al., 2006, Signal et al., 2010). 
 
There have been relatively few successful investigations of CGM devices in critical care (Goldberg et 
al., 2004, Holzinger et al., 2010, Signal et al., 2013). In particular, one set of glycaemic control (GC) 
trials using CGM technology was not particularly successful due, in part, to significant sensor noise and 
error (Chee et al., 2003a, Chee et al., 2003b). Another more recent observational study highlighted 
the potential of CGM in ICU patients, but concluded that further understanding of factors that alter 
CGM performance is required before glycaemic control can be realized (Signal et al., 2013). Hence, 
they have not been successfully applied in critical care outside of use in monitoring glucose levels and 
to reduce hypoglycaemia in adults and neonates (Harris et al., 2010, Holzinger et al., 2010). There are 
a number of reasons for this that are addressed in this work. More specifically, they are not part of 
standard care and not use outside of research at this time. 
 
Critical illness, some forms of diabetes, and athletic activity all share a common factor of systemic 
inflammation due to their condition or induced by strenuous effort. Hyperglycaemia is an 
inflammatory marker (Collier et al., 2008) and blood glucose variability is a known risk factor in T2DM 
(Monnier et al., 2006, Brownlee et al., 2006). The immune system also fails to function optimally in 
the presence of high blood glucose levels (Sanchez et al., 1973, Marik et al., 2004, Jeandidier et al., 
2006, Turina et al., 2005, Kijak et al., 1964). For example, a single 100g dose of glucose and resulting 
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hyperglycaemia can significantly impair the immune system for more than 5 hours (Sanchez et al., 
1973, Kijak et al., 1964).  Normoglycaemia is, thus, important for general health and well-being, and 
thus potentially equally or more important to a competitive athlete. Hence, well controlled glucose 
level through correct nutritional inputs during training, racing and recovery could play a critical role in 
athletic results.  
  
Studies comparing the metabolic and hormonal response to exercise between trained and untrained 
normal glucose tolerant individuals have found glucose, glycerol and free fatty acid concentrations are 
higher but lactate, pyruvate and alanine were lower in trained individuals, compared to untrained 
individuals (Kjaer et al., 1986, Bloom et al., 1976). Cortisol levels were also higher in trained individuals 
(Bloom et al., 1976). In addition, insulin secretion is diminished in well-trained individuals due to 
increased insulin sensitivity (Lohmann et al., 1978). Together, these results suggest there is significant 
adaptation to the metabolism of well-trained individuals. However, only a few studies investigate how 
metabolic parameters such as endogenous glucose production (EGP) or endogenous insulin secretion, 
change with exercise (Rossi et al., 2010, Levitan et al., 2004, American Diabetes, 2010, Kretowski et 
al., 2015, Gallwitz, 2009, Jee et al., 2005). Further, none attempt to quantify insulin sensitivity, the 
metabolic exchange between insulin and glucose uptake for storage or energy, during exercise.   
 
CGM can thus potentially be employed to enable optimal nutrition delivery using a similar model-
based approach as has been successfully used in critically ill patients and individuals with diabetes (Lin 
et al., 2011, Wong et al., 2008a, Chase et al., 2006, Bergman et al., 1981, Hovorka et al., 2008, Mari et 
al., 1997, Wong et al., 2008b, Bergman et al., 1979, Cobelli et al., 1984). CGM also has the potential to 
aid an athlete’s decision making on when and what to consume during different stages of training, 
racing and recovery, by providing information on BG levels in a minimally-invasive manner. Using this 
data, this work extends proven metabolic modelling (Lin et al., 2011) and CGM research in critical 
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illness (Signal et al., 2013) into the sporting domain to see if model-based inulin sensitivity can capture 
effort and recovery in endurance athletics.  Such research, particularly using continuous glucose 
monitors, has not been undertaken in athletic subjects before. However, the ability to have real time 
knowledge of blood variables, such as blood glucose, is noted as the “future’ of sports technology 
(Gizmag Team, 2007, Metz, 2014).  
 
This research has a twofold pathway. The first investigates, develops, and validates methods and 
algorithms to combine CGM data with validated models of patient physiology in intensive care to 
provide tighter, safer glycaemic control with reduced clinical effort. The second pathway reworks 
these existing metabolic models to create a more general metabolic modelling system and approach, 
and, in doing so, to more specifically produce ‘athlete like’ insulin sensitivity models. These models 
could then be used to investigate, simulate and validate optimal nutrition delivery based on CGM data 
for athletes during training, recovery and racing.  
 
Main Hypothesis: Systemic inflammation in extreme cases (effort and illness) causes metabolic impact 
and this impact can be captured and modulated via metabolic models coupled with high-resolution 
BG data. The goal is to determine if that the benefits of a fundamental model of metabolic dynamics 
can be translated from the ICU to the playing field. 
 
1.1 Preface 
This  thesis  is  presented  in  two  parts:  Part  I  investigates  the  use  of  CGM  in critically ill adults, 
in the ICU and,  Part II  investigates the use of CGM in competitive athletes. The chapters in this thesis 




Part I – CGM in ICU  
Chapter 2 provides an in-depth background on stress-induced hyperglycaemia in intensive care 
patients and an overview over this is currently managed, before the way CGM can potentially optimise 
blood glucose is control methods in ICU is discussed. 
 
Chapter 3 presents the result of Phase I of the Sentrino trial, a trial designed to test the latest CGM 
device designed for the ICU environment. Phase I investigated the performance of the device in an 
observational trial of 13 patients in Christchurch ICU.  
 
Chapter 4 presents the results of Phase IIA of the Sentrino trial. Phase IIA investigated the 
performance of hyper- and hypo- glycaemic alarms in 8 patients in Christchurch ICU.  
 
Chapter 5 discusses the factors that influence the success of CGM in the ICU and important issues that 
must be addressed before CGM can be relied upon in this setting.  
 
Chapter 6 creates and validates a model of CGM dynamics so that the feasibility of using CGM to drive 
glycaemic control protocols can be tested in-silico. 
 
Chapter 7 presents virtual simulations using the CGM model developed in Chapter 6 to drive the 
existing STAR glycaemic control protocol and discusses the achievability of using the current sensor 




Chapter 8 summaries the research on CGM in ICU patient, presented in Chapters 2 – 7. 
 
Part II – Glucose metabolism and CGM in Athletes  
Chapter 9 provides a detailed background of the current literature about the glucose metabolism 
during exercise, before the prospective benefits of CGM in athletes are considered. 
 
Chapter 10 investigates the extended period of hyperglycaemic and hyperinsulinemia seen post 
exercise when nutritional guidelines are followed during an exercise test in 10 trained subjects.  
 
Chapter 11 presents a model of endogenous insulin secretion during and immediately post exercise 
for well trained subjects.  Material in Chapter 11 has been presented as: Thomas, F, Pretty, CG, 
Stewart, K, Shaw, GM, Desaive, T and Chase, JG (2016). “A Model of Endogenous Insulin Secretion 
during Exercise,” 16th Annual Diabetes Technology Meeting (DTM), Bethesda, MD, USA, November 10-
12, 1-page. (Bronze Award) 
 
Chapter 12 attempts to create a model of insulin sensitivity for athletes during and immediately after 
exercise based on the successful Intensive Control Insulin-Nutrition-Glucose model designed for 
glycaemic control in the ICU.  
 
Chapter 13 presents the results of a study investigating the accuracy and performance of CGM devices, 
designed for individuals with Type 1 and Type 2 diabetes, in 10 well trained subjects to justify their 
use in this cohort. Material in Chapter 13 has been published in: Thomas, F., Pretty, C.G., Signal, M., 
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Shaw, G. and Chase, J.G., 2017. Accuracy and performance of continuous glucose monitors in 
athletes. Biomedical Signal Processing and Control, 32, pp.124-129. 
 
Chapter 14 presents the results from 6 days of CGM in 10 subelite athletes and investigates the 
potential of using CGM to improve athletes’ dietary habits. Material in Chapter 14 has been published 
in: Thomas, F., Pretty, C.G., Desaive, T. and Chase, J.G., 2016. Blood Glucose Levels of Subelite 
Athletes During 6 Days of Free Living. Journal of Diabetes Science and Technology, 
p.1932296816648344. 
 
Chapter 15 summarises the research on the glucose metabolism during exercise and CGM in athletes 
presented in Chapters 9 – 14. 
 











Part I – CGM in ICU   
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Chapter 2. Background CGM in the Intensive Care Unit  
This chapter provides background on the possible causes and effects of hyperglycaemia in critically ill 
patients. The importance of glycaemic control (GC) to regulate this hyperglycaemia is explained and the 
risks associated with GC are also considered. Finally, the potential application of CGM devices for GC in 
the intensive care unit (ICU) is reviewed. In particular, their potential to enhance the safety and efficacy 
of GC protocols, thus assessing their ability to mitigate key risks of GC, and enhance its performance.   
 
2.1 Hyperglycaemia and glycaemic control in critically ill patients 
Critically ill patients often experience high levels of insulin resistance (Capes et al., 2000, Finney et al., 
2003, Krinsley, 2003, McCowen et al., 2001, Mizock, 2001, Umpierrez et al., 2002, Van den Berghe et al., 
2001) leading to stress-induced hyperglycaemia, which negatively impacts outcomes (Capes et al., 2000, 
Finney et al., 2003, Krinsley, 2003, Bistrian, 2001, Van den Berghe et al., 2001). Stress-induced 
hyperglycaemia is prevalent in critical care, and can occur in patients with no history of diabetes (Capes 
et al., 2000, Van den Berghe et al., 2001, Mizock, 2001, McCowen et al., 2001). Hyperglycaemia worsens 
outcomes in these patients, leading specifically to further risk of complications, including sepsis (Bistrian, 
2001), myocardial infarction (Capes et al., 2000), polyneuropathy, and multiple organ failure (Van den 
Berghe et al., 2001).  
 
The principal cause of stress-induced hyperglycaemia is heightened levels of counter-regulatory 
hormones, released in response to critical illness (McCowen et al., 2001). Critically ill patients can 
experience a significant increase in several hormones including glucagon, growth hormone, 
catecholamines and glucocorticoids in response to physiological stress (Turina et al., 2005). These 
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hormones increase glucose production by stimulating the metabolic pathways for gluconeogenesis, 
glycogenolysis and lipolysis.  Gluconeogenesis  is  the creation of  glucose  from  lactic  acid  and  certain  
amino  acids,  glycogenolysis  is  the breakdown of glycogen stored in the liver into glucose, and lipolysis 
is the breakdown of lipids into smaller molecules, including glycerol, which is then converted into glucose 
by  the  liver.  This dysregulation of endogenous glucose production causes blood glucose levels to rise. In 
particular, the hormonal action raises glucose levels by blocking normal regulatory behaviours that reduce 
glucose production when glucose levels are elevated.  Finally, these hormones also increase insulin 
resistance by reducing the ability of cells to absorb glucose through insulin mediated pathways, as well as 
by inhibiting insulin secretion despite high glucose levels, resulting in further amplified BG concentration 
(Chase et al., 2011, Gearhart et al., 2006).  
 
In addition, some medications and therapies commonly used in the ICU can increase the severity of 
hyperglycaemia. Glucocorticoid  steroids,  the catecholamines epinephrine and norepinephrine, and β-
blockers have all been shown to reduce  insulin  sensitivity (SI)  and increase EGP,  thus can  increase  BG  
levels  in  critically  ill  patients (Pretty et al., 2011, Binnert et al., 2004, Perry et al., 2003, Larsson et al., 
1996, Nicod et al., 2003, Pagano et al., 1983). Other sources that increase BG levels in these patients with 
reduced SI include excess calories from parenteral and enteral nutrition, as well as dextrose infusions used 
for fluid resuscitation and drug delivery (Mizock, 2001, Nylen et al., 2004). Finally, the pro-inflammatory 
immune response heightens glucose levels similarly to catecholamines (Weekers et al., 2003, Marik et al., 
2004). Hence, the overall system can act strongly, via several pathways, with positive feedback loops, to 




Untreated hyperglycaemia, over a long time period such as 10 – 20 years, can lead to costly complications 
such as retinopathy, cataracts, ulcers, skin infections, heart disease, peripheral vascular disease, 
cerebrovascular disease and neuropathy (Bistrian, 2001, Capes et al., 2000, Van den Berghe et al., 2001, 
Barrett-Connor et al., 1988, Alberti et al., 1998, Livingstone et al., 2003, Ben-Mahmud et al., 2006). The 
immune system also fails to function optimally in the presence of high blood glucose levels (Marik et al., 
2004, Jeandidier et al., 2006, Turina et al., 2005, Weekers et al., 2003). In particular, at a blood glucose 
level of 8 mmol/L, the immune response is only 50% or less effective than at normal levels, and at 10 
mmol/L the immune response is essentially completely ineffective (Weekers et al., 2003). An ineffective 
immune response for an ICU patient can have significant consequences, as they are unable resist common 
bacterial or viral infections. In addition, a less effective response to infection may prolong illness and the 
hyperglycaemic, pro-inflammatory, immune response. Hence, controlling blood glucose to within a 
normoglycaemic range, preferably less than 8mmol/L, has the potential to speed recovery and decrease 
negative outcomes associated with hyperglycaemia.  
 
The first randomised control trial (RCT) to demonstrate that GC can improve patient outcomes was Van 
den Bergh et al. (2001). This RCT showed  tight  blood glucose  control  to  less  than  6.1  mmol/L  reduced  
mortality  in cardiac  surgical  ICU  patients  by 18-45%. Krinsley (2004) then reported in a retrospective 
study a 17–29%  total  reduction  in  mortality  over  a  wider,  more  critically  ill,  ICU population with a 
higher glucose limit of 7.75 mmol/L. In 2006 Van den Bergh et al. (2006) again reported positive results 
with reduced morbidity and mortality in patients who stayed in the ICU > 3 days.  A further retrospective 
study modulated insulin and nutrition to reduce both mortality and hypoglycaemia (Chase et al., 2008b). 
However, repeating these positive results indicating GC reduced mortality and improved other outcomes 
has been difficult (Griesdale et al., 2009). 
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Other large scale studies have shown conflicting results and a concerning increase in hypoglycaemia in 
glycaemic control cohorts (Brunkhorst et al., 2008, Finfer et al., 2009, Preiser et al., 2009, Treggiari et al., 
2008, De La Rosa et al., 2008, Finfer et al., 2008, Griesdale et al., 2009). These results are a side effect of 
poor glycaemic control protocols and a lack of understanding of the blood glucose dynamics. Patients can 
be highly variable and unless this variability is understood there is a risk of causing hypoglycaemic events 
and large fluctuations in glucose when treating patients with insulin. 
 
Hypoglycaemic and glycaemic variability have been independently linked to mortality in critically ill 
patients. In particular, Bagshaw et al (2009)  showed variability and hypoglycaemia with in the first 24 
hours of ICU stay are each associated with increased mortality and two other studies have reiterated this 
finding (Egi et al., 2006, Krinsley, 2008) .  Thus, much controversy still surrounds GC and its application in 
the ICU, even though the need to safely lower and reduce the variability of blood glucose levels is well-
known and widely accepted. 
 
The biggest challenge surrounding the application of GC in the ICU is achieving a generalizable protocol 
that can reduce hyperglycaemia and avoid hypoglycaemia, while requiring minimal nurse effort. An ideal 
protocol is difficult to achieve due to significant inter-patient variability in illness and response to insulin 
treatment (Chase et al., 2011, Lin et al., 2008, Suhaimi et al., 2010, Pretty et al., 2012) , as well as significant 
intra-patient variability as patient condition evolves over time (Pretty et al., 2012, Lin et al., 2006, Lin et 
al., 2008) . If this variability is not accounted for, especially with protocols that utilize large insulin doses, 
high glycaemia variability and/or excessive hypoglycaemia is likely to occur making it difficult to show the 




Regular, intermittent BG measurements are used to diagnose hyperglycaemia in the ICU. However, 
diagnostic criteria and levels can vary between intensive care units.  Typically, 1-2 consecutive BG 
measurements above a threshold of 8 – 10mmol/L is considered hyperglycaemia (Singer et al., 2009, 
Umpierrez et al., 2012). 
 
ICU glycaemic control protocols typically rely on intravenous insulin and require blood glucose 
measurements every 1-4 hours (Evans et al., 2012, Lonergan et al., 2006a, Plank et al., 2006, Blaha et al., 
2009, Stewart et al., 2016), resulting in approximately 12-16 blood draws a day per patient. More frequent 
measurement, is uncommon due to the clinical effort required (Mackenzie et al., 2005, Chase et al., 2008a, 
Carayon et al., 2005), particularly because these blood draws represent a significant part of nurse 
workload (Carayon et al., 2005, Holzinger et al., 2005). However, longer measurement intervals coupled 
with suboptimal insulin doing protocols can also lead to increased glycaemic variability  (Lonergan et al., 
2006b). Hence, more frequent measurement could aid control quality and safety, given a safe, effective 
insulin protocol, if it didn’t significantly increase nursing burden.  
 
2.2 The continuous glucose monitoring system and use in the critically ill  
Continuous glucose monitoring (CGM) devices were first developed in the 1980’s to help individuals with 
type 1 diabetes manage their glucose levels. The first CGM device available was the Minimed Continuous 
Glucose Monitoring System (CGMS system gold, Medtronic, MiniMed, Northridge, California), which was 
approved for commercial use by the Food and Drug Administration in 1999 (Rebrin et al., 1999). There are 
now a range of different systems available to individuals with type 1 and type 2 diabetes individuals (T1DM 





Figure 2.1 Guardian Real-Time CGM System, Medtronic, MiniMed, Northridge, California 
 
Most CGM devices consist of a small pager-like monitoring device that receives information from a sensor 
inserted into the subcutaneous layer, just beneath the skin (Rebrin et al., 1999). For the device in Figure 
2.1, the platinum sensor produces a small electrical current as glucose in the interstial fluid is oxidised. 
The sensor is coated with a flux limiting glucose-oxidase membrane, which limits the flow of glucose in 
interstitial fluid to the electrode and thus provides a stable calibration between current and local glucose 
concertation. The monitor samples the electrical current every minute and a 1 - 5 minute average glucose 
estimate is stored in the monitor (~288 measurements per day). Some devices are known to have a fixed 
10 minute time delay for every sample to account for the transport of glucose from the blood to the 
interstitial fluid, and thus enable direct comparison to blood - based measurements (Rossetti et al., 2010). 
This overall method of operation is typical of most CGM devices (Medtronic MiniMed, 2006, Medtronic 




These sensors require calibration by the user. This calibration is achieved by taking a blood glucose 
measurement with a point of care device, usually a glucometer, and entering it in to the CGM device. The 
device then knows what current correlates to what blood glucose level. These devices are recommended 
to be calibrated 2-4 times per day for best performance, depending on the specific device, and calibration 
is typically required at least every 12 hours for the device to continue recording sensor glucose (SG) values. 
 
Thus, CGM devices, with their 1-5 minute measurement interval (Girardin et al., 2009), may allow BG 
levels to be managed more successfully, while minimizing glycaemic variability  (Krinsley, 2008, Egi et al., 
2006) and reducing nurse work load (Signal et al., 2010, Holzinger et al., 2010). However, CGM devices 
have shown suboptimal accuracy resulting from error or delay in calibration measurement, sensor drift 
and delayed glucose diffusion (Facchinetti et al., 2014, Reifman et al., 2007, Kuure-Kinsey et al., 2006, 
Zimmermann et al., 2012). There have been relatively few successful investigations of CGM in critical care 
use (Goldberg et al., 2004, Holzinger et al., 2010). In particular, one set of GC trials using CGM technology 
was not particularly successful due, in part, to significant sensor noise (Chee et al., 2003a, Chee et al., 
2003b). Hence, they have not been successfully applied as a standard of care in critical care, outside of 
use in specific studies monitoring glucose levels and to reduce hypoglycaemia in adults and neonates 
(Harris et al., 2010, Holzinger et al., 2010). 
 
However, several more recent in-silico studies (Signal et al., 2010, Mombaerts et al., 2015) and a recent 
pilot observational trial (Signal et al., 2013) have shown CGM devices, when coupled with a well-designed 
GC protocol, offer several potential benefits over the standard practice of intermittent, 1-4 hourly, BG 
monitoring. These studies show CGM devices have the ability to reduce hypoglycaemia, maintain BG 
control and reduce nurse workload. However, these studies and several others have also raised several 
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potential issues relating to using CGM in the ICU, especially the reduced accuracy achieved compared to 
that seen in T1DM and T2DM (Vlkova et al., 2009, Brunner et al., 2011, Rabiee et al., 2009, Signal et al., 
2013), which would impact the GC protocol using these measurements.  
 
All of the devices studied in ICU settings so far have been off-the-shelf CGM devices designed and intended 
for use by T1DM and T2DM to aid in BG management. The fact they are not designed specifically for the 
ICU environment makes them vulnerable to interference from certain medications, treatments and 
therapies, all which can vary significantly between critical care centres.  
 
The previously mentioned pilot observational study highlighted the potential of CGM in ICU patients, but 
concluded that further understanding of factors that alter CGM performance is required before glycaemic 
control in the ICU could be realized (Signal et al., 2013). In particular, it highlighted a number of issues 
that could affect sensor performance in this cohort including, serve oedema, sepsis, and certain drugs or 
therapies. Several other studies also highlighted how patient condition may affect sensor performance in 
the ICU including the effect of sepsis and septic shock (Lorencio et al., 2012, Holzinger et al., 2010, 
Holzinger et al., 2009). 
 
 In  addition,  certain  medications/therapies  commonly  used  in  the ICU,  such  as  paracetamol,  can  
influence  CGM  device  performance (Moser et al., 2010). Contrary to expectations, commonly used 
vasoactive medications, such as dopamine, norepinephrine, ketanserin, enoximone, and nitro-glycerine, 
are reported to have little or no effect on the accuracy of at least one type of glucose sensor (Holzinger et 
al., 2009).   Muscle trauma or surgery has potential to impact sensor performance. Klueh et al. (Klueh et 
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al., 2010, Klueh et al., 2014) demonstrated how cytokine expression is related to sensor function with 
increased inflammation and decreased sensor function in mice deficient in interleukin-1-receptor-
anagonist cytokine. Muscle trauma, which is common cause of admission in the ICU, is known to alter 
cytokine expression (Jackson et al., 2011). Hence, there are several further potential factors inhibiting 
typical CGM sensor performance in ICU that do not exist in T1DM and T2DM. 
 
Finally, the severity of illness encountered and therefore the level of dysregulation of BG is a further 
challenge for these devices. However, a real-time device specifically designed for the ICU recently became 
available, The Sentrino (Medtronic, MiniMed, Northridge, California), and has displayed promising results 
in initial trials with in the cardiac ICU (Kosiborod et al., 2013) . Hence, a large scale study was designed for 
implementation in Christchurch Hospital ICU. The following chapters investigate using the Sentrino CGM 
devices in adult ICU, with the over goal of improving BG control and increasing patient safety, while 





Chapter 3. The Sentrino Trials – Phase I   
A recent observational study highlighted the potential of CGM in ICU patients, but also concluded that 
further understanding of factors that alter CGM performance is required before glycaemic control in the 
ICU could be realized (Signal et al., 2013). Therefore, a larger scale study was designed to investigate the 
performance of the latest available CGM device specifically designed for the ICU environment, the 
Sentrino (Medtronic, MiniMed, Northridge, California). The trial was designed and undertaken in 2 phases 
that were run partially in parallel. The aim of this study was to investigate the performance of these new 
devices first observationally to ensure the safety and efficacy of their performance (Phase I), then a further 
observational study the performance and integration of hyper- and hypo- glycaemic alarms (Phase IIA). 
Finally, the design and implementation of a protocol using CGM values to guide glycaemic control (GC) 
(Phase IIB). This chapter discusses the results of Phase I of the Sentrino Trials focusing on the overall device 
performance and impact of sensor site on results.  
 
3.1 Introduction  
Several in-silico studies (Signal et al., 2010, Mombaerts et al., 2015) and a recent pilot observational trial 
(Signal et al., 2013) have shown that CGM devices, when coupled with a well-designed GC protocol, offer 
several potential benefits over the standard practice of intermittent BG monitoring to guide GC. These 
studies show that CGM devices have the ability to reduce hypoglycaemia, maintain BG control and reduce 
nurse workload. However, these studies and several others have also raised several potential issues 
relating to using CGM in the ICU, especially the reduced accuracy compared to that seen in individuals 




All of the devices studied so far in ICU settings have been off-the-shelf CGM devices designed and intended 
for use by T1DM and T2DM to aid BG management. The fact they are not designed specifically for the ICU 
environment make them vulnerable to interference from certain medications, treatments, and therapies, 
all which vary between critical care centres.  Additionally, the servery of illness encountered, and 
therefore the level of dysregulation of BG, is a further challenge for these devices. However, a real-time 
device specifically designed for use in the ICU recently became available, the Sentrino (Medtronic, 
MiniMed, Northridge, California). This device has displayed promising results in initial trials in the cardiac 
ICU (Kosiborod et al., 2013) . Hence, a large scale study was designed for implementation in Christchurch 
Hospital ICU. The first step in this study (Phase I) was to validate the performance of these devices in a 
mixed-medical ICU and confirm the optimal sensor location.  
 
3.2 Subjects and Methods 
3.2.1 Subjects 
This study uses data from an observation pilot study of CGM in patients admitted to the Christchurch 
Hospital ICU during 2014. CGM and BG data were gathered from 13 patients who were recruited to this 
phase of the trial. All patients were recruited  by a  physician in the  ICU,  and informed written  consent 
was  obtained from the next  of  kin  if  the  patient  was  unable  to  consent, and follow up consent was 
obtained from the patient at a later date if applicable.   
 
Inclusion  criteria   for this study were  two consecutive  BG  measurements  greater  than  8 mmol/L,  
indicating  the  need  for insulin  therapy  using  the  local standard of care, the Stochastic TARgeted (STAR) 
GC protocol (Evans et al., 2012), expected length of stay of at least 3 days, over 18 years of age, and with 
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a platelet count > 30,000/mL.  Patients were excluded from the trial if they were not expected to survive, 
receiving Hydroxyurea, pregnant, and/or lacked clinical equipoise. This study and use of  data  was  
approved  by  the  Upper  South  A  Regional  Ethics  Committee,  New Zealand. Table 3.1 shows the patient 
demographics. 
 
Table 3.1 Patient Demographics data presented as median [interquartile range (IQR)] where appropriate.  
Patients  13 
Ages (years) 59 [57 – 62] 
Sex (M/F) 8/5 
APACHE II 17 [16 – 22] 
APACHE III 67 [50 – 87] 
SAPS II 42 [35 – 51] 
ICU admission (days) 21 [11 – 25] 
Outcome (Lived/Died) 9/4 
Diabetes (None/T1/T2) 10/0/3 
 
 
3.2.2 Continuous glucose monitoring  
Each participant in this phase of the study was monitored concurrently for a period of up to 3 days with 2 
independent CGM devices, the Sentrino (Medtronic, MiniMed, Northridge, California) CGM system. This 
device is specifically designed for ICU conditions and consists of the set up shown in Figure 3.1. The CGM 
system comes in three parts, a disposable dual filament sensor, a cable to transit the sensor signal and a 
touch screen monitor.  The underside of the sensor can be seen in Figure 3.2. The sensor in inserted 
manually using two hollow needles that encase the sensor filaments and then retract once the insertion 





Figure 3.1 The Sentrino CGM system featuring a disposable sensor, transmitting cable and touch screen monitor 
 
 
Figure 3.2 The underside of the Sentrino sensor. The two filaments are inserted in to the subcutaneous layer with the help of two 







For each patient, 1 sensor was inserted in the abdomen and 1 sensor was inserted in the thigh to allow 
the effect of sensor site to be investigated. However, it should be noted that in later trials two sensors 
were inserted in the abdomen in 3 patients instead of a thigh sensor, allowed under the existing ethics, 
to further investigate the effect of sensor site.  
 
Calibration BG measurements were obtained by specifically trained ICU nurses at least  3  times  per  day,  
as  recommended  by  the  device  manufacturer (Medtronic, MiniMed, Northridge, California) using a 
Roche Accu-chek Inform II (F. Hoffmann-La Roche Ltd, Basle, Switzerland) hospital grade glucose meter 
and arterial blood as is standard practice in the Christchurch ICU. Roche devices are reported of have a 
mean error (bias) of -0.2 (0.3) mmol/L when compared to blood gas analyser results (Thomas et al., 
2014b). Devices were not be blinded to nursing staff, but were strictly not to be used for GC. BG 
measurements for STAR were taken separately every 1-3 hours.  
  
3.2.3 Intermittent BG monitoring 
In addition to BG measurements used for calibration of SG data, each patient had intermittent BG 
monitoring every few hours.  The  STAR  protocol  requires,  on average,  12-14  BG  measurements  per  
day  to  guide  insulin/nutrition  therapy (Fisk et al., 2012, Stewart et al., 2016). In this study, BG 
measurements were determined using Roche Accu-chek Inform II (F. Hoffmann-La Roche Ltd, Basle, 
Switzerland) hospital grade glucose meter which is the standard of care in the Christchurch ICU, with blood 





3.2.4 Analysis  
To assess the accuracy of the Sentrino CGM, the mean absolute relative difference (MARD) was calculated 
between reference BG measurements collected for use with STAR and the sensor glucose (SG) values:  
 
𝑀𝐴𝑅𝐷 = 𝑚𝑒𝑎𝑛 (𝑎𝑏𝑠 (
𝑆𝐺−𝐵𝐺
𝐵𝐺
)) ∗ 100                                                   Eq. 3.1 
 
MARD was considered for each device and also between the two sensor sites, of a single patient. Bland-
Altman plots (Bland et al., 1986) were produced for the device as a whole to consider how SG errors were 
associated with blood glucose level. A MARD was only calculated if subjects had at least 5 independent 
reference measurements to compare with SG data. MARD is a commonly used reference metric for CGM 
devices to it was selected in this case to allow easy comparison to other studies. Additionally Clarke Error 
Grid analysis was undertaken to determine the clinical impact of any errors.  
 
To assess the agreement of the CGM devices, zero-lag cross-correlation was applied. Zero-lag cross-
correlation is the dot product applied to two signals with no time shift, and yields a value between -1 to 
+1 assessing measure-to-measure agreement as shown in Equation 3.2:  
 
cos 𝜃  = (
𝐴.𝐵
||𝐴||||𝐵||




Where A = [a1, a2 …. an] represents the n x 1 vector of measurements from one CGM signal and B = [b1, b2 
…. bn] the n x 1 vector of measurements from the other. The resultant angle ,𝜃, shows the trend similarity 
between two vectors and its cosine has values in the range -1 and +1 demonstrating opposing to complete 
agreement. Thus, it uses the inner product definition to define how much of vector A is projected on to 
vector B, where 1 indicates equal vectors. The resulting value is referred to as the zero lag correlation co-
efficient. All signals were first mean-centred. Cross correlation allows the trending and agreement of the 
sensor pairs to be analysed in a scale invariant manner and thus, it was selected for this analysis.  
The number of poor sensor signal (PSS) and replace sensor (RS) alarms delivered by the devices were also 
counted for each patient. PSS alarms can occur when the sensor is not performing as expected. This 
behaviour may be due to a variety of reasons, including a BG calibration value very different from that 
expected by sensor algorithm, an unexpectedly low sensor signal and/or dislodgement of the sensor 
filaments. A RS alarm will occur after 4 hours without a valid signal. This alarm thus indicates the sensor 
no longer continues to function and requires replacing. 
 
3.3 Results  
The overall results from the analysis of BG data show that intermittent BG measurements were taken 
frequently with the median time between consecutive measurements of 1.8 hours (~13 measures/day). 
The STAR protocol achieved good control in these subjects resulting in a median [interquartile range (IQR)] 
BG of 7.2 [6.3 – 8.9] mmol/L. However, this result is a little higher than the median BG normally seen in 
cohorts controlled by STAR (Evans et al., 2012) indicating more serve hyperglycaemia in this cohort, 
especially in one particularly difficult to control, spinal injury patient (Figure 3.4, B). These results are 




CGM data shown in Table 3.3 highlights that most patients had at least 2 days of monitoring. While 
calibrations were only requested every 8 hours, there is a much higher frequency of calibration with the 
median [IQR] time between calibrations across both devices being 4.2 [1.3 – 6.9] hours. The median [IQR] 
SG results are very similar to the BG results with 6.9 [5.9 – 8.0] and 7.3 [6.4 – 8.2] mmol/L for abdomen 
and thigh devices, respectively.  
 
The MARD for the abdomen device was 16.6%, while for the thigh device it was only 11%. However, there 
were more abdomen SG data sets assessed (N = 16 vs. N = 10). Trend results, Table 3.4, using the cross 
correlation show decidedly average correlation between the SG pairs. There appears to be only a slightly 
better correlation of two abdomen signals compared to an abdomen signal and a thigh signal with median 
[IQR] correlation coefficients of 0.47 [0.46 – 0.52] and 0.45 [0.22 – 0.65], respectively. Although the data 
is limited. The median [IQR] number of episodes of poor sensor signal was 1 [0 – 1] for both device 
locations. However, the abdomen sensors have a greater range (0 – 4) compared to the thigh sensor (0 – 
2). The number of replace sensor events was the same for both device locations. 
 
The Bland-Altman plots in Figure 3.3 show how SG error changes with glucose level. There does not seem 
to be any strong association between glucose level and SG error in any data set. The thigh data once again 
shows better performance with much tighter 95% range than the abdomen data. Although there are less 
measurements above 10 mmol/L in the thigh data cohort. The overall mean error of the Sentrino device 
is only -0.1 mmol/L but the 95% range values are at -3.4 and 4.4 mmol/L, suggesting error can be relatively 
large for this device.  However, once the outliers highlighted in Figure 4.4 are removed these bounds 
tighten to -2.58 and 2.18 mmol/L respectively. Removing these outliers also improve the overall 
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performance of the device with a MARD of 11.6% and median [IQR] SG value reduces to 6.9 [6.0 – 7.8] 
mmol/L which is more typical of the control achieved by STAR (results not shown). 
 
Clarke Error Grid Analysis of abdomen data, Figure 3.5 (left),  showed 96.8% of all measurements fell in 
zones A and B, with 70.4% in zone A and 26.5% in zone B, which would not lead to inappropriate treatment 
in cohorts for with this error grid was designed (Clarke et al., 2005). Only 0.8% or 2 points fell within region 
D and none within region E. Thigh data, Figure 3.5 (right),   showed even better results with 100% of 
measurements in zone A and B, with 80.1% in zone A.  
 
Table 3.2 BG and SG data results. Results are shown as median [IQR] (range) where appropriate. 
Blood Glucose Results Roche Accu-chek Inform II 
Number of Patients 13 
Time between BG (hrs) 1.8 [1.1 – 3.1] 
Median [IQR] BG (mmol/L) 7.2 [6.3 – 8.9] 
 
 
Table 3.3 SG data results. Results are shown as median [IQR] (range) where appropriate. 
CGM Results Sentrino – Abdomen Sentrino – Thigh Sentrino - Overall 
Number of SG data sets 16 10 26 
Duration of CGM (hrs) 56.8 [45.1 – 71.1] 45.6 [43.5 – 70.9] 52.4 [43.9 – 70.9] 
Time between calibration BG (hrs) 4.6 [1.2 – 6.9] 3.6 [1.3 – 6.8] 4.2 [1.3 – 6.9] 
Median [IQR] SG (mmol/L) 6.9 [5.9 – 8.0] 7.3 [6.4 – 8.5] 7.1 [6.1 – 8.2] 
MARD (%) 16.6 11.1 14.7 
Poor Sensor Signal (no. episodes) 1 [0 – 1] (0 – 4) 1 [0 – 1] (0 – 2) 1 [0 – 1] (0 – 4) 
Replace Sensor (no. occurrences) 0 [0 – 1] (0 – 1) 0 [0 – 1] (0 – 1) 0 [0 – 1] (0 – 1) 
 
Table 3.4 SG correlations results. Results are shown as median [IQR] (range) where appropriate. Ab = abdomen, Th 
= thigh  
CGM Correlation  Ab vs. Th Ab vs. Ab 
Number of pairs 10 3 




Figure 3.3 Bland Altman plot for all patients for the different device locations and overall results. Red and Green ovals correspond 





Figure 3.4 SG plots of the two patients responsible for the majority of the outliers seen in the Bland-Altman plots due to sensor 







 Figure 3.5 The Clarke error grid analysis for the abdomen SG (left) and thigh SG (right) compared to reference BG measurements 
 
3.4 Discussion  
The results in Table 3.2 show that glycaemia was monitored closely during the study, by intermittent BG 
measurements and CGM, with both methods producing similar overall glycaemic results. In terms of CGM 
accuracy, the overall error from both abdomen and thigh data is 14.7%. This is result is similar to accuracy 
seen in previous CGM studies with off-the-shelf CGM devices designed for T1DM and T2DM (Vlkova et al., 
2009, Brunner et al., 2011, Rabiee et al., 2009, Signal et al., 2013) and slightly higher than the 12.2% 
reported in an initial Sentrino study of cardiac ICU patients (Kosiborod et al., 2013). However, Kosiborod 
et al. (2013) only used the thigh location for sensor insertion. Therefore, the thigh MARD of 11% is 
comparable if not slightly better than Kosiborod et al.’s results. Additionally, the Clarke Error Grid analysis 




The MARD for the abdomen SG data is approximately 4% higher than that for the thigh SG data and a 
higher range of poor sensor signal was seen in abdomen devices. Figure 3.3 shows a much wider 95% 
range for the abdomen SG compare to reference BG data than the thigh data. These results indicate that 
sensor location does affect sensor performance and following the manufacturers’ recommendation of 
insertion in the thigh is important. However, once the outliers highlighted in Figure 3.4 are removed, this 
difference reduces significantly. These large excursions in sensor signal are uncharacteristic of a working 
sensor and are due to sensor failure causing the sensor to act erroneously. In this study, there are a lower 
number of thigh SG signals than abdomen. However, in Chapter 4 results from an additional 8 thigh SG 
data sets are analysed as part of Phase IIA of the Sentrino trial.  
 
In this study, a much higher rate of calibration is seen compared to what was required by the device 
manufacturer. This increase is predominately due to the initial start-up protocol requiring 3 blood glucose 
measurements within three hours during initialisation. However, a number of incidences of poor sensor 
signal would also increase the number of calibrations because a calibration is recommended by the 
manufacturer to correct a PSS alarm. Additionally, the Sentrino was programed to alarm 75 mins prior to 
the calibration being required to allow the nurse to align a STAR measurement with the calibration of the 
devices, but this may have resulted in more calibrations being received especially for patients requiring 
hourly BG.  The rate of calibration, approximately every 4 hrs, is still much lower than the average STAR 
measurement time of 1.8 hrs. However, if such frequent calibration is required it does call into question 
the ability of CGM to cure the time cost of GC and increased calibration may have resulted in better than 





3.5 Summary  
The aim of this chapter was to analyse the performance of the Sentrino CGM system in a mixed medical 
ICU environment and confirm the optimal sensor location. Overall, the Sentrino device achieved a MARD 
of 14.7%. This result demonstrated slightly reduced performance from what was reported in an initial trial 
in a cardiac ICU of 12.2% MARD. However, when considering device location, thigh SG achieved a MARD 
of 11.0% while abdomen SG achieved a MARD of 16.6%.  This result indicates that following the 
manufacturers’ recommendation of thigh insertion, which is different to the location used for devices 
designed for T1DM and T2DM, is important to ensure sensor performance. The number of calibrations 
undertaken was double that recommended by the protocol and may have improved overall accuracy. This 
is likely due to the Sentrino initialisation requiring 3 additional measurements within 2 hours and relatively 
short 2-3 day monitoring periods. However, a high rate of poor sensor signal, median of 1 episode per 
patient, also leads to more calibrations being undertaken to attempt to correct this reduced signal.  
Overall the Sentrino performance was acceptable, but with such a high number of additional calibration 
measurements required, questions still remain if this CGM system can reduce the time cost of glycaemic 






Chapter 4. The Sentrino Trial Phase IIA   
As noted in Chapter 3, a larger scale study was designed to investigate the performance of the latest 
available CGM device specifically designed for the ICU environment, the Sentrino (Medtronic, MiniMed, 
Northridge, California). The trial was designed and undertaken in 2 phases run partially in parallel. This 
chapter details the results of Phase IIA, run concurrently with Phase I as a further observational study in 
to the performance and integration of hyper- and hypo-glycaemic alarms.  
 
4.1 Introduction  
CGM does not just offer reduced nurse workload by reducing the number of manual BG measurements 
required. CGM also offers trend information and potentially early warning of hyper- and hypo-glycaemic 
events compared to intermittent monitoring (Signal et al., 2010), which can miss them entirely (Harris et 
al., 2010). To optimise the information provided by CGM hyper- and hypo- glycaemic alarms can be added 
in the settings of the Sentrino device. These alarms sound if the CGM value becomes lower or higher than 
a user defined threshold. The aim of this chapter was to investigate the performance of these alarms and 
how they can best be integrated in to current clinical practices, to ensure reduced nurse workload and 
increased patient safety.  
 
4.2 Subjects and Methods  
4.2.1 Subjects 
This study uses data from an observational pilot study of CGM in patients admitted to the Christchurch 
Hospital ICU during 2014. This analysis uses CGM and BG data from 8 patients who were recruited to this 
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phase of the trial, Phase II. These patients are independent of the patients examined in the Chapter 3. All 
patients were recruited  by a  physician in the  ICU  and informed written  consent was  obtained from the 
next  of  kin  if  the  patient  was  unable  to  consent and follow up consent was obtained from the patient 
at a later date if applicable.  This study and use of  data  was  approved  by  the  Upper  South  A  Regional  
Ethics  Committee,  New Zealand. Table 4.1 shows the patient demographics. 
 
Inclusion  criteria  were  two consecutive  BG  measurements  greater  than  8 mmol/L,  indicating  the  
need  for insulin  therapy  using  the  STAR  protocol (Evans et al., 2012) , expected admission of at least 3 
days, over 18 years of age, and with a platelet count > 30,000/mL.  Patients were excluded from the trial 
if they were not expected to survive, receiving Hydroxyurea, pregnant, and/or lacked clinical equipoise.  
 
Table 4.1 Patient Demographics presented as median [IQR] where appropriate 
Patients  8 
Ages (years) 66 [54 – 71] 
Sex (M/F) 5/3 
APACHE II 23 [16 – 29] 
APACHE III 72 [62 – 111] 
SAPS II 45 [35 – 63] 
ICU admission (days) 10 [7 – 14] 
Outcome (Lived/Died) 5/3 
Diabetes (None/T1/T2) 5/0/3 
 
 
Each participant in this phase of the study was monitored concurrently using 1 CGM device for a period 
up to 3 days using the Sentrino (Medtronic, MiniMed, Northridge, California) CGM system. This device is 
specifically designed for ICU conditions and is presented in detail in Chapter 3. The subcutaneous sensor 
34 
 
was inserted into the thigh of each patient based on manufacturer recommendations (Medtronic, 
MiniMed, Northridge, California).  
 
Calibration BG measurements were obtained by specifically trained ICU nurses at least  3  times  per  day  
as  recommended  by  the  device  manufacturer (Medtronic, MiniMed, Northridge, California) using a 
Roche Accu-chek Inform II (F. Hoffmann-La Roche Ltd, Basle, Switzerland) hospital grade glucose meters, 
and arterial blood samples, as is standard practice in the Christchurch ICU. Roche devices are reported of 
have a mean error (bias) of -0.2 (0.3) mmol/L when compared to blood gas analyser results (Thomas et 
al., 2014b). CGM Devices were strictly not to be used for glycaemic control 
 
4.2.2 Guardrails 
An upper guardrail of 10 mmol/L and lower guardrail of 4.2 mmol/L were added in the device settings. If 
SG was predicted to be approaching either of these values a “predicting low sensor glucose” or “predicting 
high sensor glucose” alert, which are predefined on the device, would appear on the screen of the 
monitor. This specific alert required no action from the nurse. However, when the SG value crossed either 
of the thresholds the alert on the screen would change to the device defined “Low sensor glucose” or 
“High sensor glucose” and an alarm would sound. The Nurse was now instructed to pause the alarm 
silencing it for one hour and immediately take a Roche BG measurement and compare it to the SG:  
 
 If SG <= the lower guardrail and the absolute difference between BG and SG is greater than 
0.5mmol/L the Sentrino must be calibrated using that BG value 
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 If SG >= the upper guardrail and the absolute difference between BG and SG is greater than 
2mmol/L the Sentrino must be calibrated using that BG value  
If left unattended, and the SG remained above or below the threshold the alarm would continue to sound 
every 15 minutes. In addition to BG measurements used for calibration of SG data, each patient had 
intermittent BG monitoring every few hours for GC with STAR.  The  STAR  protocol  requires,  on average,  
12 – 14 BG  measurements  per  day  to  guide  insulin/nutrition  therapy (Fisk et al., 2012). In this study, 
BG measurements were made using Roche Accu-chek Inform II (F. Hoffmann-La Roche Ltd, Basle, 
Switzerland) and arterial blood samples, which is the standard of care in the unit. 
 
4.2.3 Analysis  
To assess the accuracy of the Sentrino CGM, MARD was calculated between reference BG measurements 
collected for use with STAR and the CGM signal. The MARD was calculated for each sensor and reference 
measurement pairing, as detailed in Chapter 3. MARD was only calculated if subjects had at least 5 
independent reference measurements to compare with SG data. 
 
Alarm performance was investigated by considering the number of episodes of SG >10 mmol/L or SG < 
4.2 mmol/L, and the overall numbers of warning alerts and alarms. An episode was considered to begin 
when SG crossed either threshold and ended when SG rose above or fell below the same threshold. These 
episodes were counted independently to the number of alarms and warning alarms as once a threshold 
is crossed the alarm will sound every 15 minutes if left unattended. Once attended to, the alarm will sound 
again in 1 hour if SG is still outside of the threshold bounds. Warning alerts also can occur without the 
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bounds being crossed. Therefore, the number of episodes of hyper- or hypo-glycaemia, above and below 
the thresholds, is different to the number of warning alerts or alarms.   
The number of calibrations required due to a difference of more than 0.5 mmol/L or 2.0 mmol/L 
depending on the alarm threshold were also calculated. The number of calibrations received and time 
taken to measure BG was considered to investigate nurse compliance.  Finally, the number of false positive 
and false negative alarms was considered. A false positive alarm was defined as when an SG alarm 
occurred, for a threshold crossing, but the measured BG was still below or above the relevant threshold 
and thus still with in the 4.2 mmol/L – 10.0 mmol/L band as defined. A false negative alarm was defined 
as when any measured BG was above or below either threshold, but an SG was not and therefore an alarm 
did not occur.  
 
4.3 Results  
The overall results from the analysis of BG data show that intermittent BG measurements were taken 
frequently with the median time between consecutive measurements of 1.8 hours (~13 measures/day). 
The STAR protocol achieved good control in these subjects resulting in a median [IQR] BG of 7.2 [6.3 – 8.9] 
mmol/L.  These results are shown in the upper section of Table 4.2. 
 
CGM data shown in the lower section of Table 4.2 highlights that most patients had at least 2 days of 
monitoring. The CGM performance is similar if not slightly improved from that reported in Chapter 3 with 
a MARD of 9.7%. The median [IQR] SG results are very similar to the BG results with 7.1 [6.1 – 8.3] and 7.2 




Table 4.2 BG and SG data results. Results are shown as median [IQR] where appropriate. 
Blood Glucose Results  
Number of Patients 8 
Time between BG (hours) 1.8 [1.0 – 3.0] 
Median [IQR] BG (mmol/L) 7.2 [6.2 – 8.9] 
CGM Results  
Number of SG data sets 8 
Duration of CGM (hours) 61.1 [36.1 – 68.5] 
Time between calibration BG (hours) 6.4 [1.3 – 7.0] 
Median [IQR] SG (mmol/L) 7.1 [6.1 – 8.3] 
MARD (%) 9.7% 
 
Table 4.3 summarises the warning alert and alarm performance across the 8 patients. There were only 11 
hyperglycaemic (SG > 10 mmol/L) and 6 hypoglycaemic (SG < 4.2 mmol/L) episodes, displaying the good 
control achieved by the STAR protocol, especially considering the high rate of false positives seen (SG 
exceed the threshold but BG does not). Out of the 29 hypoglycaemic alarms 27 were false positives, 
indicating the BG had not been below 4.2 mmol/L. Figure 4.2 demonstrates how sensor artefacts, either 
drop outs or spikes in sensor glucose, generated false positive hypoglycaemic alarms. 
 








No. episodes 6 11 17 
No. warning alerts 11 17 28 
No. alarms 29 64 93 
Time taken to measure BG (mins) 4.0 [-21.3 – +19.0] -1.5 [-17.5 – +18.5] -1.0 [-18.5 – +19.0] 
No. calibrations required 25 7 32 
No.  calibrations required received  23 3 26 
No. calibrations received not required  2 10 12 
No. false positive alarms 27 29 56 




The median [IQR] time to measure BG once an alarm had sounded was -1.0 [-18.5 – 19.0] minutes. While 
the median suggests good compliance the large interquartile range with nurses using measurements from 
~20 minutes prior to the alarm or not measuring for ~20 minutes post alarm indicates otherwise. The high 
rate of false positives may have contributed to this lack of compliance with 29 false positive 
hyperglycaemic alarms and 27 false positive hypoglycaemic alarms. However, there was only one false 
negative alarm during the entire monitoring period. Figure 4.1 highlights an example of good nurse 
compliance with repeated true alarms compared to poor nurse compliance due to repeated false positive 
alarms. Only 32/93 total alarms required calibration and 26/32 of these calibrations were undertaken and 
entered in to the device. There were 12 additional calibrations made after alarms that were not required.  
 
 
Figure 4.1 Examples of repeated alarms A) displays an example of repeated false positive alarms resulting in poor compliance B) 








4.4 Discussion  
Overall sensor and alarm performance was good. Only 32/93 alarms required calibration with the majority 
of those calibrations required for the lower bound, 25/32, where the safety tolerance for the difference 
between sensor glucose was only 0.5 mmol/L in this hypoglycaemic range versus 2 mmol/L for the 
hyperglycaemic upper bound. There was only one instance of a false negative alarm, where BG was above 
10 mmol/L but SG was not, displaying a high level of safety.  
 
However, there was a high rate of false positive alarms. Many of these false positives were caused by 
sensor artefacts, unexplained spikes or dips in sensor glucose, as shown in Figure 4.2, or sensor drift as 
shown in Figure 4.1A. While false positives are safer for managing patient blood glucose than false 
A B 
Figure 4.2 Examples of sensor artefacts resulting in false positive alarms 
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negatives, they can lead to alarm fatigue and non-compliance. This issue is demonstrated in Figure 4.1A. 
where SG has drifted above the threshold for the hyperglycaemic alarm, but, measured BG is below the 
threshold. To prevent the alarm from continuing to sound the nurse has calibrated the Sentrino even 
though SG – BG < 2 mmol/L and by the protocol calibration is not required. These calibrations have not 
prevented SG drifting again above the threshold so the next 5 alarms have seen no action taken. This 
patient has diabetes so nurses have the option to adjust the target band to 4.4 – 9.0 mmol/L or 6.0 – 9.0 
mmol/L. In this case the target range has been adjusted. Therefore, even though the patients BG is above 
8.0 mmol/L the nurses still can select the longest measurement interval of 3 hourly BG measurement 
intervals. Hence, to measure BG every hour with a repeated false alarm generates extra nurse work load, 
which has resulted in non-compliance.  
 
This compliance issue is contrasted by the good compliance seen in Figure 4.1B. This patient had very high 
blood glucose and there are many more examples of true hyperglycaemic alarms (39 in total).  However, 
there has been a BG measurement taken with each alarm. This patient does not have diabetes and the 
target range has remained 4.4 – 8.0 mmol/L. Therefore, once a patients BG is above 8.0 mmol/L the STAR 
protocol will request hourly measurements so to measure with each hourly alarm when a patient is truly 
hyperglycaemic the work load is not increased due to additional alarms.  It is also interesting to note that 
none of these 39 alarms required calibration showing good agreement between SG and BG even at high 
glucose levels.  
 
One mild hypoglycaemic event (BG = 3.9 mmol/L) was captured by the Sentrino guardrails that would 
have otherwise been missed by STAR alone. This result highlights the ability improve safety with 
hypoglycaemic guardrails. However, hypoglycaemic events are rare with the STAR protocol with clinical 
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results from 286 patients resulting in only 1.35% of BG < 4.4 mmol/L (Stewart et al., 2016). Hence, the 
high rate of false alarms may generate more nurse workload and alarm fatigue that is not offset enough 
by the improved safety.  
 
There were numerous episodes of hyperglycaemia that were captured first by the Sentrino guardrails and 
only later by the STAR measurements, if at all. This result highlights the potential ability of the Sentrino’s 
ability to improve performance if nurses are altered to hyperglycaemia earlier. However, it is not possible 
to deduce what percentage improved performance could be achieved from this study as CGM was strictly 
not used for glycaemic control.  
 
The guardrails of 4.2 mmol/L and 10 mmol/L demonstrate the potential of guardrails to improve safety 
and performance while still reducing nurse workload. However, it is not clear if the values of the guardrails 
are optimal. These Guardrails were selected based on clinician and manufacturer recommendations. To 
improve performance it may be better to lower the upper guardrail to 8.0 mmol/L so the nurse is alerted 
as soon as the sensor glucose has left the desired target band. To improve safety it may be better to 
increase the lower guardrail to 4.4 or even 5.0 mmol/L so the nurse is aware that the patient has left or is 
about to leave the target band. However, both of these changes are likely to increase workload with a 
greater number of alarms, both false and true. The optimal guardrail setting is investigated further in 






4.5 Summary  
This chapter details the results of Phase IIA of the Sentrino trial which was an observational study of the 
performance and integration of hyper- and hypo-glycaemic guardrail alarms with an existing, proven GC 
protocol. This study analysed SG and BG data, and alarm data from 8 patients who were recruited to this 
phase of the trial. An upper guardrail of 10.0 mmol/L and lower guardrail of 4.2 mmol/L were added in 
the device settings. When the SG value crossed either threshold an alarm would sound. BG measurement 
was then taken and compared it to the SG, where it would be used for recalibration if the SG-BG error 
exceeded a predefined value.  
 
Overall sensor and alarm performance was good, only 32/93 alarms required calibration with the majority 
of those calibrations required for the lower bound, 25/32, where the tolerance for the difference between 
sensor glucose was only 0.5 mmol/L compared to 2.0 mmol/L for the upper bound. However, there was a 
high rate of false positive alarms. Many of these false positives were caused by sensor artefacts, 
unexplained spikes or dips in sensor glucose or sensor drift. While false positives are safer for managing 
patient blood glucose than false negatives, of which there was only one, they did lead to nursing non-
compliance in some cases. In summary, alarms performed well for the most part, but to ensure better 
integration with current practices and nurse compliance, the protocol regarding false positives needs to 





Chapter 5. Factors affecting CGM performance in the ICU  
Chapters 3-4 have detailed the specific aims and results of the first two phases of the Sentrino Trial. This 
chapter uses the data and observations of both phases of this trial to highlight the key factors affecting 
the performance of CGM in the ICU. In particular, the effect of sepsis, oedema and some medications on 
the performance of CGM are investigated in this chapter. Other practical observations such as nurse 
feedback and compliance, are also considered. 
 
5.1 Introduction 
A recent observational study highlighted the potential of CGM in ICU patients, but concluded that further 
understanding of factors altering CGM performance is required before CGM guided glycaemic control in 
the ICU could be safely and effectively realised (Signal et al., 2013). This study highlighted a number of 
potential issues that could affect sensor performance, including serve oedema, sepsis, certain drugs or 
therapies.  
 
Serval other studies have also highlighted how patient condition may affect sensor performance in the 
ICU, including the effect of sepsis and septic shock (Lorencio et al., 2012). In  addition,  certain  
medications/therapies  commonly  used  in  the ICU,  such  as  paracetamol,  can  influence  CGM  device  
performance (Moser et al., 2010). Vasoactive medications, such as dopamine, norepinephrine, ketanserin, 
enoximone and nitro-glycerine, are reported to have little or no effect on the accuracy of one type of 




Muscle trauma or surgery may also impact sensor performance. Klueh et al. (Klueh et al., 2010, Klueh et 
al., 2014) demonstrated how cytokine expression is related to sensor function with increased 
inflammation and decreased sensor function in mice deficient in interleukin-1-receptor-antagonist 
cytokine. Muscle trauma, which is one common cause of admission in the ICU, is known to alter cytokine 
expression (Jackson et al., 2011). Hence, it is another factor to consider.  
 
Given all these issues, this studied aimed for ~50% of the recruited patients to have sepsis and/or severe 
oedema, and the remaining ~50% to be non-septic/non-inflammatory ICU patients and act as a control. 
As a result, a detailed history of the cause of admission, drugs administered and therapies used during the 
monitoring period was kept to investigate the influence of these factors. A nurse survey was undertaken 
to gather feedback on the practicality of the device in an ICU setting. Nurse compliance was also analysed. 
The overall goal was to understand the variability induced by these factors and their potential clinical 
impact in using CGM for guided GC.  
 
5.2 Subjects and Methods  
5.2.1 Subjects 
This study uses data from an observation pilot study of CGM in patients admitted to the Christchurch 
Hospital ICU. This analysis uses CGM and BG data from 21 patients who were recruited to Phase I and 
Phase IIA of the Sentrino trial as detailed in Chapters 3-4. All patients were recruited  by an ICU  physician 
and informed written  consent was  obtained from the next  of  kin  if  the  patient  was  unable  to  consent 




Inclusion  criteria  were  two consecutive  intermittent BG  measurements  greater  than  8mmol/L,  
indicating  the  need  for insulin  therapy  using  the  STAR  protocol (Evans et al., 2012, Stewart et al., 
2016), expected admission of at least 3 days, over 18 years of age, and with a platelet count > 30,000/mL.  
Patients were excluded from the trial if they were not expected to survive, receiving Hydroxyurea, 
pregnant, and/or lacked clinical equipoise. This study and use of  data  was  approved  by  the  Upper  
South  A  Regional  Ethics  Committee,  New Zealand. Table 5.1 summarises the patient demographics. 
 
Table 5.1 Patient demographics displayed as median [IQR] where appropriate 
Patients  21 
Ages (years) 60 [55 – 68] 
Sex (M/F) 11/9 
APACHE II 20 [16 – 25] 
APACHE III 72 [52 – 96] 
SAPS II 43 [34 – 59] 
ICU admission (days) 14 [8 – 25] 
Outcome (Lived/Died) 14/7 
Diabetes (None/T1/T2) 15/0/6 
 
 
All patients were monitored for up to 3 days using the Sentrino monitoring system (Medtronic, MiniMed, 
Northridge, California) as detailed in Chapter 3. Patients had either one abdomen and one thigh sensor, 
two abdomen sensors or one thigh sensor inserted by a trained clinician, depending on which trial phase 
they were enrolled in.   
 
Calibration BG measurements were obtained by specifically trained ICU nurses at least  3  times  per  day  
as  recommended  by  the  device  manufacturer (Medtronic, MiniMed, Northridge, California). Calibration 
measures used a Roche Accu-chek Inform II (F. Hoffmann-La Roche Ltd, Basle, Switzerland) hospital grade 
46 
 
glucose meter and arterial blood which is standard practice in the Christchurch ICU. CGM devices were 
strictly not to be used for glycaemic control. 
 
In addition to BG measurements used for calibration of SG data, each patient had intermittent BG 
monitoring every few hours.  The  STAR  protocol  requires,  on average,  12-14  BG  measurements  per  
day  to  guide  insulin/nutrition  therapy (Fisk et al., 2012, Stewart et al., 2016). In this study, BG 
measurements were determined using Roche Accu-chek Inform II (F. Hoffmann-La Roche Ltd, Basle, 
Switzerland) hospital grade glucose meter which is the standard of care in the Christchurch ICU, with blood 
typically obtained from an arterial line.   
 
5.2.2 Analysis  
The MARD was calculated for each sensor and reference measurement pairing, as detailed in Chapter 3. 
MARD was only calculated if subjects had at least 5 independent reference measurements to compare 
with SG data. MARD results were then compared to oedema level and septic status, as well as any specific 
drug therapies.  
 
The level of patient oedema was judged based on the calculated cumulative fluid balance (FB) and an 
oedema score given by the clinician on sensor insertion. The daily fluid balance tallies all the fluids given 
minus the amount of fluid excreted by a patient. This balance obviously does not include fluid loss through 
sweat and other unmeasurable means. However, cumulative FB provides an estimate of how much fluid 
a patient is retaining and is well-accepted clinically (Boyd et al., 2011). An oedema score is based on 1 - 4 
standard scale based on a clinician’s interpretation of the response of the patient’s skin to pressure 
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(O’Sullivan, 2007). For this analysis a patient was considered severely oedematous if their cumulative FB 
increased by more than 5L during the course of monitoring, or if they were given an oedema score of 3 or 
higher at sensor insertion.  
 
A patient was considered septic if they has a systemic inflammatory response syndrome score (SIRS) > 2 
(Kaukonen et al., 2015) and were receiving antibiotics. These two factors are the best indicators available 
for sepsis. Timely treatment of sepsis is critical, clinicians often will not wait for cultures to confirm the 
septic state of a patient, and will begin a course of antibiotics immediately.  Hence, these criteria are a 
defacto standard diagnosis (Brun-Buisson et al., 1995, Kaukonen et al., 2015).   
 
When the CGM reading becomes unreliable the Sentrino device will display a poor sensor signal alarm 
and stop showing glucose values. In some instances this poor sensor signal can be corrected with 
calibration but it can also lead to sensor failure. The number of occurrences of poor sensor signal was 
considered as another measure of sensor performance. The number of poor sensor signal events was 
considered over the duration of poor sensor signal as the duration is dependent on if the sensor was 
calibrated to attempt to correct the signal or if the sensor was replaced immediately which would have 
been affected by the availability of a trained clinician to replace the sensor, among other factors. 
Therefore, one sensor could have multiple instances of poor sensor signal if the reading was corrected by 
a calibration and then proceeded to fail again during the monitoring period.  
 
The main known causes of all sensor failures were examined, and are detailed in Table 5.2. This summary 
allows known sensor failure causes to be excluded and inconclusive (IC) sensor failures to be examined 
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with respect to oedema and septic state. Other metrics relating to these methods of failure were also 
investigated, such as if the patient was receiving anti-coagulants or the number and duration of sensor 
cable disconnects.  
 
Nurse compliance was investigated by considering the time between calibrations requested by the 
Sentrino device and the calibrations being entered. The number of misentered calibrations was also 
considered based on comparison to the Accuchek meter stored value. Nurse survey results based on 
questions asking for a 1 -5 ranking, where 1 - Strongly disagree and 5 - Strongly agree, are summarised 
and presented as median [IQR], and the survey is shown in Figure 5.1.  
 
Figure 5.1 The nurse survey form that was handed out to those nurses who participated in the Sentrino study   
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5.3.1 Effect of Oedema, Sepsis, Medications, and Therapies 
A large proportion of this cohort had some level of oedema with 15/21 patients having a cumulative FB > 
5L on the day of sensor insertion as shown in Table 5.3. A total of 11/21 patients were judged severely 
oedematous during the trial with an increase in cumulative FB > 5L between day 1 and the end of the trial 
or an oedema score of >= 3 on sensor insertion. Two sensor failures were unquestionably the result of 
oedema as the adhesive dressing applied failed to remain in place on these patients and fluid leaking from 
the sensor filament holes resulted in the sensor being dislodged. These failures are shown in Table 5.2.  
 
However, comparing the MARD results from those severely oedematous patients compared to those not 
severely oedematous shows no significant difference, with a median [IQR] of 10.9 [8.0 – 15.8] % and 10.6 
[9.6 – 13.7] %, as shown in Table 5.4. The number of poor sensor signal events did increase in the severely 
oedematous patients with 15 occurrences compared to 10 in those without severe oedema.   
 
A total of 12/21 patients had a SIRS score > 2 and were receiving antibiotics, indicating sepsis. Once again, 
MARD results indicate no difference between septic patients and non-septic achieving a median [IQR] of 
10.7 [8.1 – 13.6] % and 10.7 [9.5 – 13.5] %, respectively. However, the number of poor sensor signal 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 5.4 Summary of overall sensor performance as comparing septic or oedematous cohorts and not septic or 
oedematous cohorts.  





No. Patients (No. Sensors) 
[No. MARD] 
12 (18) [15] 9 (16) [9] 11 (15) [14] 10 (19) [10] 
Median [IQR] MARD 10.7 [8.1 – 13.6] 10.7 [9.5 – 13.5] 10.9 [8.0 – 15.8] 10.6 [9.6 – 13.7] 
No. Inconclusive Sensor 
Failures (No. Adhesive 
failures) 
2 (2) 1 (0) 1 (2)* 2 (0) 
No. Poor Sensor Signal 
Occurrences 
17 8 15 10 
*Adhesive failures were directly caused by oedematous patients as leaking fluid prevented dressings from sticking 
 
5.3.2 Nurse Compliance and Feedback  
Overall, nurse compliance was good, with a median [IQR] delay between a calibration being required and 
a calibration being received only 2 [1 – 31] minutes, as seen in Table 5.5.  However, approximately 20% of 
all calibrations, 81/410, were entered incorrectly as determined by comparing the entered value to the 
stored measured value of the Roche glucometer. The median absolute difference between the measured 
value and the entered value was 0.3mmol/L with an interquartile range of 0.5 – 1.0mmol/L.  
 
Approximately 30 surveys were handed out to nurses who used the Sentrino CGM system and 22 
anonymous responses were returned. Nurse feedback suggests feelings were neutral about the Sentrino 
CGM system with the approximately 30% of responses being a 3 or 4 for all but one question, as shown in 
Table 5.6. The most common concern or complaint was the number of disconnects between the sensor 
and sensor cable, with some patients, such as Patient 1, having a total of 30 disconnects during a 
monitoring period of 71.2 hours (Table 5.3).   
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Table 5.5 Summary of total calibrations made and the rate of misentry and delay between a calibration being 
required and entered 
No. Calibrations  410 
No. Misentered Calibrations  81 
Absolute Misentry Amount median [IQR] 0.5 [0.3 – 1.0] 
Calibration Delay (min) median [IQR] 2 [1 – 31] 
 
 
Table 5.6 Summarised results of a survey undertaken by the ICU nurses involved with the Sentrino study.  
Questions (given a score 1 - Strongly disagree      3 - Neutral   
   5 - Strongly agree) 
Response (%) 
1 2 3 4 5 
The device was easy to set up and/or use: 10 5 35 30 20 
I was overall satisfied with the Sentrino CGM System: 14 10 38 33 5 
Sentrino CGM System adds clinical value into my ICU practices: 14 19 29 33 5 
I was confident using Sentrino in my routine ICU practices: 5 19 24 38 14 
I recommend the future routine use of this device in the ICU: 10 19 33 33 5 
Positive feedback for the Sentrino:    Major Concerns/Criticism:    
1. Anything that reduces time consuming 
STAR measurements is welcome  
2. Good tool aside from these issues (see 
concerns 1 and 6) 
3. Would have liked to have used it more than 
once  
 
1. Sensor often disconnecting during turns 
(requiring recalibration) 
2. Not always reading accurately and/or 
sensors diverging therefore reservations 
using Sentrino to change or commence 
new treatments 
3. Great difficulty when patient needs to be 
mobilized, CT scan etc 
4. Cable connection gets very hot and is 
difficult to position away from patient 
5. Skin probe causes oozing in oedematous 
patients 
6. Used up too much bed space which is at a 





5.4 Discussion  
5.4.1 Effect of Oedema, Sepsis, Medications and Therapies 
The level of oedema does not appear to correlate with sensor performance as judged by MARD analysis. 
However, meaningful MARD results were not calculated in two severely oedematous patients as sensor 
failure occurred before enough data (> 5 reference BG measurements) could be collected. These two 
sensor failures were conclusively caused by oedema, as the sensors were dislodged from their site of 
insertion due to fluid leaking from this area. The picture in the last row of Table 5.2 shows 100mL of fluid 
that was collected overnight from the insertion site after the sensor had been dislodged. It is evident that 
in cases of severe oedema, such as highlighted here, current CGM devices cannot provide cannot provide 
consistent performance. This issue is exacerbated by the Sentrino sensors not being waterproof. Hence, 
even if the sensors remained in place the leaking fluid could damage the sensors, which may have been 
the case in the inconclusive failure for the oedematous cohort noted in Table 5.4.  
 
Sepsis also does not appear to correlate with MARD results. However, the number of poor sensor signal 
episodes is much higher in the septic cohort. It is difficult to separate out the effect of sepsis as many 
septic patients were also oedematous and receiving anticoagulants.  
 
The effect of anticoagulants is important as often blood was noticed on the sensor probes upon removal. 
In the example shown in Table 5.2, the extent of the bleeding caused sensor failure. Blood clotting around 
the sensor filaments reduces the area for the glucose-oxidase reaction to occur and could therefore 
induce a weakened signal. However, all but 2/21 patients were receiving anticoagulant medication. 
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Hence, it impossible to quantify the direct impact of this medication on sensor performance separate from 
other factors.   
 
In addition, there is a small chance that a capillary is hit on insertion. The anticoagulants then result in the 
bleeding from this event being more pronounced. The best way avoid this interference from blood clotting 
around the filaments and fouling the sensor may be an improved sensor design or insertion technique, as 
it would be impractical to avoid all ICU patients receiving anticoagulant medication.  
 
Other medications, such as vasopressors, showed no effect on the performance of sensor signal matching 
already published results (Holzinger et al., 2009). Contrary to literature results linking sensor function to 
cytokine expression (Klueh et al., 2014, Klueh et al., 2010), which is known to be altered by muscle trauma 
(Jackson et al., 2011), patients who underwent surgical procedures or had wounds did not show any 
difference in sensor performance in this study.  Acetaminophen also showed no effect on performance. 
It is also possible that any potential influence these factors have was masked by the other issues 
mentioned, which had a far greater influence on sensor performance.   
 
 5.4.2 Nurse Compliance and Feedback  
Overall nurse compliance was good, although approximately 20% of calibration measurements were 
entered incorrectly. It is likely that given time this number would decrease, as the mistakes in entering 
calibration values occur more often when nurses are unfamiliar with the technology. Additionally, the 
entry interface could be designed to minimise errors (Ward et al., 2012). The Sentrino was also only 
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observational, so its lack of influence in care may have reduced the care taken to enter the correct value 
as the CGM value.  
 
The nursing feedback received was broadly neutral. Nurses were neither pleased nor displeased with the 
Sentrino. This is a positive outcome, as it indicates the nurses saw potential for the use of CGM in ICU 
even with the extra work load studies, such as this one, generate for nurses and the issues encountered 
during the trial.  The high number of disconnects, especially in the first few patients (Table 5.3), attracted 
the most criticism from the nurses. Most of these disconnects happened during turning which is 
undertaken every 2-4hrs in the Christchurch ICU as part of routine practice, and highlight the difficulty 
with any extra line attached to a patient.  
 
Repeated disconnects increase nurse workload. Not only must they reconnect the device, which if done 
incorrectly can lead to bent pins and sensor failure (Table 5.2), but the nurse must also follow on screen 
prompts to confirm if the sensor is a new sensor or old sensor. If this process is done incorrectly the sensor 
will go through the initialising sequence again requesting repeated calibrations. In addition, if the sensor 
is disconnected for > 30mins this reinitialising process must occur, regardless. Hence, patient mobility is 
increasingly difficult especially if the patient requires further testing outside the ICU, such as a Computer 
Tomography (CT) scan. Furthermore, early ICU patient mobility has been shown to improve patient 
outcomes (Adler et al., 2012) and is a clear focus in the Christchurch ICU. Therefore anything this that 
restricts this is discouraged, and CGM issues exacerbated by lack of mobility, such as oedema, can become 




5.4.3 Practical recommendations for CGM in ICU  
The Sentrino study has highlighted several practical issues regarding the use of CGM in the ICU. For CGM 
to be successful in reducing nurse workload and increasing patient safety, the following recommendations 
are made:  
 Avoid severely oedematous patients where fluid is likely to leak from ruptured skin 
 Waterproof CGM sensors  
 Reconsider insertion technique to lessen the risk of capillary damage   
 Wireless transmission between sensor and monitor unit for ease of patient mobility and 
minimisation of sensor disconnects 
Overall, the Sentrino and CGM has shown potential to reduce nurse workload for the glucose 
measurement and increase patient safety. However, until the above complications are addressed they are 
unlikely to be commonplace within the ICU.  
 
5.5 Summary  
The overall goal of this analysis was to better understand the impact of sepsis, oedema and some 
medications on CGM results and take note of nurse compliance and feedback to gain insight in to the 
potential clinical impact of using CGM to guide GC. This analysis used data from 21 patients enrolled in 
two different phases of the Sentrino trial. Approximately 50% of all enrolled subjects were severely 
oedematous and/or septic by design.  
 
Results indicate that while oedema and sepsis do not affect the sensor performance as judged by MARD 
they can lead to increased number of sensor failures and poor sensor signals. The medication that affected 
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sensor performance the most was likely to be anticoagulants leading to excessive bleeding if sensor 
insertion ruptured a capillary, as it generated at least one conclusive sensor failure. However, as all but 2 
patients were receiving anticoagulant medication it was impossible to quantify the direct impact of this 
medication on MARD. Nurse compliance was good and feedback was mainly neutral. The high number of 
disconnects of sensor cable and monitor was a key concern for nurses.   
 
For CGM to be successful in reducing nurse workload and increasing patient safety the following 
recommendations are made:  
 Avoid severely oedematous patients where fluid is likely to leak from ruptured skin 
 Waterproof CGM sensors  
 Reconsider insertion technique to lessen the risk of capillary damage   
 Wireless transmission between sensor and monitor unit for ease of patient mobility  
In summary, the Sentrino CGM system has shown potential to be of assistance in the ICU environments. 





Chapter 6. Sensor Modelling  
Before CGM can be used to guide glycaemic control protocols the impact of suboptimal accuracy resulting 
from error or delay in calibration measurement, sensor drift, and delayed glucose diffusion must first be 
characterised. Characterising this error allows models to be formed so in-silico simulations can test the 
performance and safety of CGM driven glycaemic control protocols and examine best and worst scenarios.  
In this chapter a CGM model is formed based on the clinical data collected in Phase I and IIA of the Sentrino 
trial. This data will then be used in the Chapter 7, to investigate the impact in silico of using Sentrino 
measurements to guide glycaemic control.  
 
6.1 Introduction  
Two in-silico studies (Signal et al., 2010, Mombaerts et al., 2015) and a recent pilot observational trial 
(Signal et al., 2013) have shown that CGM devices, when coupled with a well-designed GC protocol, offer 
several potential benefits over the standard practice of intermittent BG monitoring. These studies have 
shown that CGM devices have the ability to reduce hypoglycaemia, maintain BG control, and reduce nurse 
workload.  
 
Typical glycaemic control protocols require BG measurements every 1-4 hours (Evans et al., 2012, 
Lonergan et al., 2006a, Plank et al., 2006, Blaha et al., 2009, Stewart et al., 2016), typically resulting in 
approximately 12-16 blood draws a day per patient. This frequency can represent a measurable part of 
total nurse workload (Carayon et al., 2005, Holzinger et al., 2005). CGM devices have the potential to 
drastically reduce the number of BG measurements per day, positively impacting workload, while 
improving patient safety and increasing time in the desired BG target band.  
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However, CGM devices tend to have suboptimal accuracy resulting from error or delay in calibration 
measurement, sensor drift and delayed glucose diffusion (Zimmermann et al., 2012, Facchinetti et al., 
2014, Reifman et al., 2007, Kuure-Kinsey et al., 2006). Thus, before CGM can become ubiquitous in the 
care of critically ill patients these errors on BG control must first be quantified and understood. 
Subsequently, their interaction with GC protocols and resulting impact on performance and safety can be 
assessed.     
 
Despite significant outpatient use and promise for CGM (Breton et al., 2008, Klonoff, 2005a, Klonoff, 
2005b) the literature contains very few reports of error models derived from clinical SG data. Without a 
good model of CGM dynamics the feasibility of CGM combined with GC cannot be assessed in-silico.  Two 
studies have provided sufficient details of CGM device error characteristics to allow models to be created 
or reproduced for use in-silico (Breton et al., 2008, Goldberg et al., 2004). However, these models are now 
ten years old and significant advances in sensor technology mean the level of error produced by these 
models no longer characterises the dynamics of more recent CGM devices. Therefore, this chapter 
presents and validates a simple CGM error model based on the latest available CGM devices. 
  
6.2 Subjects and Methods  
6.2.1 Patients 
This study uses data from an observational pilot study of CGM in patients admitted to the Christchurch 
Hospital ICU during 2014-15. This analysis uses CGM and BG data from 21 patients who were recruited to 
Phase I and Phase IIA of the Sentrino trial, as detailed in Chapters 3-5. All patients were recruited by a 
physician in the ICU and informed written consent obtained. If the patient was unable to consent next of 
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kin were approached for consent and follow up consent was obtained from the patient at a later date if 
applicable.  Inclusion criteria were: 
1)  Two consecutive  BG  measurements  greater  than  8 mmol/L,  indicating  the  need  for insulin  
therapy  using  the  STAR  protocol (Evans et al., 2012) 
2) Expected admission of at least 3 days  
3) Over 18 years of age 
4) A platelet count > 30,000/mL.   
Patients were excluded if they were not expected to survive, receiving hydroxyurea, pregnant, and/or 
lacked clinical equipoise. This study and use of  data  was  approved  by  the  Upper  South  A  Regional  
Ethics  Committee, New Zealand (URA/12/02/004). Table 6.1 shows the patient demographics. 
Table 6.1 Patient demographics displayed as median [IQR] where appropriate. APACHE II = Acute Physiology and 
Chronic Health Evaluation II 
Patients 21 
Ages (years) 60 [55 – 68] 
Sex (M/F) 11/9 
APACHE II score 20 [16 – 25] 
Outcome (Lived/Died) 14/7 
 
All patients were monitored for a period of up to 3 days using the Sentrino monitoring system (Medtronic, 
MiniMed, Northridge, California), as detailed in Chapter 3. Patients had either one abdomen and one thigh 
sensor, two abdomen sensors or one thigh sensor inserted by a trained clinician, depending on which trial 
phase they were enrolled in.  Calibration BG measurements were obtained by specifically trained ICU 
nurses at least  3  times  per  day  as  recommended  by  the  device  manufacturer  (Medtronic, MiniMed, 
Northridge, California) using the Roche Accu-chek Inform II (F. Hoffmann-La Roche Ltd, Basle, Switzerland) 
hospital grade glucose meters as is standard practice in the Christchurch ICU, with blood typically obtained 
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from an arterial line. CGM devices were strictly not used for determining treatment for GC during this 
study. 
 
In addition to BG measurements used for calibration of SG data, each patient had intermittent BG 
monitoring every few hours.  The  STAR  protocol  requires,  on average,  12-14  BG  measurements  per  
day  to  guide  insulin/nutrition  therapy (Fisk et al., 2012). These additional reference measurements can 
be used to assess CGM accuracy.  
 
Each SG signal was treated separately for modelling purposes. Three patients were excluded from the 
analysis, Patients 17, 21 and 24. As noted in Chapter 5, these patients had early sensor failure and were 
deemed clinically unsuitable for replacement sensors. Hence, not enough data was collected from these 
patients to be relevant to the model. Additionally, any data characteristic of a failed sensor or 
uncharacteristic of a sensor signal was removed, shown in Figures 6.1 – 6.6. This removal resulted in 28 
separate SG signals for analysis. Table 6.2 summarises the data used for modelling and validation.   
 
Table 6.2 Data used for modelling and validation 
No. SG signals 28 
No. SG hours 1689 
No. Calibration measurements 380 
No. Reference measurements 669 
 
 
6.2.2 The Model 
The error in a CGM signal can be broken down into separate parts specifically, the true BG signal noise 
and drift:  
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𝐶𝐺𝑀 =  𝐵𝐺𝑟𝑒𝑎𝑙 + 𝑛𝑜𝑖𝑠𝑒 + 𝑑𝑟𝑖𝑓𝑡                                                             Eq. 6.1 
 
Where noise is the random error centred about zero and drift is a linear bias between calibration 
measurements. Noise and drift were modelled based on clinical Sentrino data to create a model of CGM 
behaviour to be added to reference blood glucose values in order to simulate the effects of CGM error on 




Figure 6.1 The sensor glucose that was removed from Patient 1’s sensor glucose signal is shown in red. This data was removed as 





Figure 6.2 The sensor glucose that was removed from Patient 4’s sensor glucose signal is shown in red. This data was removed as 
after the initial calibration sequence the sensor has failed immediately.    
 
Figure 6.3 The sensor glucose that was removed from Patient 5’s sensor glucose signal is shown in red. The sensor has failed very 




 Figure 6.4 The sensor glucose that was removed from Patient 6’s sensor glucose signal is shown in red. The sensor has become 
disconnected from the monitor resulting in an erroneous spike when reconnected.  
 
Figure 6.5 The sensor glucose that was removed from Patient 22’s sensor glucose signal is shown in red. Sensor has failed upon 




Figure 6.6 The sensor glucose that was removed from Patient 23’s sensor glucose signal is shown in red. These large spikes in 
sensor glucose were not seen in any other patient and are likely caused by damaged pin ports on the sensor - monitor connection. 
A hardware fault rather than a characteristic of the sensor.  
 
 
6.2.2.1 Drift  
A constant rate drift with a linear bias, was assumed for the drift model. Drift was defined as the rate of 
increase in discrepancy between CGM signal and reference BG measurements between calibration BG 
measurements. Simply, drift is the rate of change of CGM bias relative to BG measurements.  The drift 
profile between any two calibration BG measurements was then defined by delta, the accumulated drift 
magnitude. The magnitude of accumulated drift between any two calibration BGs was found by measuring 
the size of the bias (CGM value – Calibration BG) at the second calibration BG as shown in Figure 6.7.  Once 
delta is identified for each calibration measurement it can be removed from the SG for further analysis. 




Figure 6.7 Example of accumulated drift in a SG signal and a SG signal once drift is removed 
 
The section between each calibration measurement was considered independently in further analysis 
because calibration should correct for any drift. Autocorrelation of the delta data shows no tendency for 
a sensor to repeatedly drift in the same direction, as shown in Figure 6.8.  Autocorrelation is the 
normalised dot product of the signal after it has been shifted in time by some amount. The resultant angle 
,𝜃, shows the trend similarity between two vectors and its cosine has values from -1 and +1 demonstrating 
opposing to complete agreement. A lag window of up to 10 minutes was considered. Therefore, the 
similarity of the signal to itself was compared every minute from 10 minutes before to 10 minutes after 










 Figure 6.8 The autocorrelation of the delta drift data over a lag window of +10 and -10 minutes, for all data points. There is no 
correlation evident with in this window.  
 
An empirical model of drift was implemented from the cumulative distribution function (CDF) of the delta 
data across the entire cohort using inverse transform sampling, as shown in Figure 6.9. This method is 
implemented by interpolating the CDF to 100,000 points to ensure a smooth curve. A uniform random 
number generator then selects a value in the range 0 – 1 which was then used to obtain the corresponding 
interpolated CDF delta value. The process can be repeated resulting in a dataset that has the same 





Figure 6.9 The cumulative distribution function of the delta drift data  
 
6.2.2.2 Noise 
Sensor noise contributes the remaining zero mean, random error to the modelled CGM signal of Equation 
1. Noise was split into two components, low and high frequency noise.  Low frequency noise is considered 
“the long duration” sensor noise, or, in this case, the difference between reference BG and the SG once 
drift is removed. High frequency noise is the “minute to minute” noise that gives the SG signal a jagged 




The low frequency noise was considered to be the difference between the each independent reference 
BG and the drift-corrected SG signal. Low frequency noise accounts for the error that occurs intermittently 
over longer time periods, which could be induced by events such as turning or other accidental pressure 
applications on the sensor site (Helton et al., 2011a, Helton et al., 2011b). As was done for the drift data, 
an empirical model was generated from a CDF of low frequency noise by inverse sampling.  
 
Unlike low frequency sensor noise, high frequency sensor noise occurs minute-to-minute and results in 
the 'jagged' appearance of the CGM signal. High frequency noise represents electrical noise, random 
variation induced by the imperfect reading and transmission of the sensor signal.  High frequency noise is 
very small in magnitude thus does not affect the identification of low frequency noise. A simple model 
was created using the CGM data by calculating the size of the changes in glucose from sample to sample 
(every minute).  The sample-to-sample change was then halved to obtain an amplitude because noise is 
assumed to be zero mean so sample-to-sample changes would double the amplitude found over many 
measurements. Thus, it yields an independent, random added noise with sample-to-sample changes 
similar to those observed in the empirical data. 
 
6.2.3 Modelling Sensor Glucose  
To ensure the CGM model produced similar dynamics to the CGM sensors, the 28 data sets containing 
true reference and calibration BGs provided the framework to generate modelled SG signals. The 
reference and calibration BGs were linearly interpolated to give a 'true BG signal'. CGM drift, and noise 




A drift profile was then created using the empirical drift model to randomly generate a drift delta value 
for each 8 hour calibration interval, as shown in subplot B of Figure 6.10.  A low frequency noise profile 
created by sampling every 160 minutes from the low frequency error model. Samples were taken at 160 
min intervals as opposed to at the time of reference BG measurements because some data sets contained 
infrequent reference BG measurements and the mean reference measurement interval across the 
available dataset was 160 minutes. Consecutive samples were linearly interpolated and a median filter 
was used to smooth the error signal, as shown in subplot C of Figure 6.10, where the median filtering 
removes the uncharacteristic sharp edges introduced by the linear interpolation between the error points.   
Finally, a high frequency noise profile was generated every minute by randomly sampling from the 
empirical high frequency model, as shown in subplot D of Figure 6.10. The summed result of each 





Figure 6.10 Example of the process undertaken to model a SG signal. First the BG measurements are interpolated, A. Then drift, 
low frequency and high frequency error are found by sampling from their empirical distributions, B, D and C respectively. Finally, 










6.4 CGM Sensor Model Validation  
The CGM model is a created using random process. Therefore, it cannot be deterministically compared to 
actual measured CGM data and no two uses of the model for the same true BG data yield the same result. 
Thus, to validate the modelled signals, autocorrelation was used to assess the similarity of the simulated 
CGM signals to the original CGM data. All signals were first mean shifted to remove bias before 
autocorrelation was applied to remove bias. If the resulting autocorrelation coefficients of the simulated 
SG and real SG are similar then the model can be considered to provide a realistic approximation of the 
sensor dynamics.  
 
Fifty SG signals were simulated for each patient and the autocorrelation coefficient was calculated for the 
real and each simulated signal over a +10 mins to -10 mins window. The median and range of correlation 
coefficients of the modelled SG was then compared to the correlation coefficient of the measured SG. The 
closer the agreement between the correlation coefficients of the simulated signals, and the correlation 
coefficient of the real CGM signal the better the model.  
 
6.5 Results and Discussion  
Visually and qualitatively, the CGM model generates similar signals to the empirical data. An example 
signal is shown in Figure 6.11 with real SG and 3 simulated signals. In particular, it is difficult to distinguish 








Figure 6.12 displays the median and range of autocorrelation values for each time lag for each patient’s 
modelled SG signals. The modelled SG show very similar autocorrelation trends to those displayed by the 
measured data. Measured SG is less tightly correlated than the median modelled SG in the majority of 
cases. However, only 3/28 measured SG values (A, B and C in Figure 6.11) do not sit within the range of 
modelled SG across all of the 20 minute windows and the median difference between the modelled and 
measured SG correlation values was 0.007 with a range of 0 – 0.13, the biggest differences occurring at 




Figure 6.12 Comparing the autocorrelation coefficients for the real SG to the median and range correlation coefficients of the 








Figure 6.13 The sensor glucose for the three instances where the autocorrelation range of the modelled SG does not include the 







The SG of the three instances (A, B and C in Figure 6.11) where the measured SG autocorrelation does not 
fall within the range of modelled SG autocorrelation for all time lags are shown in Figure 6.13. It is evident 
the lack of agreement is most likely due to individual cases where the sensor did not behave as expected 
and the behaviour cannot be easily explained by the noise and error types defined. Subplot A corresponds 
to the A in Figure 6.12 and the high frequency noise has increased noticeably about halfway through the 
signal which is not seen in any of the other 28 SG signals. Subplot B corresponds to the SG of Figure 6.13.B. 
The sensor glucose has many small unusual spikes uncharacteristic of the other sensors. Subplot C 
corresponds to Figure 6.13.C where there is a large drop out at 300 minutes in SG compared to an 
otherwise stable signal with some strange spikes.   
 
Additionally, over all patients sensor glucose is very tightly correlated in both measured and modelled SG. 
This result is logical as the rate of which blood glucose can change is physiologically limited and under 
normal conditions blood glucose will be related over a short time period, such as 10 minutes.  However, 
if the time lag is extended to ±20 or ±30 minutes the correlation coefficients of both the modelled SG and 
measured SG reduce, as expected.    
 
6.5.1 Limitations  
This analysis is limited by only have 28 data sets to generate the model from. A larger cohort would 
provide more data to generate the empirical models from. However, the consistency of the 
autocorrelation coefficients of the simulated signals to the real SG value indicates there is enough data to 




Another limitation is the limited choice of noise/error types. However, the 3 choices cover most variations 
observed clinically without adding extra complexity and unnecessary dynamics. Finally, this model is 
limited by the fact it is data driven, not a dynamic, deterministic model.  The benefits of this method are 
that it simplifies the process of calculating exact dynamic and electronic, physiological and other noise 
causes/sources.   
 
6.6 Summary  
The CGM error model generated using the Sentrino data provides a realistic SG signal. Only 3 of 28 
measured SG values do not sit with in the range of modelled SG across the entire 20 minute window 
considered. The median absolute difference between modelled and measured SG autocorrelation values 
was 0.007 with a range of 0 – 0.13. Hence, the model is judged to be suitable for use in simulation to 
provide better insight into using CGM to guide GC will effect control and its safety and performance. The 






Chapter 7. Virtual Trials with Continuous Glucose Monitoring Data  
This chapter investigates the impact of CGM sensor errors on GC results using the simple CGM error model 
developed in Chapter 6. Virtual trials are used to test the impact of CGM guided GC using the STAR 
protocol. Virtual trials allow the safety and performance of CGM guided GC to be tested and a protocol to 
be optimally designed before attempting real world clinical trials.  These virtual trials were necessary to 
assess impact of Phase IIB of the Sentrino trial, using CGM to guide STAR, to ensure patient safety before 
the interventional clinical trial was undertaken.     
 
7.1 Introduction  
Continuous glucose monitoring (CGM) devices, with their 1-5 minute measurement interval, have recently 
been used to monitor critical care  patients’  BG in a more continuous, less invasive manner than 
intermittent bedside BG measurements alone (Pretty et al., 2010, Signal et al., 2010, Beardsall et al., 2005, 
Harris et al., 2010, Holzinger et al., 2010, Brunner et al., 2011). Typical GC protocols for intensive care 
require BG measurements every 1-4 hours (Evans et al., 2012, Lonergan et al., 2006a, Plank et al., 2006, 
Blaha et al., 2009, Stewart et al., 2016), resulting in approximately 12-16 blood draws a day per patient. 
Thus, GC related activity represents a significant component of nurse workload (Carayon et al., 2005, 
Holzinger et al., 2005). CGM devices have the potential to drastically reduce the number of BG 
measurements per day, and thus the workload associated with GC protocols, while ensuring patient safety 
and increased time in the desired BG target band.  
 
However, CGM devices can display suboptimal accuracy resulting from error or delay in calibration 
measurement, sensor drift and delayed glucose diffusion (Castle et al., 2010, Facchinetti et al., 2014, 
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Zimmermann et al., 2012, Reifman et al., 2007, Kuure-Kinsey et al., 2006). Thus, before CGM can become 
ubiquitous in the care of critically ill patients these errors and the effects of these errors on BG control 
must first be quantified and understood.  In particular, quantifying their impact on GC will enable better 
GC protocol design that best utilizes the advantages of these devices, while minimizing the impact of their 
disadvantages.  
 
This chapter uses the simple CGM error model presented in Chapter 6 to investigate the impact of the 
CGM error on  the results of the STAR protocol (Stochastic TARgeted) (Evans et al., 2012), which has been 
standard care in Christchurch ICU since.  Alarms and guardrail threshold settings are investigated to 
ensure patient safety, especially in the hypoglycaemic region, while avoiding nurse alarm fatigue.  The 
overall goal is to delineate the impact of the advantages and disadvantages offered by CGM devices on 
GC and this specific protocol.  
 
7.2 Subjects and Methods 
7.2.1 Subjects 
Virtual trials were performed using retrospective data from 286 patients treated by the STAR glycaemic 
control protocol at Christchurch Hospital ICU between 2011 and 2013. All patients were treated with the 
tablet-based STAR protocol for > 10 hours. Cohort demographics are presented in Table 7.1.  
Table 7.1 Cohort demographics of the patients used for virtual trials. Data are presented as median [interquartile 
range] where appropriate. 
Number 286 
Age (years) 64.0 [54.0 - 72.0] 
Gender (M/F) 189/97 
APACHE II score 21.0 [16.0 - 27.0] 
Hospital mortality (L/D) 192/94 
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7.2.2 Virtual Trials  
The effect of CGM error on GC was tested using a virtual trial approach (Chase et al., 2010). This approach 
uses virtual patients, each comprising an insulin sensitivity (SI) profile identified from the clinical data of 
a real patient using a pharmacokinetic-pharmacodynamic (PK-PD) model of the glucose-insulin system 
(Lin et al., 2011). The SI profile can then be used with the PK-PD model to simulate the glycaemic outcome 
of different insulin and nutrition interventions. 
 
To test different combinations of guardrails in Monte Carlo (MC) simulations a smaller sub cohort was 
randomly chosen from the original cohort to reduce computational time. Table 7.2 shows the measures 
used to characterise the cohorts are very similar and p-values calculated using the non-parametric 
Wilcoxon rank sum test show that the randomly selected test cohort and the original cohort are not 
significantly different. 
 
Table 7.2 Summary data used to characterise the original and test cohort. Data are presented as median 
[interquartile range] where appropriate. 
 Test Cohort Entire Cohort P-value 
Number 20 286  
Median time analysed [IQR] (Days): 2.17 [1.53 - 5.97] 2.21 [1.17 - 3.89] 0.40 
Median [IQR] Measures/day (Per-Patient): 12.94 [10.32 - 14.61] 12.80 [11.34 - 15.10] 0.29 
BG median (mmol/L): 6.48 [6.35 - 6.59] 6.50 [6.14 - 6.90] 0.37 
BG mean (mmol/L): 6.59 [6.46 - 6.87] 6.66 [6.36 - 7.21] 0.46 
BG SD (mmol/L): 1.27 [0.92 - 1.88] 1.17 [0.85 - 1.65] 0.55 
 
Guardrails, as outlined in Chapter 7, are upper and lower limits of SG. When the SG value crosses either 
the upper or lower limit the Sentrino will alarm, alerting the nurse that the SG has left the desired range. 
Their goal is to minimise the impact of CGM drift and also increase patient safety by alerting staff to 
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potential hypo- or hyper- glycaemic events.  In this virtual simulation, if the hypo or hyper alarm was 
triggered a BG measurement was taken to verify the event or correct the sensor.   
 
To use CGM values to drive STAR, a minutely CGM signal was created using the method and sensor model 
detailed in Chapter 6 and virtual patient data to represent patient specific response. When STAR required 
a BG input during the virtual trials the CGM value at that time point was taken and used to determine 
insulin and nutrition values. If a guardrail was crossed at any time a BG value was virtually measured and 
compared to the modelled sensor glucose value. If the absolute difference of SG and BG was greater than 
the allowed tolerance the CGM was recalibrated using this BG measure, and the BG measurement was 
used for control. This recalibration was performed by resetting the drift to zero. If the absolute difference 
of SG and BG was less than the allowed tolerance then the SG measurement was still used for control. In 
each case these added measurements count towards assessed control. 
 
To test the best possible guardrail and tolerance combination lower guardrails of 4.0, 4.5 and 5.0 mmol/L 
were selected. The absolute difference between the sensor glucose and the measured blood glucose 
when a lower alarm occurred was allowed to be 0.5 mmol/L or 1.0 mmol/L. The hyperglycaemic alarms 
trialled were at 8.0, 9.0 and 10.0 mmol/L with a tolerance of either 1.0 mmol/L or 2.0 mmol/L. The smaller 
tolerance on the hypoglycaemic alarms was selected due to safety being the most important clinical factor 






7.2.2 Analysis  
MC methods were employed to reduce the impact of randomly sampled outliers on results. A 50-run MC 
simulation was completed for each virtual patient. Blood glucose values were generated using the 
clinically validated Intensive Control Insulin-Nutrition-Glucose (ICING) model of the glucose-insulin system 
(Lin et al., 2011) was used. Sensor drift and noise was added to the measurements using the CGM model. 
These BG measurements were then given to the STAR protocol generate insulin and nutrition 
interventions. This situation simulates what it would be like if CGM devices were being used to guide the 
protocol in clinic.  
 The metric to assess performance was selected to be %time in the desired 4.4 – 8mmol/L band. To assess 
safety the percentage of time spent hypoglycaemic, %time below 4.4mmol/L and the percentage of severe 
hypoglycaemia - %time below 2.2mmol/L was considered. The total number of blood draws and number 
of alarms were used to assess the resulting workload of using CGM devices, with and without guardrails, 
to guide the STAR protocol. MC results were compared the clinical results of the 286 STAR patients. 
 
7.3 Results and Discussion  
Simulating STAR driven by sensor glucose measurements without guardrails on the test cohort resulted in 
a median [IQR] time in the 4.4 – 8.0 mmol/L band of 74.1 [73.4 75.2] %. The median [IQR] percentage of 
time below 4.4 mmol/L was 3.1 [2.7 3.4] % and time below 2.22 mmol/L was 0.0 [0.0 0.1]. The total 
number of blood draws was 291 [291 291] compared to 970 measurements required by STAR, a reduction 




Table 7.3 summarises the performance, safety and workload metrics across all 36 different combinations 
of guardrails and allowable SG error. It is evident that to improve safety most effectively, guardrails of 4.0 
– 8.0 mmol/L should be in place as the median [IQR] percentage of time below 4.4 mmol/L is reduced to 
2.5 [2.1 3.2] %. However, this slight increase in safety translates to a large increase in workload compared 
to not using guardrails with 863[850 872] blood draws required and 572[559 581] alarms and only slightly 
less blood draws than required by STAR. 
 
The most effective way to improve performance with the least measurements are guardrails of 5.0 – 10.0 
mmol/L. The median [IQR] time in the 4.4 – 8.0 mmol/L band is 77.1[76.3 77.9] % with 693[679 707] blood 
draws and 403[388 416] alarms. However, safety decreases with an increase in time below 4.4 mmol/L 
and time below 2.22 mmol/L.  
 
The lowest workload is achieved with guardrails of 4.0 – 10.0 mmol/L.  The median [IQR] number of blood 
draws is 532[519 542] with 241[228 251] alarms. However, performance and safety are no better than 
when guardrails are not applied, but the number of blood draws required is nearly double.   
 
The tolerance value, the absolute difference between the SG and the measured BG when an alarm occurs, 
does not appear to have much impact on safety, workload, or performance with the tolerance values 
selected.   Safety appears slightly better with the hyperglycaemia alarm tolerance of 1.0 mmol/L and 
counter intuitively workload appears marginally less. There is no distinguishable difference between the 
hypoglycaemic alarm tolerance of 0.5 mmol/L or 1.0 mmol/L. Hence, the tolerance of 0.5 mmol/L for 
hypoglycaemic alarms and 1.0 mmol/L for hyperglycaemic alarms was selected as the best solution.  
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Safety is one of the most clinically important factors when considering glycaemic control protocols. Hence, 
the guardrails that produced the lowest amount of hypoglycaemia were selected to be simulated with the 
entire cohort data. In addition, the improvements seen in performance for this case were not substantial 
and still required a higher workload than desired. Table 7.4 shows the comparison between STAR, STAR 
CGM without guardrails, and STAR CGM with guardrails at 4.0 – 8.0 mmol/L.  
 
When guardrails are used there are only 1474 less blood draws on average than clinical STAR resulting in 
5 less blood draws per patient on average, saving approximately 10 minutes per patient or 49 hours total. 
While, there are 8124 less blood draws on average without guardrails resulting in 28 less blood draws per 
patient, saving approximately 56 minutes per patient or 270 hours total. Guardrails make very small 
improvements in safety compared to STAR CGM with the median interquartile range for the number of 
serve hypoglycaemia events being 10 [8 11] and 10 [9 12], respectively. However there is a median of 993 
hypoglycaemic alarms and 5672 hyperglycaemic alarms, and 3 and 20 alarms per patient, respectively. 
 
In theory, guardrails are introduced to improve safety and performance by alerting the nurse to when the 
patient has or is about to leave the desired target band of 4.4 – 8.0 mmol/L. For this idea to work in 
practice, the sensors need to be accurate enough to avoid too many instances where drift results in false 
alarms. Some further discussion and examples of this behaviour can be seen in Chapter 4, in particular 
Figure 4.2. Currently, with the limitations discussed in Chapter 5 the Sentrino sensors are not accurate 
enough to display the benefit of guardrails with blood draws being required to correct the Sentrino signal 
on nearly every alarm. Additionally, the STAR protocol achieves very good and safe control already. Hence, 
improving the “safety” of the protocol is difficult with only 1.35% time below 4.4mmol/L. Perhaps, with a 




STAR achieves better control when BG measurements are used for control rather than SG measurements, 
as the protocol depends on the current and previously entered glucose values to identify SI. If there is 
large error in one or both of these entered values then the SI level identified will not be correct leading to 
a reduction in model-based control quality. In particular, the SI level identified is used with a stochastic 
model to forward predict what BG is likely to be in 1, 2 or 3 hours time and the nutrition and insulin 
required to achieve this outcome. Therefore, if SI is incorrectly identified due to erroneous SG 
measurements the nutrition and insulin recommended by STAR is also likely to be incorrect resulting in 
the patient becoming either hypo- or hyper- glycaemic depending on the direction the sensor is drifting.   
 
 
Future work in this area could include the addition of adaptive guardrails that can adjust targets and 
tolerances based on how the sensor is performing and observed patient variability. However, the sensor 
performance would need to improve for these additions to be effective and prevent alarm fatigue. Also 
to implement adaptive alarms there would need to additional functionality in the CGM device, something 
that is not currently available with the Sentrino or other similar devices.    Another future study, using the 
drift model from Chapter 6 and this virtual trial method, investigating the level of drift acceptable 
performance could be useful. This way, device manufacturers would have a better idea of what 
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Table 7.4 Summary of performance, safety and workload of STAR CGM compared to Clinical STAR data. Data are 
presented as median [interquartile range] where appropriate. 
  
STAR CGM  
 Guardrails  
STAR CGM Clinical STAR 
No. Patients 286 286 286 
No. Hours 21770 [21761 21776] 21765 [21756 21775] 21769 
No. STAR Measurements 13758 [13721 13804] 14622 [14574 14687] 11552 
No. Blood Draws 10078 [10033 10137] 3428 11552 
Median BG 7.35 [7.34 7.36] 7.20 [7.19 7.21] 6.61 
% BG  4.4 – 8.0 mmol/L 70.9 [70.4 71.0] 72.2 [71.9 72.4] 83.3 
% BG < 4.4 mmol/L 2.25 [2.19 2.33] 2.62 [2.53 2.71] 1.35 
% BG < 2.2 mmol/L 0.09 [0.07 0.10] 0.09 [0.08 0.10] 0.005 
No. Episodes BG < 2.22 mmol/L 10 [8 11] 10 [9 12] 4 
% BG > 10 mmol/L 4.56 [4.51 4.62] 4.44 [4.38 4.49] 4.10 
No. Hypo Alarms  993 [975 1017] 0 0 
No. Hyper Alarms 5672 [5614 5703] 0 0 
 
 
7.4 Summary  
This chapter investigates the impact of CGM sensor error on the STAR glycaemic control protocol using 
the simple CGM sensor error model created in Chapter 6. Alarms and guardrail threshold settings were 
also investigated to insure patient safety, especially in the hypoglycaemic region, while avoiding nurse 
alarm fatigue. The effect of CGM error on glycaemic control was tested using a clinically validated virtual 
trial approach using retrospective data from 286 patients treated by the STAR glycaemic control protocol 
at Christchurch Hospital ICU between 2011 and 2013.   
 
Multiple Monte Carlo simulations on a sub cohort displayed the trade-off between safety, performance 
and workload. A hypoglycaemic alarm threshold of 4.0 mmol/L and a hyperglycaemic alarm threshold of 
8.0 mmol/L best balanced the trade-off between performance and workload, while maintaining high 
safety. The most clinically important feature of any glycaemic control protocol. In full cohort simulations, 
89 
 
there were only 1474 less blood draws on average than clinical STAR resulting in 5 less blood draws per 
patient on average. While, there are 8124 less blood draws on average without guardrails resulting in 28 
less blood draws per patient. Guardrails, thus, make very small improvements in safety compared to STAR 
CGM without guardrails with the median interquartile range for the number of serve hypoglycaemia 
events being 10 [8 11] and 10 [9 12], respectively.  
 
Guardrails are introduced to improve safety and performance by alerting the nurse to when the patient 
has or is about to leave the desired target band. However, to be effective the sensors need to be accurate 
enough to avoid too many false alarms. Currently, the sensor technology trialled here, with the issues 
outlined in Chapter 5, is not accurate enough to display the benefit of guardrails and if it was used to guide 
glycaemic control there would be a large increase in hypoglycaemic events. Additionally, the STAR 
protocol achieves very good and safe control already hence improving the “safety” of the protocol is 
difficult with only 1.35% time below 4.4 mmol/L. Potentially, a less successful glycaemic control protocol 
would display the greater benefit of the Sentrino guardrails. 
 
Due to the concerns surrounding the performance of the sensor the interventional phase of the Sentrino 
trial, Phase IIB, was not implemented. For an interventional trial like Phase IIB to commence, the sensor 
technology would need to be improved following the recommendations presented in Chapters 2 – 7. 
Specifically, in this chapter the quality of measurement has been shown to be more important than the 




Chapter 8. Summary of CGM in ICU  
The potential benefits and pitfalls of CGM in the intensive care unit have been identified in an 
observational pilot trial using off-the-shelf CGM devices designed for use individuals with Type 1 and Type 
2 diabetes (Signal et al., 2013).  Recently, a CGM device specifically designed for the ICU became available, 
The Sentrino (Medtronic, MiniMed, Northridge, California), and has displayed promising results in initial 
trials in the cardiac ICU (Kosiborod et al., 2013) . Hence, a larger scale study was designed for 
implementation in Christchurch Hospital mixed medical ICU to gather further information about the 
feasibility of CGM in ICU. The first half of this thesis investigates using the Sentrino CGM devices in adult 
ICU, with the overall goal of improving BG control and increasing patient safety, while reducing nurse 
workload. In short, can greater data of potentially lesser quality outweigh much lesser amounts of higher 
quality data? An assumption that some in the field believe to be true (Krinsley et al., 2008).      
 
The Sentrino trial was designed and undertaken in 2 phases run partially in parallel. The aim of this study 
was to investigate the performance of these new devices first observationally to ensure the safety and 
efficacy of their performance (Phase I). A further observational study assessed the performance and 
integration of hyper- and hypo- glycaemic alarms (Phase IIA). Finally, the design of a protocol using CGM 
measures to guide glycaemic control and investigation of the feasibility of implementing this protocol 
(Phase IIB). 
 
First, the performance of the Sentrino CGM system in a mixed medical ICU environment was analysed and 
the optimal sensor location confirmed. CGM and BG data were gathered from 13 patients recruited to 
Phase 1 of the trial.  Each participant in this study phase was monitored for a period of up to 3 consecutive 
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days with 2 independent Sentrino devices. For the majority of patients, 1 sensor was inserted in the 
abdomen and 1 sensor was inserted in the thigh.  Overall, the Sentrino device achieved a MARD of 14.7%. 
This result demonstrated slightly reduced performance from what was reported in an initial trial in a 
cardiac ICU where a MARD of 12.2% was seen. However, when considering device location, thigh SG 
achieved a MARD of 11.0% while abdomen SG achieved a MARD of 16.6%.  This result indicates that 
following the manufactures recommendation of thigh insertion, which is different to the location used for 
devices designed for ambulatory individuals with diabetes, is important to ensure sensor performance. 
The number of calibrations undertaken was double that recommended by the protocol and may have 
improved overall accuracy.  Overall, the Sentrino performance was acceptable, but with such a high 
number of additional calibration measurements required, questions still remain if this CGM system can 
reduce the time and workload cost of glycaemic control.   
 
Phase IIA was an observational study of the performance and integration of hyper- and hypo- glycaemic 
guardrail alarms with an existing, proven GC protocol. This study analysed SG and BG data, and alarm data 
from 8 patients recruited to this phase of the trial. An upper guardrail of 10.0 mmol/L and lower guardrail 
of 4.2 mmol/L were added in the device settings. When the SG value crossed either threshold an alarm 
would sound. BG measurement was then taken and compared to the SG value, where it would be used 
for recalibration if the SG-BG error exceeded a predefined threshold.  
 
Overall, sensor and alarm performance was good. However, there was a high rate of false positive alarms. 
Many of these false positives were caused by sensor artefacts, unexplained spikes or dips in sensor glucose 
or sensor drift. While false positives are safer for managing patient blood glucose than false negatives, of 
which there was only one, they did lead to nursing non-compliance in some cases. In summary, alarms 
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performed well for the most part, but to ensure better integration with current practices and nurse 
compliance, the protocol regarding false positives needs to be optimised.  
 
 The next analysis was undertaken to better understand the impact of sepsis, oedema and some 
medications on CGM results, as well as to assess the nurse compliance and feedback to gain insight in to 
the potential clinical impact of using CGM to guide GC. This analysis used data from 21 patients in Phase 
I and Phase IIA. Approximately 50% of all enrolled subjects were severely oedematous and/or septic by 
design, and thus represent a worst case, but typical cohort for a mixed medical ICU.  
 
For CGM to be successful in reducing nurse workload and increasing patient safety the following 
recommendations are made:  
 Avoid severely oedematous patients where fluid is likely to leak from ruptured skin 
 Waterproof CGM sensors  
 Reconsider insertion technique to lessen the risk of capillary damage   
 Wireless transmission between sensor and monitor unit for ease of patient mobility  
 
Before CGM can be used to guide glycaemic control protocols the impact of suboptimal accuracy resulting 
from error or delay in calibration measurement, sensor drift, and delayed glucose diffusion must first be 
characterised. Characterising this error allows models to be formed so in-silico simulations can test the 
performance and safety of CGM driven glycaemic control protocols and examine best and worst scenarios. 




The CGM error model generated using the Sentrino data provides a realistic SG signal. Only 3 of 28 sets of 
SG do not sit within the range of modelled autocorrelation results across the entire 20 minute window 
considered. The median absolute difference between modelled and measured SG autocorrelation values 
was 0.007 with a range of 0 – 0.13. Hence, the model is judged to be suitable for use in simulation to 
provide better insight into using CGM to guide GC will effect control and its safety and performance. The 
overall modelling process is data driven and readily generalised to any other CGM.  
 
Finally, the impact of CGM sensor error on the STAR glycaemic control protocol was investigated using 
the simple CGM error model generated. Alarms and guardrail threshold settings were also investigated to 
insure patient safety, especially in the hypoglycaemic region, while avoiding nurse alarm fatigue. The 
effect of CGM error on glycaemic control was tested with a virtual trial approach using retrospective data 
from 286 patients treated by the STAR glycaemic control protocol at Christchurch Hospital ICU between 
2011 and 2013.   
 
Guardrails are introduced to improve safety and performance by alerting the nurse to when the patient 
has or is about to leave the desired target band. However, to be effective the sensors need to be accurate 
enough to avoid too many instances of drop outs or drift resulting in false alarms. Currently, the sensor 
technology trialled here is not accurate enough to display the benefit of guardrails and if it was used to 
guide glycaemic control there would be a large increase in hypoglycaemic events. Additionally, the STAR 
protocol achieves very good and safe control already hence improving the “safety” of the protocol is 
difficult with only 1.35% time below 4.4 mmol/L. Potentially, a less successful glycaemic control protocol 




Due to the concerns surrounding the performance of the sensor Phase IIB of the Sentrino was not 
implemented. For an interventional trial like Phase IIB to commence, the sensor technology would need 
to be improved following the recommendations listed here. Overall, the work presented in Chapters 2 – 
7 contributes valuable information and insight to the use of CGM device in the intensive care unit. This 
work provides clear guidelines for how CGM devices can be optimised for this environment considering 
both the engineering and clinical perspective. The results presented provide a significant advancement to 
the body of knowledge surrounding the use of these devices in ICU and should be of significant use to 










Part II – Glucose Metabolism and CGM in Athletes   
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Chapter 9. Background Glucose Metabolism and CGM in Athletes  
This chapter provides background on the effects of exercise on the glucose metabolism during exercise 
and the effects of exercise on the overall glucose metabolism of athletes. An interesting comparison 
between the metabolism of intensive care patients and athletes is also made. Finally, the potential 
application of CGM devices to aid in improving athlete nutrition is reviewed. In particular, their potential 
to improve race performance and recovery.  
 
9.1 The Athlete Glucose Metabolism 
Exercise is well known and accepted to improve insulin sensitivity via acute and long-term training effects 
(Borghouts et al., 2000). However, the intensity of exercise defines the main source of energy, lipids or 
carbohydrates, during this exercise period and the metabolic response of the glucose metabolism (Marliss 
et al., 2002). Thus, the effects may vary not only between athletes, but by relative intensity and its impact 
on metabolism.  
 
During moderate exercise an increase in glucose utilisation is apparent (Goodyear et al., 1998, Marliss et 
al., 2002, Richter, 1996). This increased utilisation may in part be due to increased insulin sensitivity, as 
exercise increases the delivery of insulin to muscle by increasing peripheral blood flow allowing better use 
of plasma insulin (Marliss et al., 2002, Goodyear et al., 1998, Richter, 1996). However, an increase of non-
insulin mediated glucose uptake is likely to be the dominant factor based on published literature, because, 
despite falling plasma insulin and similar insulin secretion levels, glucose utilisation increases (Marliss et 




This increase in glucose utilisation is attributed to exercise allowing glucose uptake to occur through non-
insulin mediated GLUT4 transporters that are translocated to the cell wall without the need for the insulin 
signalling cascade (Goodyear et al., 1998, Marliss et al., 2002). Thus, while an increase in catecholamine 
production, which is known to inhibit glucose utilisation (Marliss et al., 2002), is likely to be present, the 
dominant effects of increased GLUT4 transport and delivery of insulin to muscles allows blood glucose 
utilization and production to remain stable.  
 
However, during intense exercise (VO2max > 80%) blood glucose and insulin secretion rise. This response 
is generated by the marked catecholamine response to intense exercise (Marliss et al., 2002, Calles et al., 
1983, Kjaer et al., 1986).  In general, this catecholamine response leads to increased hepatic glucose 
production and restriction of peripheral glucose utilisation resulting in hyperglycaemia and 
hyperinsulinemia at the end of an intense exercise session (Marliss et al., 2002, Kjaer et al., 1986, Calles 
et al., 1983). This response is similar to the stress-induced hyperglycaemia seen in ICU patients, the 
common factor being systemic inflammation due to their illness or induced by strenuous effort and its 
impact on insulin sensitivity, glucose uptake and hepatic glucose production (Collier et al., 2008). 
 
Studies comparing the metabolic and hormonal response to exercise between trained and untrained 
normal glucose tolerant individuals have found that glucose, glycerol, and free fatty acid concentrations 
are higher, but lactate, pyruvate, and alanine were lower in trained individuals, than in untrained 
individuals (Kjaer et al., 1986, Bloom et al., 1976). Cortisol, another stress hormone with hyperglycaemic 
effects, levels were also found to be higher in trained individuals (Bloom et al., 1976). Additionally, insulin 
secretion is known to be diminished in well trained individuals due to increased sensitivity and non-insulin 
mediated uptake (Lohmann et al., 1978). These results suggest there is significant adaptation of the 
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metabolism in well-trained individuals. However, there are only a few studies that investigate how 
metabolic parameters, such as endogenous glucose production change with exercise (Jeukendrup et al., 
1999, McConell et al., 2000), and none that attempt to quantify endogenous insulin secretion or sensitivity 
during exercise.   
 
9.2 Continuous Glucose Monitoring in Athletes 
Carbohydrates and lipids are the main fuel sources utilised during exercise. The more intense and longer 
duration the exercise the greater the dependence on carbohydrates.  Lipids require more energy to be 
broken down for fuel. Hence, the body will rely more and more on carbohydrates as the intensity of 
exercise increases (respiratory exchange ratio > 0.75), primarily from muscle glycogen stores.  
 
When exercise is prolonged (>60mins) muscle glycogen stores become depleted. Therefore, the body 
becomes more reliant on plasma glucose, liver glycogenolysis and gluconeogenesis for energy. After 
approximately 90 minutes of fasted exercise, blood glucose will begin to fall because glycogen stores are 
depleted and liver gluconeogenesis cannot fully compensate for energy expenditure (Felig et al., 1982).  
 
Plasma glucose levels are known to remain stable during moderate exercise < 60min (Romijn et al., 1993), 
but as intensity and duration increase it is likely this balance is difficult to maintain, especially in ultra-
distance events when gastrointestinal problems, reducing calorie intake, are common (Jeukendrup, 2004, 
Rehrer et al., 1992, Glace et al., 2002, Pfeiffer et al., 2012). Athletes are advised to consume 30-60g of 
carbohydrate/h during endurance exercise lasting > 1hr (American Dietetic et al., 2009, Jeukendrup, 2004) 
to ensure optimal performance and maintain blood glucose levels.   In one study (Fallon et al., 1998), 
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blood glucose was measured four times during an ultra-distance race (100km race, average finishing time 
10hr 39min) and found to remain relatively constant at each time point even though carbohydrate intake 
varied between 21.8 – 66.0 g/h. However, it is difficult to extrapolate between these time points to have 
any real understanding of blood glucose trends, and thus metabolic changes, during long distance events.  
 
An individual’s tolerance of carbohydrate is highly variable and is related to a number of factors including 
age and genetics (Zeevi et al., 2015, Vrolix et al., 2010). CGM devices have the potential to personalise 
nutrition based on post prandial glucose response (Zeevi et al., 2015). In addition, many athletes do not 
meet sports nutritional recommendations for carbohydrate intake, especially those in the sub elite 
category (Masson et al., 2016).  CGM could provide a greater insight in to what impact this failure to meet 
recommended guidelines has on plasma glucose levels, before, during and after an event.   
 
Such research using continuous glucose monitors has not been undertaken in athletic subjects before. 
However, real time knowledge of blood variables, such as glucose, is noted as the “future” of sports 
technology (Gizmag Team, 2007, Metz, 2014). It is important to assess if knowledge of real-time blood 
glucose can provide a deeper insight in to athletic performance or if it will just be a gimmick provided by 
sports device manufacturers to increase the popularity of their device. The following chapters investigate 




Chapter 10. Hyperglycaemia and Hyperinsulinemia Post Exercise 
Chapter 10 investigates the glycaemic response during and after strenuous exercise. Strenuous exercise 
leads to a marked catecholamine response and rise in blood glucose, similar to that seen in stress-induced 
hyperglycaemia in ICU patients. While this effect is noted in existing literature, the effect has not been 
examined thoroughly and not in a manner that is typical of an endurance event.  This chapter characterises 
the hyperglycaemia and hyperinsulinemia seen post exercise to better understand athlete metabolism, 
enabling a more realistic model to be developed.  
 
10.1 Introduction 
To ensure optimal recovery of glycogen stores, it is recommended and common practice to consume 1.0 
- 1.5 gcarbohydrate/kg within 30 mins after intense exercise (American Dietetic et al., 2009). This 
recommendation stems from the 1988 study by Ivy et al. (1988) that compared the level of glycogen 
restoration when 2g carbohydrate/kg was delivered immediately after exercise or delayed for two hours. 
The results of this study displayed a marked increase in muscle glycogen synthesis when carbohydrate 
was ingested immediately after exercise.  
 
However, this study and others also noted a persistent  elevation  of  insulin-antagonistic  hormones  and  
free  fatty  acids post intense exercise (Conlee et al., 1978, Danforth, 1965, Galbo et al., 1979, Ivy et al., 
1988, Marliss et al., 2002). This behaviour results in hyperglycaemia, hyperinsulinemia, and effective 
whole body insulin resistance, at the end of an intense exercise session. Marlis and Vranic (2002) reported 
that marked catecholamine responses to intense exercise are the main cause of the increase in hepatic 
glucose production and restraint of glucose utilization. 
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 Hyperglycaemia is an inflammatory marker (Collier et al., 2008) and blood glucose variability is a known 
risk factor in type 2 diabetes (Monnier et al., 2006, Brownlee et al., 2006). The immune system also fails 
to function optimally in the presence of high blood glucose levels (Sanchez et al., 1973, Marik et al., 2004, 
Jeandidier et al., 2006, Turina et al., 2005, Kijak et al., 1964). A single 100g dose of glucose can significantly 
impair the immune system for more than 5 hours (Sanchez et al., 1973, Kijak et al., 1964).  Furthermore, 
according to some surveys common minor illnesses, such as sore throats and flu-like symptoms are more 
common in athletes and may last longer (Gleeson, 2006). This compromised immune response has been 
linked to depression of immune system function, which is most pronounced after prolonged moderate to 
high intensity training or competition performed without food intake (Gleeson, 2006). Hence, as 
normoglycaemia is important for general health and well-being, it is thus equally or more important to a 
competitive athlete.  
 
This chapter examines the immediate effect of post intense effort glucose ingestion in a fashion more 
comparable to an actual athletic event to consider the duration and effect of post exercise hyperglycaemia 
and hyperinsulinemia induced by following current recommended nutritional guidelines for during and 
after exercise.  
 
10.2 Methods  
10.2.1 Subjects 
Ten fit, healthy, sub-elite athletes (resting heart rate (HR) < 60 beats per minute (BPM)) were recruited 
under informed written consent for a study investigating optimal athlete nutrition (henceforth referred 
to as athletes). Table 10.1 summarizes the cohort demographics. Seven out of the ten participants cycled 
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regularly and all subjects trained >6 hours per week in a range of endurance based sports, predominantly 
running and cycling. The research procedures and use of data were approved by the University of 
Canterbury Ethics Committee. 
Table 10.1 Cohort demographics of the participants. Data are presented as median [interquartile range] where appropriate 
Number 10 
Age (yr) 28 [23 37] 
Gender (M/F) 7/3 
BMI (kg/m2) 22 [21 24] 
Resting HR (bpm) 55 [53 56] 
VO2max (mL/kg/min) 46 [39 59] 
Trained Cyclist (Y/N)  7/3 
 
 
10.2.2 Experimental protocol 
Fasting exercise tests were carried out, as shown in Figure 10.1. Subjects were required not to exercise 
the day before the test. On the day of testing, the exercise protocol began at 8am after overnight fasting, 
and is defined: 
 0 - 60 min: Cycling on a stationary trainer (Cyclus 2, RBM elektronik-automation GmbH, Lepzig, 
Germany) in the submaximal endurance HR zone <70%VO2max with a resistance set to 2 W/kg 
for female and untrained cyclists or 2.5 W/kg for trained males.  
 30 min: Consume a 0.5 g/kg of body weight (30-45 g) glucose drink as per recommended practice 
of 30-60 g/h during endurance exercise lasting > 1hr (American Dietetic et al., 2009). This drink 
was consumed after blood samples for 30 min were taken. 
 60 min exhaustion (EX) (~90 min): Steadily increase effort until volitional exhaustion by 
increasing required power by 20W every 5 minutes mimicking the later stages of an endurance 
event where the effort required is likely to increase until the finish 
103 
 
 EX: Consume a 1 g/kg of body weight (60-90 g) glucose drink as per recommended practice to 
consume 1-1.5 g/kg of glucose for recovery of muscle glycogen post strenuous exercise lasting > 
1hr (American Dietetic et al., 2009). This drink was consumed after blood samples for EX were 
taken. 
Blood Samples assayed for plasma insulin and C-peptide were taken at:  
 0, 30, 45, EX, EX + 15 min, EX + 30 min (5/10 subjects), EX + 60 min 
Reference BG measurements were taken: 
 0 - 60 min: Every 10 min 
 60 min – EX + 30 min (~120 min): Every 5 min to better capture the changes in blood glucose after 
the during an intense work period and after the large glucose bolus 
 Exhaustion + 30 min (~120 min) – exhaustion + 60 min (~150 min): Every 10 min 
Other measurements:  
- Body weight, BMI, Body composition Analyser (InBody230, InBody Bldg, Seoul, Korea) 
- Indirect calorimetry (MetaLyzer 3B - R2, CORTEX Biophysik GmbH, Lepzig, Germany) 
- Lactate (Lactate Pro, Arkray Inc, Kyoto Miyuki Bldg. 10F, 689 Takanna-cho, Nakagyo-ku, Kyoto 
604-8153, Japan) 
 
Reference and calibration BG measurements were taken using capillary finger stick measurements and 
the Abbott Optimum Xceed (Abbott Diabetes Care, Alameda, CA) glucometer. The Abbott device has 
reported error of 5-10% (Abbott Diabetes Care, 2010, Thomas et al., 2014a, Signal, 2013). Insulin  and  C-
peptide  concentrations  were  determined  using  immunometric assays  (Elecsys  2010,  Roche  
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Diagnostics,  Germany). Only 5/10 subjects Ath06-Ath10 had a blood sample at exhaustion+30 minute due 
to an amendment in the protocol to allow the additional measurement.  
 
 
Figure 10.1 Schematic displaying experimental procedure 
 
10.2.3 Analysis  
Pancreatic insulin secretion can be determined from a series of plasma C-peptide measurements.  C-
peptide is produced by the pancreatic β-cells as a by-product of splitting insulin from its precursor, 
proinsulin, and is secreted in equimolar ratio with insulin (Rubenstein et al., 1969). Unlike insulin, C-
peptide is cleared almost entirely by the kidneys, making it a much more reliable marker of endogenous 
secretion than plasma insulin concentrations.  Therefore, models describing C-peptide kinetics and insulin 
kinetics can be used to determine and capture pre-hepatic insulin secretion (Polonsky et al., 1986, Van 
Cauter et al., 1992).  The pharmacokinetic model and population kinetic parameters reported by Van 
Cauter et al. (1992) were  used  to  deconvolve  insulin  secretion  rates  from measured  C-peptide  data.  




To report the overall impact on blood glucose, median and IQR are reported for BG, C-peptide, insulin 
secretion, and plasma insulin for each measured blood parameter at key points during the test. The 
individual values of each athlete for these parameter are also reported.  
 
10.4 Results  
Figure 10.2a, Figure 10.2b, and Table 10.2 show that during the first 30 minutes of cycling at submaximal 
levels (65-70% VO2max) blood glucose utilization and production remain in equilibrium as blood glucose 
remains constant with median [IQR] 5.5 [5.2 6.1] mmol/L at 0 minutes to 5.7 [5.3 6.3] mmol/L at 30 
minutes. However, there is a decrease in plasma insulin from median [IQR] 52 [38 63] pmol/L to 30.5 [20 
40] pmol/L during this initial phase of exercise. This decrease is important as it sensitizes the liver to 
glucagon to enhance hepatic gluconeogenesis (Marliss et al., 2002). Once the glucose bolus at 30 minutes 
is delivered there appears to be an increase in non-insulin mediated glucose uptake for 8/10 athletes, as 
seen in Figure 10.3a and 10.3b, because only Ath09 and Ath10 display any increase in insulin secretion 
and rise in blood glucose in response to this oral glucose does during this time.  
 
From 30 minutes until exhaustion, blood glucose levels rise, 5.7 [5.3 6.3] mmol/L to 8.0 [7.1 10.1] mmol/L, 
as a result of the first glucose bolus at 30min and increased hepatic glucose production due to the ramp 
test from 60min until exhaustion (>80%VO2max).  However, plasma insulin and C-peptide do not begin to 
rise until exhaustion is reached with concentrations similar to basal levels measured at exhaustion of 46.5 
[37 55] pmol/L and 635 [363 698] pmol/L, respectively. Insulin secretion rate is higher than basal levels 




After exhaustion, hyperglycaemia and hyperinsulinemia persists for >60min in 9/10 subjects with glucose 
concentrations of 9.6 [7.6 10.5] mmol/L at EX + 60min. Plasma insulin peaks for the same 9/10 subjects at 
EX + 60min with a median cohort value of 256 pmol/L, which is approximately 5 times greater than basal 
levels. C-peptide levels also peak at EX + 60min, 2010 [1700 2500] pmol/L. The median cohort value of 
insulin secretion, 1150 pmol/min, is approximately 8 times greater than fasting levels 133 pmol/min, at 
EX + 60min.  
 
In Figure 10.3b panel B, it can be seen that 7/10 subjects reach their maximum insulin secretion at EX + 
60min. Of the remaining 3 subjects, two, Ath07 and Ath10, whose insulin levels peak 30 minutes post 
exhaustion, continue to secrete elevated levels of insulin after their 30 minute peak. Only 1/10 subjects, 
Ath08, returns to a basal level of insulin secretion within 60 minutes post exercise.  
 
Table 10.2 Summary of blood glucose, plasma insulin, C-peptide, and insulin secretion across the cohort at four key 
points during the exercise test. Results are presented as median [IQR]. 
Median [IQR] 0 min 30 min EX (75-105 min) EX + 60 min 
Blood Glucose (mmol/L) 5.5 [5.2 6.1] 5.7 [5.3 6.3] 8.0 [7.1 10.1] 9.6 [7.6 10.5] 
Plasma Insulin (pmol/L) 52 [38 63] 30.5 [20 40] 46.5 [37 55] 256 [193 586] 
C-peptide (pmol/L) 562 [345 601] 405 [298 517] 635 [363 698] 2010 [1700 2500] 
Insulin Secretion (pmol/min) 133 [91.4 155] 179 [93.9 323] 600 [323 824] 1150 [817 1482] 
 
10.5 Discussion  
During the initial 60 minutes of submaximal exercise (65-70%VO2max) an increase in non-insulin 
mediated glucose uptake is apparent after the initial oral glucose bolus. This response is attributed to the 
observed increased uptake of glucose without an increase in insulin secretion in 8/10 Athletes. This result 
may in part be due to increased insulin sensitivity, as exercise increases insulin delivery to muscle by 
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increasing peripheral blood flow allowing better utilization of plasma insulin (Marliss et al., 2002, 
Goodyear et al., 1998, Richter, 1996). However, an increase of non-insulin mediated glucose uptake is 
likely to be the dominant factor, based on published literature, because despite falling plasma insulin and 
similar insulin secretion levels, glucose utilization increases (Marliss et al., 2002, Douen et al., 1989, 
Coderre et al., 1995, Richter, 1996).  
 
This increase in glucose utilization is further attributed to exercise allowing glucose uptake to occur 
through non-insulin mediated GLUT4 transporters (Goodyear et al., 1998). Exercise has been shown to 
cause GLUT4 to migrate to the cell-wall without the need for the insulin signalling cascade (Goodyear et 
al., 1998, Marliss et al., 2002). Thus, while an increase in catecholamine production, which is known to 
inhibit glucose utilization (Marliss et al., 2002), is likely to be present, the dominant effects of increased 
GLUT4 transport and delivery of insulin to muscles allows blood glucose utilization and production to 
remain stable.  
 
After 60 minutes of moderate exercise, the subjects commenced intense exercise (>80%VO2max) in the 
form of a ramp test (+20W every 5 min) until exhaustion. During this period of intense exercise blood 
glucose and insulin secretion begin to rise. This response is generated by the marked catecholamine 
response to intense exercise (Marliss et al., 2002, Marliss et al., 1992, Dimsdale et al., 1984, Purdon et al., 
1993, Zouhal et al., 2008, Kjaer et al., 1986).  In general, this catecholamine response leads to increased 
hepatic glucose production and restriction of glucose utilization resulting in hyperglycaemia and 
hyperinsulinemia at the end of an intense exercise session (Marliss et al., 2002, Marliss et al., 1992, Purdon 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 10.3a Measured variables blood glucose (A) and plasma insulin (B) during the exercise test. The black dots represent the 






Figure 10.3b Measured variables C-peptide (A) and insulin secretion (B) during the exercise test. The black dots represent the point 





However, rapid waning of catecholamine response is typically observed after short duration intense 
exercise (Marliss et al., 2002, Ivy et al., 1988, Marliss et al., 1992, Dimsdale et al., 1984, Purdon et al., 
1993, Kjaer et al., 1986).  This rapid reduction leads to blood glucose and plasma insulin to return to fasted 
levels within 60min post exercise if post exercise carbohydrate is not received (Marliss et al., 2002, Ivy et 
al., 1988, Marliss et al., 1992, Purdon et al., 1993, Kjaer et al., 1986). In studies where exercise is prolonged 
and carbohydrate > 1g/kg is ingested immediately post exercise blood glucose and plasma levels remain 
elevated 60min post exercise. However, the maximum value of blood glucose is achieved within 30mins 
post exercise and mean maximum plasma insulin achieved is 160 - 270pmol/L (Blom et al., 1987, Burke et 
al., 1993, Ivy et al., 1988) . In this study the duration and amount of hyperglycaemia and hyperinsulinemia 
seen is extended and increased, peaking at EX + 60min for the majority of athletes, with a maximum mean 
cohort plasma insulin value of 340pmol/L.  
 
There are several potential reasons for this increased and extended period of hyperglycaemia. The 
combination of prolonged and intense exercise caused a larger catecholamine response. The 
aforementioned studies, where carbohydrates were administered post exercise were similar or longer in 
duration to the protocol described here, but perhaps did not require as intense a final effort. Another 
possible cause is the relative fitness levels of the subjects. It has been shown that compared to untrained 
individuals, trained subjects have a higher catecholamine response leading to a greater rise in blood 
glucose and insulin post exercise (Koivisto et al., 1982, Zouhal et al., 2008, Kjaer et al., 1986, Bloom et al., 
1976). So there is likely to be some difference between subjects who are trained to different levels of 
fitness. However, the mean VO2max of athletes in this study is actually lower than that of the comparative 




The most interesting reason to consider is that the athletes were not fasted at the end of the exercise. 
They had received a glucose bolus at 30mins into the exercise protocol as per recommended practice of 
30-60g/h during endurance exercise lasting > 1hr (American Dietetic et al., 2009). It is likely that during 
competition and training, athletes will not be fasted and will be following the nutritional guidelines as 
above. The majority of studies on the glycemic response post exercise have been carried out in the fasted 
state, which does not represent how an athlete would train and compete in real life.  It is also interesting 
to note that while the rate of carbohydrate oxidation is ~1g/min during exercise (Jeukendrup, 2004) at 
high intensity exercise (>80% VO2max) reduced blood flow to the gut may result in decreased absorption 
of glucose and water (Brouns et al., 1993). Thus, slowing the rate of appearance of the glucose challenge 
and potentially prolonging the period of hyperglycemia, as it is unlikely that this effect wanes immediately 
once exercise ceases.  
 
Hyperglycaemia acts to induce a pro-inflammatory state, which includes both cellular inflammation and 
oxidative stress (Collier et al., 2008). A 75g glucose load given orally can result in significant oxidative 
stress and inflammatory changes at the cellular and molecular level (Collier et al., 2008, Mohanty et al., 
2000). The immune system also fails to function optimally in the presence of high blood glucose levels 
(Marik et al., 2004, Jeandidier et al., 2006, Turina et al., 2005, Kijak et al., 1964, Sanchez et al., 1973). 
Hence, maintaining constant, normal, blood glucose levels is important for general health and well-being. 
Based on the results of this study, athletes following the recommended practice of consuming 1.0-1.5g 
carbohydrate/kg within 30 mins of an intense training session or competition are likely to be regularly 
inducing a prolonged period of hyperglycaemia and hyperinsulinemia to an extent that has not been 




This outcome potentially puts their bodies under significant inflammatory and oxidative stress while also 
weakening their immune systems.  Furthermore, there is evidence to show athletes experience an 
immune system function depression, which is most pronounced after prolonged moderate to high 
intensity training or competition (Gleeson, 2006). The cause of this immune system depression is not fully 
understood (Gleeson, 2006) but the hyperglycaemic and hyperinsulinemia state induced could be 
additionally detrimental.   
 
10.5.1 Limitations 
This study is limited by the lack of catecholamine analysis to assess or segregate inflammation induced 
effects from other metabolic impacts.  Therefore, in particular, we are unable to confirm the hypothesis 
that the catecholamine response is prolonged after intense, long duration exercise. However,  Marlis and 
Vranic (2002) have conclusively shown the catecholamine response is responsible for hyperglycaemia and 
hyperinsulinemia after 15 minutes of intense exercise, which supports our hypothesis and is worthy of 
further investigation.  
 
Another limitation is not having muscle glycogen measurements. Therefore, the amount of muscle 
glycogen storage obtained post-test is unknown. It is unlikely this rate differs much to those found in 
already published results studying carbohydrate load directly after exercise (American Dietetic et al., 
2009).  However, this study cannot develop conclusive statements, it does provide the foundation to 






To ensure optimal recovery of glycogen stores it is common practice to consume 1.0-1.5g carbohydrate/kg 
within 30 mins after intense exercise (American Dietetic et al., 2009). However, this practice does not 
ensure optimal blood glucose and plasma insulin levels. Hyperglycaemia persists >60 mins post exercise. 
Plasma insulin and insulin secretion both peak 60 mins post intense exercise to median [IQR] cohort values 
of 256 [193 586] pmol/L and 1150 [817 1482] pmol/min respectively.  
 
In general, this response greater and more prolonged than reported in previous metabolic studies.  The 
most likely reason for this is the subjects received two glucose boluses, one during and immediately one 
post exercise, as per recommended nutritional guidelines. Therefore, the main outcome of this chapter is 
to highlight the glycaemic dysregulation seen post exercise and potential for a re-examination of the post 
exercise feeding protocol used by many athletes to achieve both optimal glycogen recovery and optimal 




Chapter 11. Insulin Secretion During and After Exercise  
This chapter investigates a mathematical model to represent an important aspect of athlete metabolism, 
pancreatic insulin secretion. The endogenous insulin secretion model is of particular importance as, unlike 
critical care patients, athletes are not receiving exogenous insulin. Thus, any model of endogenous insulin 
secretion determines the identified values of insulin sensitivity (SI). Hence, understanding secretion in 
exercise and immediately after could shed significant insight on the metabolic changes induced by 
exercise.   
 
11.1 Introduction  
Endogenous insulin secretion models have a significant role in model-based glycaemic management. 
Endogenous insulin secretion can have a significant impact on identified parameters such as SI, especially 
in the absence of exogenous insulin or with low doses. Hence, reducing error in the insulin secretion model 
can reduce variability in identified SI and thus increase the accuracy and utility of the parameter for 
glycaemic control.  
 
The models of endogenous insulin secretion already established in the literature are almost exclusively 
based on sedentary, healthy, and individuals with diabetes (Camastra et al., 2005, Ferrannini et al., 2005, 
Mari et al., 2002b). These models primarily focus on the endogenous response to glycaemic change 





Intense exercise causes a marked catecholamine response (Marliss et al., 2002, Calles et al., 1983, Kjaer 
et al., 1986).  In general, this catecholamine response leads to increased hepatic glucose production and 
restriction of glucose utilization, resulting in hyperglycaemia and hyperinsulinemia at the end of an 
intense exercise session (Marliss et al., 2002, Kjaer et al., 1986, Calles et al., 1983). This response is similar 
to the stress-induced hyperglycaemia seen in ICU patients, the common factor being systemic 
inflammation due to their illness or induced by strenuous effort (Collier et al., 2008).  
 
Studies comparing the metabolic and hormonal response to exercise between trained and untrained, 
normal glucose tolerance individuals have found that in trained individual’s, glucose, glycerol, and free 
fatty acid concentrations are higher, but lactate, pyruvate, and alanine were lower than untrained 
individuals (Kjaer et al., 1986, Bloom et al., 1976). Cortisol levels were also found to be higher in trained 
individuals (Bloom et al., 1976). Additionally, insulin secretion is known to be diminished in well trained 
individuals as an adaptation to physical training (Lohmann et al., 1978). These results suggest there are 
significant differences of metabolism in well-trained individuals compared to sedentary, healthy subjects.  
 
A thorough search of the literature has not located any studies in which endogenous secretion was 
determined for trained subjects during exercise. The significant metabolic impact of exercise on the 
metabolism indicates a potential gap in knowledge. Therefore this chapter develops an endogenous 






11.2 Subjects and Methods  
11.2.1 Subjects and Exercise Test Protocol 
Table 11.1 summarises the cohort demographics. Data from the ten fit, healthy, sub-elite athletes 
described in Chapter 10 was used for this analysis.  Fasting exercise tests were carried out as shown in 
Figure 11.1. Subjects were required not to exercise the day before the test. On the day of testing, the 
exercise protocol typically began at 8am after an overnight fast and followed the protocol that is described 
in detail in Chapter 10. The research procedures and use of data were approved by the University of 
Canterbury Ethics Committee. 
 
BG measurements were taken using capillary finger stick measurements and the Abbott Optimum Xceed 
(Abbott Diabetes Care, Alameda, CA) glucometer. The Abbott device has reported error of 5-10% (Abbott 
Diabetes Care, 2010, Brunner et al., 2011, Thomas et al., 2014a, Signal, 2013).  Insulin  and  C-peptide  
concentrations  were  determined  using  immunometric assays  (Elecsys  2010,  Roche  Diagnostics,  
Germany). Only 5/10 subjects Ath06-Ath10 had a blood sample at exhaustion + 30 minute due to an 
amendment in the protocol to allow the additional measurement.  
 
Table 11.1 Cohort demographics of the participants. Data are presented as median [interquartile range] where 
appropriate 
Number 10 
Age (yr) 28 [23 37] 
Gender (M/F) 7/3 
BMI (kg/m2) 22 [21 24] 
Resting HR (bpm) 55 [53 56] 
VO2max (mL/kg/min) 46 [39 59] 
Trained Cyclist (Y/N) 7/3 






Figure 11.1 Schematic of exercise trial protocol 
 
11.3 Analysis  
11.3.1 Insulin Secretion 
Pancreatic insulin secretion can be determined from a series of plasma C-peptide measurements.  C-
peptide is produced by the pancreatic β-cells as a by-product of splitting insulin from its precursor, 
proinsulin, and is secreted in equimolar ratio with insulin (Rubenstein et al., 1969). Unlike insulin, C-
peptide is cleared almost entirely by the kidneys, making it a much more reliable marker of endogenous 
secretion than plasma insulin concentrations, which have multiple clearance routes to consider.  
Therefore, models independently linking C-peptide kinetics and insulin kinetics can be used to determine 
and capture pre-hepatic insulin secretion (Polonsky et al., 1986, Van Cauter et al., 1992).  The 
pharmacokinetic model and population kinetic parameters reported by Van Cauter et al. (1992) were  
used  to  deconvolve  insulin  secretion  rates  from measured  C-peptide  data.  Age-based kinetic 




11.3.2 Secretion Rate Bounds 
It is physiologically likely that there is an upper limit and lower limit on pancreatic secretion rate as 
described by Pretty (2012). The upper and lower  bounds  of insulin  secretion  rates  of  16000 mU/hr  and 
1000 mU/hr were selected as in Pretty (2012). These limits were selected based on results of measured 
insulin secretion in healthy controls (Ferrannini et al., 2005, Kjems et al., 2003). Due to a lack of data 
specifically from athletic or active cohorts these limits were deemed to be the suitable for this analysis, 
and are wide enough to include a range of potential results.   
 
11.3.3 Model Fitting  
As in previous studies (Camastra et al., 2005, Ferrannini et al., 2005, Mari et al., 2002b), models were 
fitted to the data, defined:  
                               𝑓(𝑥) = ∑ 𝑎𝑗𝑥𝑗𝑗 + c                                                   Eq. 11.1 
 
Where 𝑓(𝑥) is estimated endogenous insulin production, xj denotes the independent variables (BG, 
dBG/dt, plasma insulin) and c is a constant bias. 
Model fitting was performed by minimising the sum of the geometric means of the squared deviations in 
each dimension. This method allows for uncertainty in both the dependent and independent variables, 
while maintaining scale invariance (Tofallis, 2002, Draper et al., 1997). Goodness of fit was assessed using 





11.4 Results and Discussion  
Endogenous secretion was  constrained  between  upper  and  lower  bounds  of  16000 mU/hr  and  1000 
mU/hr.  The model parameters were identified across all values, and then separately to the measurements 
collected during exercise and after exercise. The resulting model coefficients (aj) and goodness of fit values 
are shown in Table 11.2. 
 
A simple 1-dimensional model, shown in Figure 11.2, using all the measured values demonstrates the best 
fit with R2 = 0.53. There was no benefit from additional complexity as shown in the goodness of fit values 
of Table 11.2. In addition, creating separate models for during and after exercise periods provided no 
benefit, most likely as there was then not enough values to generate an accurate model.  
 
Table 11.2 Coefficients for endogenous insulin secretion models fitted with 1, 2 and 3 independent variables 
(dimensions) for all values measured, the values measured during exercise and the after exercise.  
 Model  Coefficients Goodness 














1 dim. -14140 2559 
  
0.54 
2 dim.  -15973 2977 -728 
 
0.33 
3 dim.  -24954 4734 -1161 -185 -0.13        
During 
exercise 
1 dim. -5325 1153 
  
-0.50 
2 dim. -11717 2429 -745 
 
-1.19 
3 dim.  -9859 2369 -639 -225 -0.92        
After  
exercise 
1 dim. -18667 3049 
  
0.04 
2 dim.  -27076 4142 -845 
 
-0.71 





The insulin secretion model depicted in Figure 11.2 is defined: 
𝑈𝑒𝑛 = 2559 × 𝐵𝐺 − 14140                                                Eq. 11.2 
The equation is constrained to [1000 – 16000] mU/hr 
There are numerous data points below the minimum secretion level of 1000 mU/hr. Both the inter- and 
intra- patient variability, and the number of points below the lower bound are likely a result of using 
population kinetic parameters for the C-peptide model.  The study by Van Cauter et al. (1992) shows 
considerable variation between patients. Coefficients of variation for the kinetic parameters of normal 
subjects were reported in the range 16-36% and the linear regression of long half-life against age had a 
correlation coefficient, r=0.28. Thus, there was significant variation of individual subject kinetic 
parameters around the best-fit population values, which can lead to errors in the calculated secretion 
rates. This variation is not uncommon when modelling insulin secretion in this way and similar variability 
was seen in an intensive care unit patient cohort (Pretty, 2012). Despite the variability in the resulting 
model, it is now successfully used for model based control in the intensive care unit (Pretty, 2012, Stewart 
et al., 2016).  
 
Additionally, these parameters are calculated for “normal” subjects, as is the lower bound. It is reported 
in literature that athletes have a much lower plasma insulin concentrations when a glucose bolus and 
infusion are given when compared to healthy controls (Lohmann et al., 1978). This lack of secretion is not 
attributed to a diminished secretion capacity, as with individuals with diabetes, but because they are more 
efficient in insulin-mediated glucose disposal expressing a metabolic adaption to training. It is thus likely 
the lower bounds for insulin secretion do not represent an athletic cohort accurately, even though insulin 
secretion rates have not been deconvoled from c-peptides in this cohort before. Hence, using a healthy 
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sedentary population bound until more data is collected in this cohort is the most valid option especially 
as fitting with lower bounds does not improve the goodness of fit reported.  
 
 Figure 11.2 Pre-hepatic insulin secretion data from the 10 athletes and the one dimensional model fit (R2 = 0.53) 
 
To  validate  the  secretion  model,  comparisons  were  made  to  published  data. There no data available 
in the literature concerning insulin secretion rates in athletes. Most studies tend to focus on sedentary, 
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healthy subjects and those with diabetes. Table 11.3  presents  the  results  of  a  number  of  published 
studies  in  which  insulin  secretion  profiles  have  been  related  to  blood  glucose levels. All these studies 
used the method and kinetic parameters of Van Cauter et al. (1992) to calculate insulin secretion rates 
from measured plasma C-peptide concentrations. Reported results for the glucose coefficient (a1) are at 
the upper end of the reported range of 2646 – 485 mU.L/mmol.hr for healthy subjects.  Some of the 
reason for this large variation in coefficients may be due to model variables not being completely 
independent. Therefore, if models are built with a different number of parameters then the coefficients 
will be affected. 
 
11.4.1 Limitations  
One of the major limitations of this study is that there is no other published data from athletic subjects or 
any subjects during exercise and immediately after exercise. This lack of data restricts the upper and lower 
limits of the model to match that of “healthy” or “normal glucose tolerance” individuals. It also prevents 
a more thorough validation of the model, as the resulting glucose coefficient (a1) can once again only be 
compared to control subjects. However, this study provides a good first initial investigation in to the 
effects of training and exercise on insulin secretion which later studies can build on.  
 
The second major limitation of the study is that insulin secretion rates calculated in this study rely on the 
population kinetic parameters reported by Van Cauter et al. (1992) for sedentary, healthy subjects. Use 
of these values assumes that renal uptake of C-peptide in athletic subjects during exercise is not 
significantly different to sedentary, healthy subjects. There is no existing literature reporting renal C-




Table 11.3 Glucose coefficient data from the literature. Results have been converted to the units of measurement 
used in this study where necessary. Assumptions used for these conversions were: w = 80 kg; BSA = 1.8 m2; Bold face 
indicates those subject most similar to this athletic cohort.  
Study Cohort Glucose coefficient, a1, [mU.L/mmol.hr] 
Ferrannini et al. (2005) Lean normal glucose tolerance 2646 
Obese normal glucose tolerance 19332 
Impaired glucose tolerance 1155 
T2DM 294 
Mari et al. (2002a) Control 2664 
T2DM 1113 
Mari et al. (2002b) Healthy 24 hr  meal test (5-7 mmol/L) 2196 
Healthy 2 hr protocol (5-7 mmol/L) 2592 
Healthy OGTT (5-7mmol/L) 2754 
Camastra et al. (2005) Healthy controls 1290 
20 Obese Non-Diabetic 1860 
Kjems et al. (2003) Healthy saline infusion 480 
T2DM saline infusion 160 
Healthy GLP-1 max. infusion 5360 
T2DM GLP-1 max. infusion rate 1040 
Jones et al. (1997) Non-diabetic insulin sensitive 485 
Non-diabetic insulin resistant 664 
Byrne et al. (1995) No MODY1 mutation baseline 761 
No MODY1 mutation glucose-primed 1400 
Chang et al. (2003) T2DM with NN2211 (GLP-1 derivative) 1008 
T2DM with Placebo 432 
Controls 1152 
 
11.5 Summary   
A simple 1-dimensional model demonstrates the best model of endogenous insulin secretion with an R2 
= 0.53 and a glucose coefficient (a1) of 2559 mU.l/mmol.hr. The proposed model of endogenous insulin 
secretion, based on physiological measurements, provides a simple estimate of insulin secretion with 
comparable physiological parameters to existing literature. Overall, the endogenous insulin secretion 
model provides a valuable addition to glucose-insulin modelling, specifically for athletic individuals during 




Chapter 12. Insulin Sensitivity During and After Exercise 
The Intensive Control Insulin-Nutrition-Glucose (ICING) model has been successful in accurately 
identifying SI for glycaemic control. However, this model and its model parameters are formulated for 
intensive care patients, rather than healthy subjects. Therefore, this chapter aims to adapt this model to 
allow insulin sensitivity to be identified during and after exercise in a well-trained, athletic cohort.  
 
Exercise is well known to increase insulin sensitivity by both long and short term effects. This chapter is 
the first attempt to formally quantify this value during exercise and immediately after exercise. An 
improved understanding insulin sensitivity levels during and after exercise has the potential to optimise 




Models of glucose-insulin dynamics have been developed with varying degrees of complexity for a range 
of purposes, primarily to identify SI in individuals with type 1 or type 2 diabetes and intensive care patients 
(Bergman et al., 1981, Hovorka et al., 2008, Mari et al., 1997, Wong et al., 2008b, Bergman et al., 1979, 
Cobelli et al., 1984). This identified insulin sensitivity can then be used to create targeted treatment 
strategies for individuals in these cohorts. In some cases, normally in the Intensive Care Unit (ICU), SI is 
used to predict nutritional and insulin inputs to optimise BG levels in patients with stress-induced 




The ICING model was based on the minimal model (Bergman et al., 1981) and developed to be used with 
a GC protocol in the intensive care unit (Lin et al., 2011).   The ICING model is uniquely identifiable 
(Docherty et al., 2012) and has been a major factor in the success of the STAR GC protocol (Evans et al., 
2012) in the Christchurch Hospital ICU (Stewart et al., 2016). The model has been revised and optimised 
several times since it was first published to ensure the most up to date, physiologically representative, 
model as possible (Pretty, 2012, Fisk et al., 2012, Stewart et al., 2015).   
 
Exercise is well known and accepted to improve insulin sensitivity by both short term acute effects and 
long term training effects (Borghouts et al., 2000). Moderate exercise increases non-insulin mediated 
glucose uptake during exercise and for up to 2 hours post exercise. A single bout of exercise can increase 
also insulin sensitivity for up to 16 hours post exercise (Borghouts et al., 2000). Finally, as a result, insulin 
secretion is known to be diminished in well trained individuals due to increased sensitivity (Lohmann et 
al., 1978).  
 
However, during intense exercise blood glucose and insulin secretion rise, due to the marked 
catecholamine response to intense exercise (Marliss et al., 2002, Calles et al., 1983, Kjaer et al., 1986). 
This behaviour is similar to stress-induced hyperglycaemia seen in ICU patients (Collier et al., 2008). The 
catecholamine response leads to increased hepatic glucose production and restriction of peripheral 
glucose utilisation, resulting in hyperglycaemia and hyperinsulinemia at the end of an intense bout of 
exercise. This change can last for over 60 minutes, as discussed in Chapter 10. This overall physiological 
response indicates a significant potential reduction in insulin sensitivity during and immediately after 




Better understanding variations in insulin sensitivity during and after exercise has the potential to 
optimise and individualise nutrition plans for athletes, and could provide an indication of recovery from 
an intense bout of exercise. To the author’s knowledge, a model of insulin sensitivity for an athletic cohort 
has not been reported in the literature. This chapter aims to create a physiological model of insulin 
sensitivity based on the successful ICING model and fit insulin sensitivity during and immediately after 




Table 12.1 summarises the cohort demographics. Data from the 10 fit, healthy, sub-elite athletes 
described in Chapter 10 was used for this analysis.  Fasting exercise tests were carried out as shown in 
Figure 12.1. Subjects were required not to exercise the day before the test. On the day of testing, the 
exercise protocol typically began at 8am after an overnight fast and followed the protocol and followed 
the protocol that is described in detail in Chapter 10. The research procedures and use of data were 
approved by the University of Canterbury Ethics Committee. 
Table 12.1 Cohort demographics of the participants. Data are presented as median [interquartile range] where 
appropriate 
Number 10 
Age (yr) 28 [23 37] 
Gender (M/F) 7/3 
BMI (kg/m2) 22 [21 24] 
Resting HR (bpm) 55 [53 56] 
VO2max (mL/kg/min) 46 [39 59] 
Trained Cyclist (Y/N) 7/3 




Figure 12.1 Schematic of exercise trial protocol 
 
BG measurements were taken using capillary finger stick measurements and the Abbott Optimum Xceed 
(Abbott Diabetes Care, Alameda, CA) glucometer. The Abbott device has reported error of 5-10% (Abbott 
Diabetes Care, 2010, Brunner et al., 2011, Thomas et al., 2014a, Signal, 2013).  Insulin  and  C-peptide  
concentrations  were  determined  using  immunometric assays  (Elecsys  2010,  Roche  Diagnostics,  
Germany). Only 5/10 subjects Ath06-Ath10 had a blood sample at exhaustion + 30 minute due to an 
amendment in the protocol to allow the additional measurement.  
 
12.2.2 Model 
The ICING model (Lin et al., 2011) was simplified and adapted to describe athlete glucose insulin metabolic 






𝑃1̇ = −𝑑1 ∗ 𝑃1 + 𝑃(𝑡)                                                                                                                                   Eq. 12.1 
𝑃2̇ = −𝑑2 ∗ 𝑃2 + 𝑑1 ∗ 𝑃1                                                                                                                             Eq. 12.2 
𝑃(𝑡) = min([𝑑2 ∗ 𝑃2 ∗ 𝐻𝐸, 𝑃𝑚𝑎𝑥])                                                                                                              Eq. 12.3                                                                                                             
?̇? = (𝐼 − 𝑄) ∗ 𝑛𝐿 − 𝑄 ∗ 𝑛𝑐                                                                                                                            Eq. 12.3 
?̇? = 𝑆𝐼 ∗
𝑄
1+𝛼𝑔






                                                                                                    Eq. 12.4 
The model parameters are described in Table 12.2 and the key variables are listed in Table 12.3.  
 
First pass hepatic extraction (HE) was added to the model because in health individuals 5 -10% of a glucose 
load is extracted on first pass of the liver and does not reach the blood stream (Radziuk et al., 1978). 
During exercise there is potential for this value to be even higher as glycogen stores are being rapidly 
diminished. However, there have been no published studies looking at hepatic extraction during exercise. 
Stomach and gut clearance parameter values, d1 and d2, are taken from Dalla Man et al. (2006) in a study 
of health individuals during an oral glucose tolerance test (OGTT). Non-insulin mediated glucose uptake 
(pg) was identified in Bergman et al. (1981) for 5 lean subjects with good glucose tolerance. The value used 
for endogenous glucose production (EGP) was taken from a study that investigated the glucose 
metabolism in the leg of healthy individuals while cycling at three different workloads (Wahren et al., 
1971). This study used arterial-femoral venous difference to calculate the EGP. They did not find EGP to 
be constant. However, EGP is held constant for simplicity, as in the ICING model, as there is currently no 
non-invasive means to effectively monitor or measure it. More modern tracer studies of EGP while 
exercising also provide a range of 0.00 – 3.23 mmol/min depending on the amount of glucose ingested 
(Jeukendrup et al., 1999, McConell et al., 2000). All other parameters in Table 12.2 have remained the 




In this study, the model was simplified, as plasma insulin was measured during the exercise test and did 
not need to be explicitly modelled. Therefore, instead of calculating plasma insulin from an endogenous 
insulin model, the measured insulin was entered directly into this model. If the plasma insulin is not 
available the endogenous insulin model presented in Chapter 11 could be used as per the most current 
variant of the ICING model (Stewart et al., 2015) to calculate the plasma and interstitial insulin 
concentrations.    
 
Table 12.2 Parameter values and description for the Athlete ICING model.  
Variable  Description Athlete Value  Reference  
pg Non- insulin mediated glucose uptake 0.0464 min
-1 (Bergman et al., 1981) 
d1 Stomach clearance  0.222 min
-1 (Dalla Man et al., 2006) 
d2 Gut clearance  0.013 min
-1 (Dalla Man et al., 2006) 
EGP Endogenous glucose production 3.00 mmol/min (Wahren et al., 1971) 
HE First pass hepatic extraction 0.90 (Radziuk et al., 1978) 
(Radziuk et al., 2001) 
Pmax Maximal gut clearance  6.11 mmol/L (Noah et al., 2000) 
VG Glucose volume of distribution 13.3 L (Lin et al., 2011) 
αG Saturation of insulin mediated glucose uptake  0.01538 L.mU
-1 (Doran, 2004) 
nL Hepatic clearance  0.1578 min
-1 (Lotz et al., 2008) 
nC Interstitial clearance  0.006 min
-1 (Pretty et al., 2014) 
 
 
Table 12.3 Key time dependent variables for the Athlete ICING model.  
Variable Unit Description 
Q(t) mU/L Interstitial insulin concentration 
P(t)  mmol/min Glucose appearance in plasma from oral glucose 
intake 
I(t)  mU/L Measured plasma insulin concentration 
G(t) mmol/L Measured blood glucose concentration  





12.3.3 Analysis  
SI was identified using the integral based fitting method (Hann et al., 2005). This method holds SI constant 
over a fitting period, but allows it to change each fitting interval. For each subject, SI was identified over 
3 different time intervals to try to best capture the changes in insulin sensitivity during exercise and assess 
any cohort trends, specifically: 
- Every plasma insulin measurement  - 0 – 30, 30 – 45, 45 – EX, EX – EX + 15, EX + 15 – EX + 60 min 
- Moderate exercise, intense exercise and post exercise  - 0 – 60, 60 – EX,  EX +60 min 
- Across the entire period  - 0 – EX + 60 min 
 
12.4 Results and Discussion 
Figure 12.2 shows SI identified over every plasma insulin measurement interval. It is evident from this 
figure that the boluses at 30 min and exhaustion have a large impact on the model. SI jumps significantly 
with the boluses, especially the first bolus. Within the model, this jump occurs because a substantial 
amount of glucose has been delivered in a short time frame and blood glucose has remain relatively 
constant for most subjects. Thus, the gut model dynamics do not capture this bolus intake and its 
appearance well, and since EGP and pg are fixed the model cannot adapt to the observed glucose data 
well. In reality, SI is unlikely to jump in this manner, because other factors, such as EGP and/or pg, will be 
altered instead. However, the model cannot capture this behaviour when only fitting one variable, and 
thus SI must rise to match this data.  The effect is not so pronounced at the end of intense exercise, as 
intense exercise causes blood glucose to rise due to increases hepatic glucose production, masking some 




Figure 12.3 and Table 12.2 show SI identified during moderate exercise, intense exercise and immediately 
after exercise. If the 30 minutes after each bolus is ignored, as in Table 12.2, to remove the initial transient 
effects of the bolus it is evident that SI is highest during moderate exercise with a median interquartile 
range of 0.0000 [-0.0003 0.0027]. SI then drops substantially during intense exercise to a median 
interquartile range of -0.0042 [-0.0118 -0.0008] and then recovers somewhat 30 minutes post exercise, 
but is still diminished compared to the first 30 min with a median interquartile range of -0.0012 [-0.0035 
-0.0009].  
 
These changes in insulin sensitivity support what is reported in literature and reported in Chapter 7. 
Moderate exercise increases insulin sensitivity through an exercise induced increase in glucose utilisation 
exercise allowing glucose uptake to occur through non-insulin mediated GLUT4 transporters (Goodyear 
et al., 1998) by relocating them closer to the blood stream (Goodyear et al., 1998, Marliss et al., 2002). 
However, during intense exercise the increase in non-insulin mediated uptake is countered by a marked 
catecholamine response to intense exercise (Marliss et al., 2002, Marliss et al., 1992, Dimsdale et al., 1984, 
Purdon et al., 1993, Zouhal et al., 2008, Kjaer et al., 1986).  In general, this catecholamine response leads 
to increased hepatic glucose production and restriction of glucose utilization resulting in hyperglycaemia 
and hyperinsulinemia at the end of an intense exercise session (Marliss et al., 2002, Marliss et al., 1992, 
Purdon et al., 1993, Kjaer et al., 1986). This response is comparable to the stress induced hyperglycaemia 
seen in the intensive care unit. It is thus logical that this response would generate a reduction in insulin 
sensitivity, as shown in Figure 12.3. 
 
The fact that SI is still reduced 30 minutes post exercise is not necessarily in line with current literature as 
the a rapid waning of catecholamine response is typically observed after short duration intense exercise 
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(Marliss et al., 2002, Ivy et al., 1988, Marliss et al., 1992, Dimsdale et al., 1984, Purdon et al., 1993, Kjaer 
et al., 1986). Thus, blood glucose and plasma insulin are expected to return to fasted levels within 60min 
post exercise, if post exercise carbohydrate is not received (Marliss et al., 2002, Ivy et al., 1988, Marliss et 
al., 1992, Purdon et al., 1993, Kjaer et al., 1986). However, as reported in Chapter 10, this outcome did 
not occur during this study. Hyperinsulinemia and hyperglycaemia remained for at least 60 min post 
exercise. Therefore, it is possible that insulin sensitivity also does not return to the same or a similar level 
as initially observed, which is shown in column four of Table 12.2.  
 
Figure 12.4 shows SI identified across the entire exercise test and post exercise period, approximately 140 
minutes. Ath04 has a much higher overall SI then any of the other subjects. This interesting result relates 
to the findings of Chapter 14, when the subject’s blood glucose was monitored over a 6 day period, it was 
evident that Ath04 achieved the most stable blood glucose trace (Figure 14.3). Over 99% of the monitoring 
time, when meals are accounted for, blood glucose was between 4.0 – 6.0 mmol/L for Ath04.   However, 
this correlation between long term blood glucose trends and the SI identified across the entire test period 
does not hold. Ath01 and Ath10 both spent 86.6% of the 6 day monitoring period in the 4.0 – 6.0 mmol/L 
band, but have the lowest SI, while Ath09 only spent 9.7% and has a mid-range SI value.  
 
Another interesting point to note is that SI is often identified as negative.  In a purely physiological sense, 
negative SI does not make sense. Negative or zero SI indicates that the body is producing glucose faster 
than dissipating it.  This result indicates that model is not capturing the true dynamics due to the 
oversimplification of holding EGP and/or pg constant. To model both moderate and intense exercise, a 
model would need to be able to account for both non-constant non-insulin mediated uptake and 
endogenous glucose production.  This goal could be potentially be achieved by making pg, and EGP 
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dependent on heart rate or some other suitable marker of effort. However, this choice would add 
additional complexity, would likely be subject and/or day specific, and would thus be difficult to 
generalise. Before a model of SI can be used to accurately identify SI in an athletic cohort during exercise 
accuracy further studies in to EGP and pg during both moderate and intense exercises are necessary.     
 
Figure 12.2 SI identified over every plasma insulin measurement interval (0 – 30, 30 – 45, 45 – EX, EX – EX + 15, EX + 15 – EX + 60 
min). N.B. Ath01 had a slightly different protocol that Ath02 – 10 resulting in the first glucose bolus being delivered at 60 min  
 
 
This model and assumptions appears to be able to best physiologically represent SI during periods of 
steady state, away from bolus periods. This outcome is evident from the fact the cohort follows the 
expected trends for SI during moderate exercise, intense exercise, and post exercise when the bolus 
periods are not considered, as shown in Table 12.3. The model is currently unable to deal with the rapid 
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and transient effects of boluses, especially as the gut model parameters, d1 and d2, may not be suitable 
during exercise.  
 
The ICING model has similar issues when exogenous insulin is not delivered to patients and must thus rely 
on estimates of endogenous secretion. Exogenous insulin delivery saturates the endogenous insulin 
secretion model and overwhelms the effects of the gut model, lessening the dependence of these 
assumed dynamics on the modelling process. Additionally, ICU patients do not receive bolus meals, but 
constant infusions, so the gut model is much more useful in steady state.  Improving the gut model would 
be a first step to allowing the model to better cope with the dynamics induced when glucose is consumed.  
 
Figure 12.3 SI identified during moderate exercise, intense exercise and post exercise (0 – 60, 60 – EX,  EX +60 min) N.B. Ath01 had 




Table 12.3 SI values during moderate exercise, intense exercise and post exercise removing 30 minutes after every 
glucose bolus to reduce impact of the gut model, values are presented as median [interquartile range (IQR)] where 
appropriate.  
  SI moderate exercise 
(0 – 30 min) 
SI intense exercise 
(60 min – EX) 
SI post exercise 
(EX + 30 – EX + 60 min) 
ATH01 0.0028 -0.0043 -0.0011 
ATH02 0.0014 -0.0042 -0.0046 
ATH03 0.0001 -0.0118 -0.0035 
ATH04 0.0044 -0.0236 -0.0013 
ATH05 -0.0002 -0.0069 -0.0062 
ATH06 -0.0003 -0.0007 -0.0016 
ATH07 -0.0001 -0.0014 -0.0008 
ATH08 -0.0017 -0.0292 -0.0001 
ATH09 -0.0032 -0.0005 -0.001 
ATH10 0.0027 -0.0008 -0.0009 
Median [IQR] 0.0000 [-0.0003 0.0027] -0.0042 [-0.0118 -0.0008] -0.0012 [-0.0035 -0.0009] 
 
 
Figure 12.4 SI identified across the entire period (0 – EX + 60 min) 
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12.5 Summary    
This chapter aimed to adapt the successful ICING model to allow insulin sensitivity to be identified during 
and after exercise in a well-trained cohort. Exercise is well known to improve insulin sensitivity by both 
long and short term effects, but this chapter is the first attempt to formally quantify during exercise and 
immediately after exercise.  
 
The ICING model was simplified to remove the unnecessary plasma insulin compartment as plasma insulin 
was measured regularly during exercise. All other parameters were adjusted to be values from athletic or 
lean, healthy cohorts where possible. SI was identified using the integral fitting method over various 
different intervals to investigate how to best capture the changes in insulin sensitivity during exercise and 
assess any cohort trends. The model appears to be best able to identify insulin sensitivity during steady 
state periods of exercise, as SI trends in these periods match known physiology. When boluses are 
delivered non-physiological jumps in SI take place as the model cannot cope with the transient effects of 
glucose boluses and non-constant endogenous glucose production or non-insulin mediated glucose 
uptake.  
 
Identified SI was often negative, indicating the model was not able to accurately capture the BG dynamics 
with current parameter values and assumptions. While an improved understanding of insulin sensitivity 
levels during and after exercise has the potential, further research is needed to understand how to model 
the ingestion of glucose, endogenous glucose production and non-insulin mediated glucose uptake in a 




This chapter provides a unique insight in to the day to day glucose levels of athletes that could only be 
achieved through the use of CGM devices highlighting the need for further investigation on the 
recommend diets of athletes to better determine the causes and impact of the hyperglycaemia seen on 




Chapter 13. Accuracy and Performance of CGM in Athletes 
CGM devices have the potential to provide important feedback to athletes to aid in the optimisation 
of blood glucose levels during training, racing and recovery. However, these devices are designed for 
use in T1DM and T2DM, who typically experience different glycaemic ranges, and have not been 
tested in this cohort before. Therefore, their performance in athlete subjects during intense physical 
exercise is unknown. This chapter investigates the accuracy and performance of the retrospective 
Ipro2 and Guardian Real-time CGM devices (Medtronic Minimed, Northridge, CA, USA), while subjects 
are exercising in a manner representative of an endurance event or sport. 
 
13.1 Introduction  
CGM devices, with their 1-5 minute measurement interval, allow BG dynamics to be captured more 
frequently and less invasively than traditional measures of BG. CGM devices typically consist of a small 
pager-like monitoring device that receives a signal from a sensor inserted into the subcutaneous layer. 
The sensor creates a signal using the glucose oxidase reaction and produces a current proportional to 
the glucose concentration in the surrounding interstitial fluid. Calibration algorithms convert the signal 
into a BG value by comparing it to calibration BG measurements, which are entered into the monitor 
by the user every 6-8hrs. 
 
These devices are primarily designed for use  in individuals with type 1 and type 2 diabetes to aid BG 
regulation and are well studied in this cohort (Gandhi et al., 2011, Hoeks et al., 2011). However, 
because of the increased measurement frequency and reduced invasiveness they have recently been 
applied to other cohorts, such as intensive care patients, to manage stress-induced hyperglycaemia, 
and neonates, to prevent hypoglycaemia, with varying success (Chee et al., 2003a, Holzinger et al., 
2010, Brunner et al., 2011, Thomas et al., 2015, Signal et al., 2013, Signal et al., 2010, Beardsall et al., 
141 
 
2005, Harris et al., 2010).  Another cohort where CGM may be beneficial is athletes. This cohort is yet 
to be thoroughly investigated, but optimisation of an athlete’s BG has the potential to increase race 
performance, speed recovery, and aid training (Jeukendrup, 2004, Achten et al., 2004, Koopman et 
al., 2004, Brown, 2002, Halson et al., 2004)  
 
 In particular,  there is ongoing research to improve carbohydrate delivery and oxidation, resulting in 
less accumulation of carbohydrate in the gastrointestinal tract to decrease gastrointestinal problems 
during prolonged exercise (Jeukendrup, 2004). CGM data could aid optimal carbohydrate delivery by 
allowing an athlete to know the best time and the amount of carbohydrate to consume. Additionally, 
optimal timing and rate of carbohydrate delivery has the potential to increase glycogen storage, 
speeding athlete recovery and providing additional energy for racing and training (Ivy et al., 1988, 
Conlee et al., 1978).   
 
However, before these benefits can be realised, the accuracy and performance of CGM devices in 
active, trained athletes must be evaluated, which has not been done before. This evaluation is 
especially important as in populations with type 1 diabetes CGM has shown suboptimal accuracy 
during exercise (Kumareswaran et al., 2013) while other studies have shown improved accuracy 
(Yardley et al., 2013). Hence, the aim of this chapter is to characterise the accuracy and performance 







13.2 Subjects and Methods 
13.2.1 Subjects and Experiments  
Table 13.1 summarises the cohort demographics. Data from the ten fit, healthy, sub-elite athletes 
described in Chapter 10 was used for this analysis.  The research procedures and use of data were 
approved by the University of Canterbury Ethics Committee. This is the same cohort that has been 
used in Chapters 10 – 12.  
Table 13.1 Cohort demographics of the participants. Data are presented as median [interquartile range] where 
appropriate 
Number 10 
Age (yr) 28 [23 37] 
Gender (M/F) 7/3 
BMI (kg/m2) 22 [21 24] 
Resting HR (bpm) 55 [53 56] 
VO2max (mL/kg/min) 46 [39 59] 
Trained Cyclist (Y/N) 7/3 
Length of CGM data (hr) 140 [105 141] 
 
Two Ipro2 and one Guardian Real-time CGM devices (Medtronic Minimed, Northridge, CA, USA) 
(Medtronic MiniMed, 2006, MiniMed, 2010) were inserted into the abdomen of each athlete at least 
24 hours prior to the first ‘fasted exercise test’. The CGM device remained in each subject for 4-6 days.  
For all athletes, the Ipro2 CGM devices were both inserted in to the left side of the abdomen and the 
Guardian in the right side as shown in Figure 13.1. These devices are referred to as sensor 1 (SG1), the 
lower left abdomen sensor, sensor 2 (SG2), the upper left abdomen sensor and real-time sensor, the 
right abdomen sensor (SGrealtime).   
During the 6 days of CGM:  
- Blood glucose was measured 4 times per day prior to meals and sleeping. These 
measurements were used to calibrate the device (calibration BG)   
- All meals and snacks were recorded and carbohydrate intake calculated 




Figure 13.1 Photo showing the locations of each CGM devices 
 
 
Figure 13.2 Schematic of exercise trial protocol 
 
Fasting exercise tests were carried out as shown in Figure 13.2. Subjects were required not to exercise 
the day before the test. On the day of testing, the exercise protocol typically began at 8am and is 
defined: 
 0 – 60 min: Cycling on a stationary trainer (Cyclus 2, RBM elektronik-automation GmbH, 
Lepzig, Germany) after overnight fast. Cycling was carried out in the submaximal endurance 
HR zone <70% VO2max resulting in a resistance set to 2 W/kg for female and untrained cyclists 
or 2.5 W/kg, replicating the earlier stages of an endurance event where the athlete is likely to 






 30 min: Consume a 0.5 g/kg of body weight (30-45g) glucose drink as per recommended 
practice of 30-60g/h during endurance exercise lasting > 1 hr (American Dietetic et al., 2009) 
 60 min – Exhaustion (~90 min): Steadily increase effort until volitional exhaustion by 
increasing required power by 20W every 5 minutes mimicking the later stages of an endurance 
event where the effort required is likely to increase until the finish 
 Exhaustion: Consume a 1 g/kg of body weight (60-90g) glucose drink as per recommended 
practice to consume 1-1.5 g/kg of glucose for recovery of muscle glycogen post strenuous 
exercise lasting > 1 hr (American Dietetic et al., 2009) 
 
Reference BG measurements: 
 0 – 60 min: Every 10 min 
 60 – exhaustion+ 30 min (~120 min): Every 5 min to better capture the changes in blood 
glucose after the during an intense work period and after the large glucose bolus  
 Exhaustion + 30 min (~120 min) – exhaustion + 60 min (~150 min) : Every 10 min 
Reference measurements were not used for CGM calibration.   
 
Other measurements:  
- Body weight, BMI, Body composition Analyser (InBody230, InBody Bldg, Seoul, Korea) 
- Indirect calorimetry (MetaLyzer 3B - R2, CORTEX Biophysik GmbH, Lepzig, Germany) 
Reference and calibration BG measurements were taken using capillary finger stick measurements 
and the Abbott Optimum Xceed (Abbott Diabetes Care, Alameda, CA) glucometer. The Abbott device 
has reported error of 5-10% (Abbott Diabetes Care, 2010, Brunner et al., 2011, Thomas et al., 2014a, 
Signal, 2013).   
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13.2.2 Analysis  
To assess the accuracy of the CGM during exercise the mean absolute relative difference (MARD) was 
calculated between reference BG measurements collected during the fasting tests and the CGM trace:  
𝑀𝐴𝑅𝐷 = 𝑚𝑒𝑎𝑛(𝑎𝑏𝑠 (
𝐶𝐺𝑀−𝐵𝐺
𝐵𝐺
)) ∗ 100                                              Eq. 13.1 
MARDs were assessed during three different phases during the trial, 0 – 30 min, 30 min – exhaustion 
and exhaustion – exhaustion + 60 min. MARD was also calculated over the entire test.  This 
consideration of different phases allowed an assessment of accuracy when glucose levels were rapidly 
changing, after each glucose bolus, and when they are relatively stable, during exercise.   
 
To assess the agreement of the CGM devices during the exercise test, zero-lag cross-correlation was 
applied. Zero-lag cross-correction is the dot product applied to two equal length signals with no time 
shift, and yields a metric of “measure to measure” agreement:  
cos 𝜃  = (
𝐴.𝐵
||𝐴||||𝐵||
)                                                                Eq. 13.2 
Where A = [a1, a2 …. an] represents the n x 1 vector of measurements from one CGM signal and B = 
[b1, b2 …. bn] the n x 1 vector of measurements from the other.  
 
The resultant angle,𝜃, shows the trend similarity between two vectors and its cosine has values from 
-1 and +1 demonstrating opposing to complete agreement. Thus, it uses the inner product definition 
to define how much of vector A is projected on to vector B, where 1 indicates equal vectors. This 
resultant value is referred to as the zero lag correlation co-efficient. All signals were first mean-centred 




13.3 Results and Discussion 
Figure 13.3 provides an example of the good sensor agreement seen over the 6 days of monitoring. 
Both sensor current and sensor glucose visually agree well across the entire 6 days of monitoring. The 
results in Figure 13.4, Table 13.2 and Table 13.3 clearly show Ipro2 CGM devices, SG1 and SG2, are 
accurate during intense exercise. The MARD values in Table 13.2 and Table 13.3 are equivalent if not 
better than the performance reported for CGM in diabetic subjects (Keenan et al., 2012, Kovatchev et 
al., 2008, Bailey et al., 2014, Matuleviciene et al., 2014, Calhoun et al., 2013) .  
 
Bailey et al. (2014) reported an overall MARD of 13.6% from a study using the same sensors in 90 type 
1 diabetic subjects. Overall, the Ipro2 devices match this performance and performed better than 
expected during 0 – 30 min of steady state exercise with median MARD of 9.7% and 9.6% for SG1 and 
SG2, respectively. Even during times of rapid glucose change after the glucose boluses were given and 
changes in exercise intensity (Figure 13.4) the Ipro2 CGM devices proved accurate resulting in an 
overall median [IQR] MARD of 11.2 [10.8 13.2] % and 13.6 [11.9 14.7] %. 
 
However, the Guardian real-time performance was mixed. The literature reports an overall MARD of 
15-17.8% for Guardian CGM in diabetic individuals (Kovatchev et al., 2008, Matuleviciene et al., 2014, 
Calhoun et al., 2013). During the first 30min of exercise the Guardian out-performed the expected 
result with a median [IQR] MARD of 11.1 [7.2 16.0] %. However, across the entire test, the Guardian 
devices only achieved a median [IQR] MARD of 20.3 [16.1 23.8] %. This result indicates the Guardian 
struggled to track the fast changing glucose dynamics once the glucose boluses were taken and 
exercise intensity changed, and which might not necessarily be seen in the individuals with diabetes 




The Guardian device is calibrated in real-time and provides a real-time approximation of blood glucose 
concentration on a monitor that communicates wirelessly with the sensor.  This real-time 
approximation means that the device can only use the previous and current calibration measurements 
to calibrate the current signal from the interstitial fluid. In comparison, the Ipro2 devices (SG1 ad SG2) 
store all current data on the sensor, which is then downloaded at the end of monitoring and calibrated 
retrospectively. Thus, both future and past measurements can be used for calibrating the iPro2 signal. 
However, to generate a real-time control algorithm for athlete nutrition a real-time device like the 
Guardian would be necessary.  However, these issues might be offset if glucose ingestion, such as from 
an energy drink, was known, and this information could be available to the device.  
 
The more accurate results obtained during steady state exercise compared to published results in 
diabetes cohorts are likely due to interstitial fluid not being actively pumped like blood. Interstitial 
fluid relies on muscle movement to circulate and mix. Thus, it can be expected that during exercise 
more accurate results are seen as the rigorous movement and increased overall blood flow allows 
rapid mixing and equilibrium between the blood and interstitial fluid. In addition, more accurate 
reference BG measurements due to high skin temperatures and increased circulation, might be 
expected,  Haupt et al. (2005) and  King, et al. (1995) suggest lower skin temperatures lead to BG 
meters producing lower than expected values. This conclusion is supported by the results of Yardley 
et al (2013) who found increased CGM performance during exercise in a population with type 1 
diabetes.   
 
However, as evident with the real-time calibrated device, rapid mixing between the interstitium and 
blood is not enough to ensure ideal performance when large disturbances, such as glucose boluses, 
are added to the system. This increased error is likely due to the gradient of BG change being higher, 
so the delay in transport to interstitial fluid and sensor results in a larger discrepancy in measured 
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values compared to a blood-based reference (Boyne et al., 2003). The cessation of exercise prior to 
the ingestion of the bolus may slow the mixing of the interstitial fluid and blood also increasing the 
error. 
Table 13.2 MARD results for each athlete and sensor combination for the entire duration of the test. The gaps 
in column three represent where sensor failures prevented the collection of CGM data. 
Subject SG1 MARD (%) SG2 MARD (%) SGrealtime MARD (%) 
ATH01 11.2 13.4 19.0 
ATH02  15.2 14.9 15.9 
ATH03 9.0 8.9 24.9 
ATH04 12.3  16.3 
ATH05 13.8 11.9 10.7 
ATH06 12.7 13.8 23.9 
ATH07 11.1 32.3 23.8 
ATH08 10.6 14.2 20.5 
ATH09 10.9 11.9 20.3 
ATH10 20.0  28.9 
Median[IQR] 11.2 [10.8 13.2] 13.6 [11.9 14.7] 20.3 [16.1 23.8] 
 
 
Table 13.3 MARD presented as median [IQR] of the cohort for each stage during the exercise test. 
 0 – 30min 30min – Exhaust Exhaust – Exhaust+60min 
SG1 9.7 [6.0 17.8] 11.3 [8.9 13.8] 11.4 [8.5 15.7] 
SG2 9.6 [7.3 17.5] 12.5 [10.1 17.4] 17.0 [12.1 20.3] 
SGrealtime 11.1 [7.2 16.0] 19.9 [16.9 23.5] 21.1 [18.2 27.0] 
 
 
Table 13.4 Correlation coefficient for each sensor combination using the CGM data generated during the 
exercise test.  
Correlation Coefficient  SG1 vs. SG2 SG1 vs. SGrealtime SG2 vs. SGrealtime 
ATH01 0.99 0.90 0.89 
ATH02  0.98 0.97 0.98 
ATH03 0.96 0.92 0.81 
ATH04  0.80  
ATH05 0.98 0.89 0.95 
ATH06 1.00 0.81 0.79 
ATH07 0.92 0.96 0.84 
ATH08 0.74 0.32 0.87 
ATH09 0.95 0.81 0.89 
ATH10  0.96  







Figure 13.3 Examples of current and sensor glucose data captured over the 6 days of monitoring. Subject ATH03 is presented 
in A and ATH06 in B.  
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Figure 13.4 Blood glucose reference values. CGM values and glucose bolus data for each athlete. Ath01-Ath10 in descending 
order as reading from right to left. 
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The zero-lag correlation between all three sensors is very good, as seen in Table 13.4. SG1 and SG2 
have a median [IQR] correlation coefficient of 0.97 [0.94 0.99]. It is expected that these signals would 
correlate the best as they are the same device inserted in the same side of the abdomen. Both SG1 
and SG2 also correlate very well with the SGrealtime, with median correlation coefficients of 0.90 and 
0.88, respectively. This good correlation between all three signals suggests the error between glucose 
concentrations measured by CGM and from blood is not random, but likely due to effects such as 
transport delays and local glucose uptake. As the interstitial fluid is the medium from which glucose 
enters muscle cells, this CGM value might be more useful than BG in determining glucose availability 
for athletes.  
 
13.3.1 Limitations  
This study is a proof of concept demonstration and thus the relatively small data set is a limitation. 
These tests were trialled in 10 athletes and results are likely to vary between individuals. However, 
there is a clear difference in signal quality between retrospective and real-time devices, as well as 
between periods of steady state exercise and periods of glucose disturbance. A larger trial in a bigger 
cohort is recommended to confirm these findings, as well as incorporating further investigation in to 
the optimisation of an athletes BG using CGM technology. 
 
 Ideally, a retrospective device, such as the Ipro2, should be used for these further investigation, 
especially if rapid changes in BG are likely, as they demonstrated improved performance compared to 
the real-time device. However, to be able to optimise an athletes BG in real-time, a real-time CGM is 
necessary. In this case, this potential error must be considered if devising nutritional strategies based 





Optimisation of an endurance athlete’s BG via intra-event nutrition has the potential to increase race 
performance, speed recovery, and aid training. During steady state exercise, all sensors performed 
better than results reported for diabetes cohorts, with median MARD of 9.7%, 9.6% and 11.1% for 
SG1, SG2 and SGrealtime, respectively. However, there is increased error after an oral glucose bolus 
likely due to the gradient of BG change being higher, so the delay in transport to interstitial fluid and 
sensor results in a larger discrepancy to measured blood based reference values.  
 
CGM devices agree very well with each other during rigorous exercise with median zero-lag cross-
correlation coefficients between 0.88 and 0.97 for the different sensor pairings. The good correlation 
between all three signals suggests the error between glucose measured by CGM and from blood is not 
random. The error is likely due to transport/uptake effects differing between the blood and interstitial 
fluid from which the CGM measures glucose.  
 
The interstitial fluid is the medium from which glucose enters muscle cells. Therefore, it is possible 
this CGM value might be more useful than BG in determining glucose availability for athletes. Overall 
these results demonstrate the good accuracy and performance of CGM devices in active athletes while 




Chapter 14. Blood Glucose Levels of Sub-Elite Athletes during 6-days of Free Living 
This chapter examines blood glucose levels of sub-elite athletes over a 6 day monitoring period using 
continuous glucose monitor devices. Blood glucose levels during exercise have been examined previously 
and the increased overall insulin sensitivity of athletes noted. However, CGM devices provide an 
opportunity to examine what effect this increased insulin sensitivity has over a much longer time period.  
In addition, it is well documented that athletes, especially those in the sub-elite category, do not meet 
nutritional recommendations for their level of energy expenditure. Therefore, CGM devices have the 
potential to highlight the effect of not meeting these recommendations on blood glucose levels and the 
subsequent potential impact on recovery. Data from CGM would present significant new insight into 
managing recovery, a key element in overall athlete management, along with the capability of CGM 
devices to enable this assessment.  
    
14.1 Introduction   
The World Health Organisation (WHO) defines normal glycaemia as fasting glucose less than 6.1mmol/L 
and recommends glucose <7.8 mmol/L 2 hours after a 75g oral glucose tolerance test (OGTT)  test (World 
Health Organisation, 2006). The American Diabetes Association (ADA) considers those with a fasting 
glucose of 5.6 – 6.9 mmol/L and blood glucose (BG) > 7.8 - 11.0 mmol/L after an OGTT at increased risk of 
diabetes (American Diabetes, 2010). However, as the WHO guidelines explain, there is no definitive cut 
off for “normoglycaemia” (World Health Organisation, 2006), and dysglycaemia thus exists on a 




CGM devices allow BG dynamics to be captured far more frequently and less invasively than traditional 
BG measures. These devices are primarily designed for use in individuals with  type 1 and type 2 diabetes  
to aid BG regulation and are well studied in this cohort (Gandhi et al., 2011, Hoeks et al., 2011). However, 
because of the increased measurement frequency and reduced invasiveness they have recently been 
applied to other cohorts, such as intensive care patients and neonates, with varying success (Chee et al., 
2003a, Holzinger et al., 2010, Bloom et al., 1976, Thomas et al., 2015, Signal et al., 2013, Signal et al., 2010, 
Dimsdale et al., 1984, Koivisto et al., 1982).  These cohorts all suffer a combination of inflammation and 
dysglycaemia. Thus, another perhaps overlooked, cohort where the more intensive metabolic monitoring 
provided by CGM may be beneficial is athletes.  
 
Physical training is known to improve insulin sensitivity, both immediately post exercise and through 
multiple long term adaptations in glucose transport and metabolism (Borghouts et al., 2000) and athletes 
are traditionally encouraged to consume a diet rich in carbohydrates to ensure adequate glycogen stores 
and improve performance (IOC, 2010, 2000, Jacobs et al., 1999).. However in contrast, strenuous exercise 
is known to increase circulating concentrations of pro-inflammatory catecholamines, such as adrenalin 
and noradrenaline, to near pathological levels (Bloom et al., 1976, Rehrer et al., 1992). This combination 
of high carb input and circulating hormones can result in hyperglycaemia and hyperinsulinemia post 
intense exercise (Bloom et al., 1976, Ivy et al., 1988, Marliss et al., 2002) and discussed in Chapter 10.   
 
This chapter aims to use the CGM blood glucose profiles and dietary habits of sub-elite athletes to 
investigate if this cohort is achieving optimal blood glucose levels during normal free living and training.  
In particular, it asks what impact their increased insulin sensitivity, heightened energy expenditure, and 
increased exposure to stress hormones have on their blood glucose levels. The CGM data provides a 
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unique insight in to the day to day blood glucose levels of athletes that could not be achieved without the 
application of this technology.  
 
14.2 Subjects and Methods 
14.2.1 Subjects 
Table 14.1 summarises the cohort demographics. Data from the ten fit, healthy, sub-elite athletes 
described in Chapter 10 was used for this analysis.  The research procedures and use of data were 
approved by the University of Canterbury Ethics Committee. 
 
Two Ipro2 and one Guardian Real-time CGM devices (Medtronic Minimed, Northridge, CA, USA) were 
inserted into the abdomen of each athlete. These devices are referred to as sensor 1 (SG1), the lower left 
abdomen sensor, sensor 2 (SG2), the upper left abdomen sensor, and the real-time sensor in the right 
abdomen sensor (SGrealtime). Figure 14.1 shows these locations which are typical for these devices 
(Medtronic MiniMed, 2010, Medtronic MiniMed, 2006). The Guardian Real-time data was not used in this 
analysis as it is less accurate than the Ipro2 data, as seen in Chapter 13. Chapter 13 also details the protocol 
followed by each athlete during the 6 days of monitoring,  
 
Calibration BG measurements were taken using capillary finger stick measurements and the Abbott 
Optimum Xceed (Abbott Diabetes Care, Alameda, CA) glucometer. The Abbott device has reported error 
of 5-10% (Abbott Diabetes Care, 2010, Brunner et al., 2011, Thomas et al., 2014a, Signal, 2013).  An 
impedance based body composition analysis was undertaken by 8 of the 10 participants prior to the 
fasting test using a Body composition Analyser (InBody230, InBody Bldg, Seoul, Korea).  
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Table 14.1 Cohort demographics of the participants. Data are presented as median [interquartile range] where 
appropriate 
Number 10 
Age (yr) 28 [23 37] 
Gender (M/F) 7/3 
BMI (kg/m2) 22 [21 24] 
Resting HR (bpm) 55 [53 56] 




Figure 14.1 Photo showing the locations of each CGM devices 
 
 14.2.2 Analysis  
Sensor glucose (SG) data from measured CGM traces of the two Ipro2 devices was analysed. These devices 
have been shown to have very good accuracy and sensor agreement in active individuals (Bailey et al., 
2014, Thomas et al., 2015), as discussed in Chapter 13. The two signals were averaged at each time step 
for the time period they were worn to provide a single, reliable trace of BG. For Ath04, Ath09, and Ath10 







For each athlete, the cumulative distribution (CDF) of BG data was analysed for the entire 5-6 days of 
monitoring, and re-analysed with the 2 hour period following any meal or snack removed. Time in band 
was calculated as the percentage of SG with in the 4.0 - 6.0 mmol/L during the two different monitoring 
periods. Although a consensus has yet to be reached on what constitutes normal glucose levels, intensive 
insulin therapy studies show achieving higher time in this band results in improved patient outcomes 
(Krinsley, 2004, Chase et al., 2008b, Van den Berghe et al., 2001) and it lies below typical thresholds for 
diabetes diagnosis (World Health Organisation, 2006, American Diabetes, 2010). Many studies have also 
demonstrated the linearly increasing risks associated with hyperglycaemia, regardless of diabetes status, 
with lower limits between 4.0 – 6.0 mmol/L (Brunner et al., 2006, Jee et al., 2005, Kijak et al., 1964, Levitan 
et al., 2004, Nishida et al., 2006, World Health Organisation, 2006, Tirosh et al., 2005).  
 
The average carbohydrate, sugar, and fibre intake (g/day) while using CGM were calculated from nutrition 
diaries kept by each subject.  First, daily caloric intake was calculated using basal metabolic rate (BMR) as 
estimated by the body composition analysis. For 2/10 athletes, Ath02 and Ath03, body composition 
analysis results were not available. Therefore, BMR was estimated using the standard equations (Harris 
et al., 1918) that take in to account height, weight and age. This BMR was then multiplied by an activity 
factor (Black, 2000) considering the amount of exercise undertaken by the athlete during the monitoring 
period. This process and relating caloric requirements are shown in Table 14.2.  
 
US dietary guidelines (USDA, 2015b) recommend 45-65% of total calorie intake be from carbohydrates 
and the recommended amount of added sugars is also related to calorie level in these guidelines. Added 
sugar content of food consumed during the monitoring period was obtained from the United States 
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Department of Agriculture (USDA) database (USDA, 2015a). If the added sugar content was not available 
from the database it was assumed to be zero, providing an overall conservative estimate. 
 
Table 14.2 The process of calculating the caloric requirements based on BMR and activity level and the average 
calorie intake achieved by each subject. * Values were calculated using standard equations rather than a body 











Intake per Day 
(kcal/d) 
ATH01 1342 84 1.9 2550 2147 
ATH02 1868* 41 1.7 3176 3864 
ATH03 1927* 68 1.9 3661 1877 
ATH04 1770 93 2.1 3717 3555 
ATH05 1680 158 2.3 3864 2568 
ATH06 1694 28 1.5 2541 2654 
ATH07 1780 20 1.5 2670 2838 
ATH08 1895 24 1.5 2843 4144 
ATH09 1379 102 2.1 2896 2726 
ATH10 1400 42 1.7 2380 2363 
 
Fasting blood glucose (FBG) was calculated as the median value of the calibration measurements taken 
prior to breakfast over the 5 – 6 days of CGM monitoring. Fasting plasma insulin (FPI) was determined by 
the first plasma insulin measurement taken prior to starting the fasted exercise test on Day 2 (the fasting 
exercise test protocol is detailed fully in Chapter 10). Fasting insulin secretion (FIS) was calculated from 
the initial C-peptide measurement taken prior to starting the fasted exercise test using the method of Van 
Cauter et al. (1992) assuming steady-state, as subjects were fasted.  
 
Postprandial glucose response (PPGR) was calculated as the incremental area under the BG curve after a 
meal (Wolever et al., 1986). Only the area above the starting glucose value was considered. PPGR was 
only considered for meals that had greater than 30g of carbohydrate, and where there was no meal of 
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greater than 15g carbohydrate in the 2 hours prior to or after this meal. If meals were consumed within 
15 minutes then carbohydrate content was combined and the 2 hour area under the curve considered 
from the start of the second meal. Postprandial glucose (PPG) was the glucose value recorded two hours 
after a meal under the same conditions as above.  
 
14.3 Results  
Individual SG profiles are shown in Figures 14.2 and 14.3. These profiles highlight the very unique response 
of each individual to exercise and carbohydrates. Ath02 and Ath04 both show very little variation in SG 
but Ath02 SG, is centred on a higher glucose value resulting in more time out of the 4.0 – 6.0 mmol/L. 
Other subjects such as Ath03 and Ath09 show a large variation in SG, once again centred on different 
glucose levels, resulting in Ath03 displaying the most hypoglycaemia and Ath09 displaying the most 
hyperglycaemia.  
 
In Figure 14.4 it is further evident several participants spend a significant amount of time outside the 
normoglycemic 4.0 - 6.0 mmol/L range. Once meals are removed, in the bottom plot, there is a distinct 
separation between 4/10 of the subjects (Ath05, 07, 08, 09) who have less than 30% time in the 4.0 - 
6.0mmol/L range. In contrast, the remaining 6/10 participants achieve over 85% time in the desired 4.0 - 
6.0mmol/L range, which is clear when comparing the distributions.  
 
All but 4 participants consumed on average an amount of carbohydrate that was between 45 – 65% of 
their recommended daily calorie intake. Ath03, Ath05 and Ath09 did not reach the minimum 
recommended amount of carbohydrate. Ath08 consumed more than 65% of their recommended intake 
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as carbohydrate. All participants achieved their recommended fibre intake of >25g. Some participants, 
such as Ath07 and Ath08, have a very low fibre to sugar ratio and nearly double the recommended intake 
of added sugars (Figure 14.5). Ath03 consumed on average ~150g of carbohydrate less than the lower 
recommended limit, 1770 kcal less than required (Table 2) and was the only participant to demonstrate a 
significant amount time below 4.0mmol/L.  
 
Table 14.3 shows Ath05, Ath07 and Ath09 have elevated fasting glucose within the pre-diabetes range 5.6 
- 6.9 mmol/L suggested by the ADA. However, none of the subjects met the pre-diabetes criteria of PPG 
> 7.8 mmol/L. Although this PPG criteria is  based on the BG 2 hours after a 75g glucose tolerance test, 
rather than after an uncontrolled meal.  The mean PPGR ranges from 0.2 – 2.0 mmol/L.hr displaying a 
wide range intra- and inter- carbohydrate sensitivity. High PPGR did not necessarily correlate with time 
out side of the 4.0 – 6.0 mmol/L band.  
 
14.4 Discussion  
Physical training is known to improve insulin sensitivity, both immediately post exercise (up to 2 hrs) and 
through multiple adaptations in glucose transport and metabolism (Borghouts et al., 2000). Therefore, it 
could be expected high BG would not be frequently seen in athletes and low BG would be of greater 
concern due to increased energy expenditure. However, this hypothesis does not appear to be the case 




Figure 14.2 CGM profiles for the first 5 subjects. The 2 hour postprandial meal response is highlighted in red and periods of exercise 




Figure 14.3 CGM profiles for the last 5 subjects. The 2 hour postprandial meal response is highlighted in red and periods of exercise 




Figure 14.4 Cumulative distribution plots of measured CGM values. The Top plot is the CDF of the entire averaged CGM signal. 
The bottom plot is the CGM signal with 2 hours from the beginning of each meal and snack removed. The green band represents 




Figure 14.5 Bar plot showing the average intake per day of carbohydrate, sugar, fibre, and the recommended daily intake of 
carbohydrate, upper (65% of calorie intake) and lower (45% of calorie intake)  
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In particular, 4/10 subjects spent more than ~70% of the total monitoring period with SG > 6.0 mmol/L, 
even with the two hour period after meals removed.  Only one athlete experienced a significant time 
below 4.0 mmol/L and this behaviour appears largely due to a considerably decreased calorie intake 
compared to recommended guidelines.   
 
Ath09 and Ath05 undertook the most exercise during the monitoring period, averaging 102 and 158 
min/day respectively.  This high training load could have contributed to the low time in the 4.0 – 6.0 
mmol/L band, as exercise is known to increase blood glucose and induce hyperglycaemia and 
hyperinsulinemia as a result of this catecholamine response (Bloom et al., 1976, Ivy et al., 1988, Marliss 
et al., 2002).  Both subjects had the lowest fasting plasma insulin and insulin secretion recorded suggesting 
efficient glucose uptake. In addition, both achieved VO2max values that put them in the excellent category 
based on their gender and age.  
 
Ath07 and Ath08 carried out the least amount of exercise during the monitoring period only averaging 20 
and 24 min/day of exercise, while over consuming added sugars (World Health Organisation, 2006) and 
Ath08 over consuming on the recommended carbohydrate intake.  Lowering physical activity is known to 
impact the glycaemic control of healthy individuals and the increased insulin sensitivity witnessed due to 
training wanes with 5 days of detraining (Borghouts et al., 2000, Mikus et al., 2012, Heath et al., 1983, 
Mikines et al., 1989). The large amount of time spent out of band by Ath07 and Ath08 is likely to be 
attributed to these diet and lifestyle choices. This conclusion is supported by Ath07 and Ath08 showing 
the highest fasting plasma insulin levels and fasting insulin secretion and only achieving average or above 




An individual’s tolerance of carbohydrate is highly variable and is related to a number of factors including 
age and genetics (Zeevi et al., 2015, Vrolix et al., 2010). A differing ability to tolerate carbohydrates in this 
cohort is demonstrated with the wide range of cohort values of mean PPGR and mean PPG, 0.2 – 2.0 
mmol/L.h and 5.5 – 7.4 mmol/L, respectively. Also PPGR and PPG do not necessarily correlate with time 
in band or FBG. A subject can achieve good overall control or even experience low BG, such as Ath03, but 
still demonstrate a high mean PPGR indicating a high sensitivity to carbohydrates. A subject like ATH09 
also appears to have a very high sensitivity to carbohydrates achieving high PPGR and low time in band 
while under consuming on the recommended carbohydrate intake. However, a subject like Ath04 displays 
a very high tolerance of carbohydrates, achieving the greatest time in band and very low PPGR, while still 
over consuming added-sugars. It is interesting to note that normalising results by grams of carbohydrate 
consumed did not change the trends seen.   
 
Athletes are traditionally encouraged to consume high carbohydrate diets to replenish muscle glycogen 
stores and improve performance, with a particular focus on post exercise carbohydrate consumption (IOC, 
2010, 2000, Jacobs et al., 1999).  However, this advice may be negatively impacting the blood sugar levels 
of athletes predisposed to have a low tolerance of carbohydrates. In addition it is unlikely that low BG in 
day to day life is a real concern for athletes, unless they are significantly under consuming calories. Hence, 
the potential for a more personalised nutrition plan aided by CGM to optimise the BG levels during 
different phases of athletes training is highlighted by these results.   
 
This study warrants further investigation on the recommend diets and the blood glucose levels of athletes, 
in particular those in the sub-elite category studied here. Sub-elite athletes are unlikely to have the same 
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nutritional and dietary support from trained professionals as elite athletes. Hence, their nutritional intakes 
are more perhaps likely to be sub-optimal, as demonstrated in this study. 
 
14.4.1 Limitations 
This study is limited by the small cohort size. However, this initial pilot investigation has highlighted some 
interesting points where there is potential to optimise an athlete’s diet. Hence, it has raised questions 
where further studies are thus justified. 
 
 A second limitation is that activity was only monitored by self-reporting in future studies it would be much 
better to use a specific activity monitoring device to capture energy expenditure more accurately. Equally, 
activity could be directly controlled in a more homogenous cohort, in a more strictly controlled study than 
this pilot investigation.  
 
14.5 Summary  
Physical training is known to significantly increase insulin sensitivity and improve PPG and PPGR. 
Therefore, it could be expected sustained high BG during free living would not be frequently seen in 
athletes and low BG would be of greater concern due to increased energy expenditure. However, this 
hypothesis does not appear to be the case in the data we have collected.  
 
When the sensor glucose profiles of 10 trained, sub-elite athletes were analysed over a 6 day monitoring 
period 4/10 athletes studied spent more than 70% of the total monitoring time above 6 mmol/L even with 
169 
 
the 2hour period after meals removed. FBG was also in the range of pre-diabetes for 3/10 athletes, as 
defined by the ADA. Only one participant spent substantial time below 4 mmol/L and this was largely due 
to a significantly lower overall calorie intake compared to recommendations.  
 
A differing ability to tolerate carbohydrates in this cohort is demonstrated with the wide range of cohort 
values of mean PPGR and mean PPG, which were 0.2 – 2.0 mmol/L.h and 5.5 – 7.4 mmol/L, respectively. 
Therefore, a diet rich in carbohydrates may not be beneficial in some athletes. This outcome is particularly 





Chapter 15. Summary Glucose Metabolism and CGM in Athletes   
The glucose metabolism of athletes is not fully defined in current literature and neither are the effects of 
exercise on the overall glucose metabolism of athletes. Studies comparing the metabolic and hormonal 
response to exercise between trained and untrained normal glucose tolerant individuals have found 
significant differences in the metabolism of athletes. However, there are only a few studies investigating 
how metabolic parameters, such as EGP change with exercise, and none that attempt to quantify 
endogenous insulin secretion or insulin sensitivity during exercise.   
 
Additionally, an individual’s tolerance of carbohydrate is highly variable and is related to a number of 
factors including age and genetics. CGM devices have the potential to personalise nutrition based on 
glucose response. Such research using CGM devices has not been undertaken in athletic subjects before. 
However, real time knowledge of blood variables, such as glucose, is noted as the “future’ of sports 
technology (Gizmag Team, 2007, Metz, 2014). The second half of this thesis examined the glucose 
metabolism of athletes further, and investigated the potential of CGM to provide accurate information 
and personalise nutritional strategies for athletes.   
 
In a study of 10 sub-elite athletes, it was found that after race simulation exercise test hyperglycaemia 
persists >60 mins post exercise. Plasma insulin and insulin secretion both peaked 60 mins post intense 
exercise to median [IQR] cohort values of 256 [193 586] pmol/L and 1150 [817 1482] pmol/min, 
respectively. These median peak values of plasma insulin and insulin secretion were approximately 5 and 
9 times higher than the median fasting levels in this cohort, respectively. In general, this response greater 
and more prolonged than reported in previous metabolic studies.  The most likely reason is the subjects 
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received two boluses, one during exercise and one immediately one post exercise, as per recommended 
nutritional guidelines for competition, while in other studies, the athletes remained fasted. Therefore, the 
main outcome of this chapter was to highlight the potential for a re-examination of the post exercise 
feeding protocol used by many athletes to achieve both optimal glycogen recovery and optimal blood 
glucose levels in a manner more representative of how athletes train and race. 
 
Using data collected from the 10 subjects during and immediately after the exercise test, a simple 1-
dimensional model of endogenous insulin secretion was created, with a coefficient of determination, R2 
= 0.53 and a glucose coefficient (a1) of 2559 mU.l/mmol.hr. The proposed model of endogenous insulin 
secretion, based on physiological measurements, provides a simple estimate of insulin secretion with 
comparable physiological parameters to existing literature. Overall, this endogenous insulin secretion 
model provides a valuable addition to glucose-insulin modelling, particularly for athletic individuals during 
exercise and immediately after. 
 
The next step was to attempt to adapt the successful ICING model to allow insulin sensitivity to be 
identified during and after exercise in a well-trained cohort. The ICING model was simplified to remove 
the unnecessary plasma insulin compartment as plasma insulin was measured regularly during exercise in 
this study. All other parameters were adjusted to be values from athletic or lean, healthy cohorts where 
possible  
 
The model appeared to be best able to identify insulin sensitivity during steady state periods of exercise 
as SI trends in these periods match known physiology. However, when boluses are delivered non-
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physiological jumps in SI occur due to under-modelling of gut dynamics and glucose appearance, as well 
as necessary assumptions of constant endogenous glucose production and non-insulin mediated glucose 
uptake. SI was often negative, indicating the model was not able to accurately capture the BG dynamics 
with current parameter values and assumptions. While an improved understanding insulin sensitivity 
levels during and after exercise has potential, further research is needed to understand how to model the 
ingestion of glucose, endogenous glucose production and non-insulin mediated glucose uptake, in a way 
that does not over-complicate the model, while remaining physiologically realistic.  
 
CGM devices have the potential to provide important feedback to athletes to aid in the optimisation of 
blood glucose levels during training, racing and recovery. However, these devices are designed for use in 
T1DM and T1DM, who typically experience different glycaemic ranges, and have not been tested in this 
cohort before. Therefore, their performance in athlete subjects during intense physical exercise is 
unknown.  
 
The performance of CGM during exercise was investigated by comparing reference measurements to 
CGM data collected form the 10 subjects during the exercise test. For all athletes, the Ipro2 CGM devices 
were both inserted in to the left side of the abdomen and the Guardian real-time in the right side. These 
devices are referred to as sensor 1 (SG1), the lower left abdomen sensor, sensor 2 (SG2), the upper left 
abdomen sensor and real-time sensor, the right abdomen sensor (SGrealtime).   
 
 During steady state exercise, all sensors performed better than results reported for diabetes cohorts, 
with median MARD of 9.7%, 9.6% and 11.1% for SG1, SG2 and SGrealtime, respectively. However, there 
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was increased error after an oral glucose bolus likely due to the gradient of BG change being higher, so 
the delay in transport to interstitial fluid and sensor results in a larger discrepancy to measured blood 
based reference values.  
 
CGM devices agree very well with each other during rigorous exercise with median zero-lag cross-
correlation coefficients between 0.88 and 0.97 for the different sensor pairings. The good correlation 
between all three signals suggests the error between glucose measured by CGM and from blood is not 
random. The error is likely due to transport/uptake effects differing between the blood and CGM values. 
Overall these results demonstrate the good accuracy and performance of CGM devices in active athletes 
while exercising, confirming the applicability of these monitors to this new domain.  
 
Physical training is known to significantly increase insulin sensitivity and improve both PPG and PPGR 
metrics. CGM devices provide an opportunity to examine what effect this increased insulin sensitivity has 
over a much longer time period.  In addition, it is well-documented that athletes, especially those in the 
sub-elite category, do not meet nutritional recommendations for their level of energy expenditure. 
Therefore, CGM devices have the potential to highlight the effect of not meeting these recommendations 
on blood glucose levels and the subsequent potential impact on recovery.  
 
When the sensor glucose profiles of 10 trained, sub-elite athletes were analysed over a 6 day monitoring 
period 4/10 athletes studied spent more than 70% of the total monitoring time above 6 mmol/L even with 
the 2hour period after meals removed. Only one participant spent substantial time below 4 mmol/L and 




A differing ability to tolerate carbohydrates in this cohort is demonstrated with the wide range of cohort 
values of mean PPGR and mean PPG, which were 0.2 – 2.0 mmol/L.h and 5.5 – 7.4 mmol/L, respectively. 
Therefore, a diet rich in carbohydrates maybe benefical in some athletes and not others. This outcome 
appears particularly valid considering low BG is unlikely to be of concern to an athlete consuming 
adequate caloric intake.  
 
This study provides a unique insight in to the day to day glucose levels of athletes that could only be 
achieved through the use of CGM devices highlighting the need for further investigation on the 
recommend diets of athletes to better determine the causes and impact of the hyperglycaemia seen on 
health and performance.   
 
Overall the work presented in Chapters 8 – 15 provides unique insight in to the glucose metabolism of 
athletes. The glucose metabolism has not attempted to be quantified in this way before, considering both 
the engineering and clinical perspective. The results presented provide a significant advancement to the 
body of knowledge surrounding glucose metabolism during and immediately after exercise. In addition, 
the proof of concept trials of CGM in athletes show promise and potential for this device to work 




Chapter 16.  Future Work  
The work presented in this thesis show the potential and pitfalls of using CGM to optimise blood glucose 
levels in ICU patients and athletes. In particular, it highlights areas that need to be improved before they 
can be relied upon to guide glycaemic control protocols in ICU. In addition, the ability to examine blood 
glucose trends over a longer period highlighted several aspects of the athlete metabolism that are 
contradictory to current literature. Overall, the results are promising for these devices in both fields. 
However, improvements in sensor technology and further research are needed before the maximum 
benefits of CGM can be realised. This chapter outlines aspects of future work that could be investigated 
to allow the advancement of CGM in these areas.  
 
16.1 CGM in ICU Future Work  
Chapters 2-7 highlighted that before CGM can be successful in reducing nurse workload and increasing 
patient safety sensor technology must improve to cope with the challenging ICU environment.  The 
following recommendations were made to advance the technology to allow more reliable sensor glucose 
outputs: 
 Waterproof CGM sensors  
 Reconsider insertion technique to lessen the risk of capillary damage   
 Wireless transmission between sensor and monitor unit for ease of patient mobility  
Once these recommendations have been addressed in a device, a large scale trial such as this would need 
to be repeated to prove the performance of the device once again. Another option for CGM technology 
in the ICU is devices which sample continuously from existing arterial lines which are currently being 
developed and refined (Schierenbeck et al., 2013, Hage et al., 2010). These devices remove the need for 
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subcutaneous sensors and eliminating the difficulties of translating subcutaneous glucose levels to blood 
glucose levels accurately. However, these devices face their own challenges, but if they are able to meet 
the above criteria, they show much promise to aid in the reduction of nurse workload and increase of 
patient safety with in the ICU. 
    
With an improved sensor other future work in this area could include the addition of adaptive guardrails. 
These adaptive guardrails would provide flexibility to allow targets and tolerances to be adjusted based 
on how the sensor is performing and observed patient variability. Further reducing nurse workload and 
alarm fatigue.  To implement adaptive alarms there would need to additional functionality in the CGM 
device, something that is not currently available with the Sentrino or other similar devices. Another option 
with guardrails would be to investigate only having a lower bound, to ensure patient safety but prevent 
alarm fatigue.      
 
Another future study that would aid in the development of sensor technology, would be to use the CGM 
model from Chapter 6 and virtual trial method in Chapter 7, to investigate the level of drift that could be 
present in the sensor and still achieve acceptable performance. This way, device manufacturers would 
have a better idea of what performance is needed before a device will be successful in a clinical setting. 
 
The overall aim of future studies should be to create the technology and develop the protocols to allow a 
fully automated closed loop system for ICU patients.   These protocols need to be able modulate insulin 
and/or nutrition with little input from nurses while still maintaining good blood glucose control and high 
patient safety.  With the promise of emerging sensors specifically designed for this environment this 
closed loop system could be achieved in the not too distant future.  
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16.2 The Glucose Metabolism and CGM in Athletes 
The research presented in Chapters 8 – 15 provides novel insight into the athlete metabolism that would 
not be achievable without the long term sensing capability of CGM. In addition, the athlete metabolism 
has not been quantified thoroughly in this manner before. To the author’s knowledge, no studies have 
attempted to identify insulin sensitivity in athletes during and immediately after exercise. This research 
holds much promise to aid in personalising nutritional guidelines for athletes to improve recovery, 
training, and race performance.  
 
It was noted that hyperglycaemia and hyperinsulinemia are prolonged post intense exercise to a far 
greater extent than previously noted in literature when following current nutritional guidelines. However, 
this study is limited by the lack of catecholamine analysis to assess or segregate inflammation induced 
effects from other metabolic impacts and not having glycogen measurements to confirm the amount of 
glycogen storage post exercise. Therefore, considering the glycaemic dysregulation seen post exercise and 
there is potential for a re-examination of the post exercise feeding protocol used by many athletes to 
achieve both optimal glycogen recovery and optimal blood glucose levels 
 
The adapted and simplified ICING model developed for athletes is currently unable to deal with the rapid 
and transient effects of boluses. In particular, the gut model parameters, d1 and d2, may not be suitable 
during exercise. Conducting an experiment to improve the gut model during exercise and under bolus 
conditions would be the first step to allowing the model to better cope with the dynamics induced when 




Another important step to improving the model, to make it more physiologically realistic, would be to 
model EGP and/or non-insulin mediated glucose uptake (pg) rather than holding these constant.  This 
could be potentially be achieved by making pg, and EGP dependent on heart rate or some other suitable 
marker of effort. However, it is difficult to capture the dynamics of these parameters in a non-invasive 
manner and it may have to wait until technological advancements allow such parameters to be measured 
non-invasively.  
 
Finally, while CGM in athletes proved to be successful as a proof-of-concept analysis further investigation 
is needed in to the recommended dietary intakes and resulting blood glucose levels of athletes. A larger 
study with more detailed nutritional intake data and specific activity monitoring is necessary before 
sweeping conclusions can be made. Equally, activity could be directly controlled in a more homogenous 
cohort, in a more strictly controlled study than this pilot investigation.  In particular, those in the sub-elite 
category as studied here are of interest. Sub-elite athletes are unlikely to have the same nutritional and 
dietary support from trained professionals as elite athletes. Hence, their nutritional intakes are perhaps 
more likely to be sub-optimal, as demonstrated in this study. 
 
Ultimately, it is anticipated that CGM could prove interesting insights into the metabolism of athletes not 
yet captured due to their long duration of data collection. However, generating a metabolic model that 
can then use this data to recommend optimal, personalised, nutrition is still a long way off. Further 
advancements of technology, including better non-invasive measurement of metabolic parameters such 











“What we call the beginning is often the end. And to make an end is to make a 
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